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Detergents have historically been used to solubilise membrane proteins for structural studies and 
pharmacological research, however detergents can alter the lipid environment surrounding a membrane 
protein. The styrene-maleic acid (SMA) copolymer has been designed to solubilise membrane proteins 
from the cell membrane, with the lipid bilayer intact, thus forming styrene-maleic acid lipid particles 
(SMALP). This would retain the native conformation of the protein and therefore suitable for 
applications such as drug discovery. In this project, the adenosine 2A receptor (A2AR) and the calcitonin 
gene-related peptide receptor (CGRPR) were solubilised into SMALPs. Various techniques were used 
to characterise the SMA-solubilised receptors. 
Out of the SMA copolymers tested, SMA2000 was chosen as the copolymer to solubilise the GPCRs. 
The copolymer was also compared with the new diisobutylene-maleic acid (DIBMA) copolymer, which 
has better resistance to divalent cations than the SMA copolymer. Molecular techniques confirmed the 
expression of the GPCRs in membranes and after solubilisation into SMALPs. Radioligand binding 
assays demonstrated that the A2AR retained its binding capability when solubilised and purified. The 
binding assay showed that the A2AR was more stable in SMALPs than DIBMA lipid particles 
(DIBMALP). Various techniques were used to characterise the A2AR-SMALP, providing novel 
properties of GPCRs in SMALP. The x-ray radiolytic footprinting (XRF) was used to detect regions of 
the GPCR-SMALP which were exposed to hydroxyl modification. The transmembrane domain, and the 
intracellular surface of the SMA-solubilised A2AR were exposed to water, demonstrating the SMALPs 
can successfully be used in XRF. Fluorescence correlation spectroscopy (FCS) was implemented to 
characterise the pharmacology of a single ligand binding to a single receptor, where the pharmacological 
profile of the A2AR was successfully characterised when in a SMALP.  
SMALPs were also tested for their applicability in phage display in order to generate GPCR-specific 
nanobodies against receptors in their native conformation. The M13 phage used in this project were 
conjugated with a VHH nanobody. The A2AR-SMALP was immobilised onto ELISA plates for phage 
binding, where approximately 22% of the total phage were A2AR-SMALP specific, which was lower 
than the control Fab protein. Avi-tagged A2AR and CGRPR constructs were designed to improve the 
immobilisation of the SMALPs, to yield a higher enrichment of phage, specific to the GPCR of interest. 
Finally, the photoaffinity cross-linking assay was implemented in this project, which has potential 
implications in drug discovery as receptors can be locked into a particular conformation when cross-
linked with a ligand. The technique can theoretically be applied to receptors in SMALPs. Residues of 
the extracellular loops 1 and 3 of the CGRPR were studied. The assay showed residues A199, N200 and 
N201 of the extracellular loop 1 forming crosslinks with the ligand, when substituted with 
azidophenylalanine.  
Overall, the project demonstrated techniques which are applicable to study SMA-solubilised receptors. 
Using the various techniques revealed novel properties of the GPCRs in SMALPs. SMALPs were also 
applied to the drug discovery technique, phage display, with limited success. Techniques were 
incorporated into this study to improve the applicability of SMALPs in phage display. 
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Chapter 1: Introduction 
1.1: Introduction to pharmacology 
Pharmacology is the study of how drugs affect living systems and how they interact within living 
systems (Currie, 2018). The drugs can range from pharmaceutically approved drugs, natural and 
synthetic compounds and exogenous or endogenous compounds, however they all achieve a similar goal 
of producing a response within a living organism (Currie, 2018). Pharmacology is split into disciplines, 
such as pharmacodynamics and pharmacokinetics. Recently, pharmacogenomics has been developed as 
an additional discipline, however all of them are essential in pharmacology (Currie, 2018) 
Pharmacology has been practised by scholars since 150 AD, where theories and experiments were 
utilised to discover drug properties (Vallance and Smart, 2006). Over time, the information gathered 
from scientists has led to the development of synthetic drugs, using natural compounds to assist with 
drug design (Pors, 2011). Drug discovery techniques have eventually improved and expanded, leading 
to a higher rate of drug and receptor discovery, however current drugs in pharmaceuticals and in clinical 
trials target approximately 3% of human proteins (Ryaboshapkina and Hammar, 2019). Challenges in 
drug discovery can hinder the process of the production of new drugs, where only 10-14% of proteins 
encoded by the human genome are deemed ‘druggable’ (Pors, 2011). Proteins which are difficult to 











1.2: Overview of receptor pharmacology 
1.2.1: Membrane proteins are key drug targets 
Existing in living organisms are proteins, which are macromolecules involved in biochemical processes 
(Chandel et al., 2018). They also have roles to structurally support a cell, such as cytoskeletons, as well 
as providing mechanical processes to complex organisms, such as muscle tissue (Chandel et al., 2018). 
In pharmacology, molecules involved in signalling are of key interest, such as receptors and their 
ligands. 
Membrane proteins are proteins which interact with a phospholipid bilayer. Membrane proteins 
expressed on the cell surface are the main drug targets for pharmaceutical industries, therefore 
understanding their function and structure is essential for drug development (Yin and Flynn, 2016). 
Around 30% of the human genome encodes transmembrane proteins and approximately half of the 
pharmaceutical agents available target membrane proteins to prevent onset of diseases (Dobson et al., 
2015). Membrane proteins differ from each other based on their structure and function and include: 
enzymes, receptors, ion channels and transport proteins (Cournia et al., 2015).  
Receptors are commonly transmembrane proteins, which are essential for cells to respond to and adapt 
to their surrounding environment (Uings and Farrow, 2000). They function by responding to an external 
stimuli, which docks into a binding site present on the receptor (Currie, 2018). This in turn leads to 
receptor activation, which then activates intracellular signalling cascades to achieve a response (Uings 
and Farrow, 2000). Some substances can inactivate a receptor upon binding, reducing intracellular 
activity associated with the receptor (Currie, 2018). Exogenous chemicals, polypeptides, 
neurotransmitters, hormones and sugars are potential stimuli which can activate their respective receptor 
(Currie, 2018, Uings and Farrow, 2000). There is a huge diversity of receptors encoded by the human 
genome, categorised by their types. There are cytokine receptors, receptor tyrosine kinases, ligand gated 
ion channels and G protein coupled receptors (GPCRs), where each type is further divided into classes 




1.2.2: The use of structural and computational biology to identify drug targets in receptors. 
Synthetic chemistry, organic chemistry, pharmacogenomics, proteomics and biology have provided an 
understanding of synthetic drug design against receptors, categorising receptors based on gene and 
protein sequences and studying their function in living systems. Structural and computational biology 
have provided knowledge of the molecular mechanisms of protein activity at an atomic resolution, which 
is essential for designing synthetic compounds against crevices and binding sites of a receptor (Congreve 
et al., 2005). Structural biology involves the use of techniques such as x-ray crystallography to generate 
static structures of proteins or the capture of images of a protein in different orientations. In silico 
methods can be used to generate a hypothetical scenario of receptor conformational changes, based on 
existing structural data. 
For around 50 years ago, structural biology has been used to discover drug targets (Congreve et al., 
2005). 3D structures have initially been identified for soluble proteins such as enzymes and globins, 
whereupon ligands have been developed against haemoglobin to relieve sickling in sickle cell patients 
(Beddell et al., 1976). There are now over thousands of structures on the protein data bank (PDB) due 
to the development of structural techniques (PDB [online] last accessed: 20.12.2019). Pharmacological 
data can also be rationalised by structural data, which is important in pharmacology to understand the 
molecular connections a receptor makes with a ligand and second messenger-generating proteins 
(Congreve et al., 2005). Comparison of different receptor structures allows the organisation of receptors 
into families or superfamilies, which in turn allows the catergorisation of drugs (Congreve et al., 2005). 
Sequence homology can be combined with structural homology of a family of receptors to identify key 
residues associated with their function (Congreve et al., 2005). This also simplifies the identification of 
new proteins, which may have homologous sequences and structure to a family of proteins. There are 
many structural techniques to solve the structure of a protein, however the most commonly used 
techniques are: X-ray crystallography, cryo-electron microscopy and nuclear magnetic resonance 
(Chandel et al., 2018; Moraes et al., 2014; Cheng, 2018). 
X-ray crystallography, in biology, is used to study proteins and has generated 3-dimensional (3D) 
structures (Congreve et al., 2005; Cheng, 2018; Moraes et al., 2014). It is currently the most used method 
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due to its consistency in providing high resolution crystallisation data and over 112,000 protein 
structures in the protein data bank (PDB) have been solved in this technique (Carpenter et al., 2008; 
Loll, 2003; Shoemaker and Ando, 2018). Crystal structures can be obtained using purified protein from 
natural sources, such as the squid rhodopsin from Todarodes pacificus (Shimamura et al., 2008). 
Recombinant proteins expressed in cell expression systems can be solubilised and purified, prior to 
crystallisation (Congreve et al., 2005). Once a successful crystal is obtained, the structure can be 
determined (Congreve et al., 2005). There are issues associated with obtaining a structure of a protein 
in one conformation, such as GPCRs which exist in multiple conformations at its basal state (Gurevich 
and Gurevich, 2017). The heterogeneity in conformation of certain proteins can lead to differences in 
different crystal structures of a protein in one sample. 
Cryo-electron microscopy (cryo-EM) is a method which has recently gained popularity as an alternative 
structural method to study proteins, where the technique has improved over time, with current 
resolutions reaching approximately 2 - 3 Å (Cheng, 2018; Kumar et al., 2020; Zhao et al., 2020; Liang 
et al., 2018). Cryo-EM can also provide structural information on protein complexes (Chandel et al., 
2018). This technique differs from crystallography due to the protein sample being incorporated into a 
fine layer of glass-like ice in random orientations, instead of being crystallised (Cheng, 2015). Electron 
microscopy is subsequently used to take images of the protein orientations, which are then averaged and 
analysed. The images can then be converged to generate a 3D protein model (Cheng, 2015). This gives 
cryo-EM an advantage over X-ray crystallography as proteins can be analysed in many orientations 
(Cheng, 2018). Cryo-EM also requires less protein than crystallography. Furthermore, the improvement 
of algorithms, beam-induced image motions and the use of a direct electron detection camera have 
providing resolution of protein images which rival x-ray crystallography (Cheng, 2018; Wang and 
Wang, 2016). Cryo-EM has had success in the generation of structures of large transmembrane proteins 
and complexes, which were difficult to achieve with x-ray crystallography (Cheng, 2018). Crystal 
structures dominated cryo-EM prior to 2014 where the first membrane protein structure was obtained in 
2013 using cryo-EM (Cao et al., 2013; Cheng, 2018). 5% of total protein database (PDB) structures 
were based on cryo-EM in 2014, however this increased to around 35% in 2018 (Cheng, 2018). This 
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demonstrates the rapid growth of cryo-EM as a new structural technique to identify protein structures. 
A disadvantage of cryo-EM however is the difficulty of capturing images of small proteins. GPCRs 
were often considered too small to analyse with cryo-EM, however scientists have coupled GPCRs with 
a G protein or stabilising antibodies in order to provide enough soluble mass for cryo-EM (Zhang et al., 
2017; Gao et al., 2019; Tsai et al., 2019). Therefore proteins which are too small for cryo-EM can be 
complexed with another complementary protein, such as an antibody fragment or an accessory protein, 
to provide enough soluble mass for cryo-EM (Cheng, 2018). 
Structural methods have demonstrated the importance of analysing protein structures, and this comes 
hand-in-hand with in silico modelling programmes. For drug-receptor interactions, using in silico 
programmes can identify structural grooves a ligand can occupy and how these change the conformation 
of the receptor (Geux, 1999; Congreve et al., 2005).  
There are challenges when obtaining structures of membrane proteins, in which many issues arise from 
the solubilisation and preparation of samples as well as the protein itself. Cell expression systems are 
essential for generating protein structures, where cell systems which expressing proteins in their native 
conformation at a high yield is considered ideal (Cheng, 2018). Membrane proteins are also insoluble, 
therefore a detergent is often used to solubilise proteins into micelles. Detergents are particularly 
important in crystallography where once the protein is solubilised and purified, crystals can be generated 
using the soluble protein (Moraes et al., 2014). An issue with detergents however is that they can remove 
some or all of the surrounding lipid bilayer, potentially distorting the proteins conformation (Moraes et 
al., 2014; Jamshad et al., 2015; Gulamhussein et al., 2020). As detergents have been used frequently in 
structural research, the protein structures available may have alternations to their natural conformation, 
affecting the development of synthetic drugs. Methods to incorporate membrane proteins into lipid 
nanodiscs have been developed to rectify this problem, where styrene-maleic acid has become the latest 
trend in protein research to solubilise proteins in their native lipid environment (Jamshad et al., 2015). 
However there are still issues in structural biology with nanodiscs, where capturing atomic structures of 
protein-nanodiscs provides low resolution data with high noise (Cheng, 2018). The membrane protein 
itself may be structurally challenging. Large transmembrane proteins often crystallise poorly as the 
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solubilised material must be folded in its native state and disordered, flexible structure can make the 
protein difficult to generate a homogenous crystal structure (Carpenter et al., 2008). Thermostablising 
mutations provide the protein stability in detergent micelles. The mutations also push a membrane 
receptor to certain conformational states (Carpenter et al., 2008; Serrano-Vega et al., 2008). A T4 
lysozyme has also been used to replace and intracellular loop of GPCRs to stabilise its structure for 
crystallisation (Carpenter et al., 2008; White et al., 2018; Thorsen et al., 2014). The T4 lysozyme has 
been used as it is well-folded and soluble and can crystallise under different conditions (Thorsen et al., 
2014). Nanobodies have also been used to stabilise GPCRs for crystallography (Warne et al., 2018). 
Although there are challenges in structural studies, the techniques to resolve protein structures are 
improving over time. 
1.2.3.1: The pharmacodynamics of ligand-receptor interactions 
Pharmacodynamics is a major discipline in pharmacology, studying the mechanisms of a drug binding 
to a receptor. Binding kinetics and drug affinity are important factors to consider when designing a drug 
and many methods have been developed to identify the potency and affinity of drug-receptor interactions 
(Chandel et al., 2018). Ligand-receptor interactions are governed by the law of mass action and chemical 
events such as the formation of non-covalent and covalent bonds (Chandel et al., 2018). Many 
techniques have been developed to study ligand-protein interactions, such as: structural techniques, 
radioligand binding assays, UV/Visible absorption and fluorescence spectroscopy and surface plasmon 
resonance (Chandel et al., 2018). 
A receptor and its ligand can form a complex, which can also dissociate back into receptor and ligand. 
The equilibrium between ligand, receptor and ligand-receptor complex depend upon the reactions which 
drive complex formation and its dissociation. This equilibrium can be altered by adjusting the 
concentration of ligand and receptor within an assay (Chandel et al., 2018). The ratio of forward and 
reverse reactions (or on and off reactions) in figure 1 determine the affinity of a ligand to its receptor, 
where at an equilibrium, the reactions occur at the same rate. A ligand with a high affinity for a receptor 





Figure 1| A chemical equilibrium equation showing the forward and reverse ligand binding interactions, 
based on the law of mass action. The forward and backward binding reactions. (L) is a ligand and (R) is 
a receptor. Kon is the rate constant for the forward reaction, where a ligand and receptor form a complex 
and Koff is rate constant reverse reaction where the LR complex becomes uncoupled. E is the effect 
produced upon complex formation. (Upton and Mould, 2014; Chandel et al., 2018). 
 Drug affinity is determined by the dissociation constant (Kd) (Strange, 2008, Upton and Mould, 2014). 
The Kd was derived from the law of mass action and is now commonly used to compare the affinity of 
different ligands for the same receptor (Goutelle et al., 2008). Kd is defined as the ratio of the two rate 
constants, koff reaction and kon, showing the concentration of a drug which occupies half the receptors 
(figure 2). The Kd can be calculated from the concentration of ligand [L] and receptor [R] divided by 




Figure 2| The dissociation constant, Kd, is defined by the ratio of the forward and reverse reactions. L] 
is the concentration of ligand, [R] is the concentration of receptor and [LR] is the concentration of 
ligand-receptor complexes. Kon is the forward reaction and Koff is the reverse reaction (Upton and Mould, 
2014; Chandel et al., 2018). 
 
In saturation binding models, when receptor occupancy is plotted against drug concentration, the 
resulting curve is a hyperbola (Uddin et al., 2018; Hein and Michel, 2005). The graph (figure 3), also 
known as a Rosenthal plot, is used to identify the Bmax of a drug and the Kd, which is the drug 
concentration which occupies half the receptors (Hein et al., 2005). Radioligand binding saturation 
23 
 
experiments are often used to identify the Kd (Hulme and Trevethick, 2010). The saturation experiments 
are be done at equilibrium to observe the formation of ligand-receptor complexes whilst increasing the 
concentration of labelled ligand (Uddin et al., 2018). The Kd can be calculated through kinetic 
experiments, which observe the binding of a concentration of ligand at increasing time points (Uddin et 
al., 2018). This can establish the kon and koff  rate constants, effectively providing a Kd value of a drug 








Figure 3| Drug-receptor binding model demonstrating the relationship between an increasing drug 
concentration and an increasing drug-receptor complex. In the graph the ligand concentration is plotted 
on a linear scale on the x axis where a hyperbolic relationship between an increasing agonist 
concentration and amount bound, b, is seen. The Bmax is the maximum receptor binding achieved by 





When plotting a saturation curve on a semi-logarithmic scale, the curve becomes sigmoidal. The 







Figure 4| [LR] represents the proportion of bound receptors. [L] represents the concentration of free 
ligand. Bmax is the maximum binding achieved by the ligand. Kd is the dissociation equilibrium 
constant. Equation was obtained and modified from (Kenakin, 2016). 
 
Competition binding experiments are useful to assess the affinity of a ligands and to observe their 
displacement by a competitive ligand. The experiments often involve a radioligand, used at a constant 
concentration, as well as a non-labelled ligand at increasing, logarithmic concentrations to outcompete 
the radioligand. The concentration of receptors used in competitive binding experiments are also kept 
constant (Hulme and Trevethick, 2010). The data obtained can be plotted on a semi-logarithmic scale, 
where the law of mass action equation can be applied to determine the relationship between receptor 
occupancy and drug concentration (Kenakin, 2016). Figure 5 demonstrates how a competitive binding 
assay is analysed and plotted on a semi-logarithmic scale (Hulme and Trevethick, 2010). When 
experimenting with two different ligands in a binding curve and one is an inhibitor, the Cheng-Prusoff 
transformation (Ki= IC50/(1+[L]/KdL) can be used (Hein and Michel, 2005; Hulme and Trevethick, 
2010).  The IC50 value of competitive inhibitors is calculated by finding the concentration of inhibitor 
which inhibits half the specific binding to the receptors (Burlingham and Widlanski, 2003). The IC50 
value takes into consideration the concentration of the labelled ligand and its Kd (Uddin et al., 2018), 
therefore conversion of IC50 to Ki via the Cheng-Prusoff equation can determine the affinity of the 
competitive inhibitor. (Uddin et al., 2018). A successful displacement with the competitive ligand would 
yield a mass action sigmoidal curve as shown in figure 5. The extent of sigmoidicity is determined by 
the hill coefficient. A homogenous receptor sample would theoretically follow the Hill slope of unity, 
where a 1:1 relationship between a ligand and a receptor is present (Hein and Michel, 2005; Uddin et 
al., 2018). If the Hill coefficient is higher than a value of 1, the data could show positive cooperativity, 
suggesting the sample containing multiple ligand binding sites, where binding of one ligand eases the 
binding of another ligand (Uddin et al., 2018). A value less than 1 suggests negative cooperativity, where 
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a ligand may be interacting with more than one receptor type or binding site. In a majority of binding 
experiments, non-specific binding will be observed. The non-specific binding should be eliminated from 
the total binding data in order to observe specific binding of a ligand to its receptor (Uddin et al., 2018). 
The LogIC50 can be calculated from a specific binding curve by identifying the concentration of ligand 







Figure 5| Hypothetical graph demonstrating a sigmoidal curve of a competitive binding assay, on a 
semi-logarithmic scale. *Ligand is the labelled ligand where its concentration is kept constant for all 
assay points. The competitive ligand is used to compete against the *Ligand for the receptor binding site 
at various concentrations. The total *ligand binding observed at high concentrations of competitor ligand 
(10-6-10-5 M) show non-specific binding (Hulme and Trevethick, 2010) 
 
1.2.3.2: Mode of ligand binding and ligand classification 
Upon a ligand binding a receptor, a signal is generated by the receptor to produce the appropriate 
response to trigger signalling cascades. The ligand must make contact with the receptors binding site in 
order to achieve signalling. The understanding of ligand-receptor interactions have been developed over 
time. The initial model proposed by Emil Fischer in the year 1894 was the lock and key model, 
suggesting a protein-ligand complex being rigid with perfect complementarity (Chandel et al., 2018). 
However, there is often an imperfect complementarity between a protein and ligand in structural 
research (Chandel et al., 2018). The induced-fit model proposed that binding of a ligand to a receptor 
induces a conformational change to the receptor, as the binding site is flexible (Chandel et al., 2018). 
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However both the lock and key model and the induced-fit model assumes a receptor undergoing a single, 
stable conformational change. Many receptors such as GPCRs can experience many conformational 
changes to reach an active conformation. The conformational selection model presumes that a receptor 
is in a multiple conformations at equilibrium, where the interaction between a ligand and a receptor 
pushes the equilibrium of the receptor to a complex formation state, in order for binding to occur 
(Chandel et al., 2018). Therefore the receptor is not in a rigid and single state at equilibrium. Figure 6 













Figure 6| An Illustration of the three simplified models of ligand binding. A) The lock and key model 
proposes the idea of perfect complementarity between a ligand and a protein receptor, allowing complex 
formation. B) The induced-fit model demonstrates a ligand altering the binding site of a protein in order 
to bind. C) The conformational selection model demonstrates a protein assuming different 
conformations at equilibrium. Interaction with a ligand promotes the protein to form an active 






In the absence of ligands, receptors are in their “quiescent” state, although not all receptors are inactive. 
GPCRs in their quiescent state can differ from each other in terms of basal activity (Wootten et al., 
2018). At equilibrium, GPCRs can exist in different conformations, where the addition of ligands 
stabilise a conformation of a GPCR (Sato et al., 2016) and so push the equilibrium towards a particular 
state. As GPCRs can undergo multiple conformations to reach an active or inactive state, there are many 
types of ligands to stabilise a particular configuration of the receptors. Therefore there is more to ligands 
than agonists and antagonists. Ligands can alter the response and conformation of a receptor and are 
classified as: agonists, antagonists, partial agonists and inverse agonists, depending on their effect of a 
protein (Currie, 2018). Agonists are ligands which activate a receptor. Endogenous ligands can activate 
a receptor and drugs which are made to activate receptors are often mimics of an endogenous ligand 
(Currie, 2018). They shift the equilibrium of a receptor to an active conformation, where a signalling 
response would be activated (Sato et al., 2016). Partial agonists have the characteristics of both an 
agonist and an antagonist. They alter the conformation of a receptor and produce a response, however 
the efficacy of partial agonists are not as high as full agonists, therefore a maximum response would not 
be observed (Currie, 2018. Sato et al., 2016). Reversible, neutral antagonists compete with an agonist 
for the binding site of a receptor. Once bound, the antagonist prevents agonist binding, however they do 
not alter the activity of the receptor (Sato et al., 2016. Currie, 2018). The equilibrium of a receptor would 
not be changed by neutral antagonists, therefore basal activity of the receptor would still occur (Sato et 
al., 2016). A higher concentration of an agonist can outcompete a reversible antagonist from the receptor 
binding site. Irreversible antagonists however do not dissociate from the receptor due to their high 
affinity (Currie, 2018). Inverse agonists have a negative efficacy, where they push the equilibrium of a 
receptor to an inactive conformation, inhibiting the activity of a receptor (Strange, 2008. Currie, 2018). 
In a clinical setting, inverse agonists would be used to inactive the basal signal of a receptor. Mutant 
receptors with aberrant signalling may lead to disease states, such as hyperthyroidism caused by a 
mutation of the thyrotropin receptor, leading to constitutive activity (Sato et al., 2016). Inverse agonists 
are useful to treat constitutively active receptors by lowering their activity; which neutral antagonists 
would not be able to do (Sato et al., 2016). Figure 7 demonstrates a simulated signalling response with 
the addition of different ligand types (Sato et al., 2016).  
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In the field of GPCRs, there is an emerging class of ligands which have an additional level of 
pharmacological selectivity (Violin et al., 2014). Biased ligands are of interest to pharmaceutical 
companies. These ligands can now target specific pathways of a receptor instead of fully activating 
them, which has benefits such as the limitation of adverse effects that may occur with certain drug types 








Figure 7| Graph demonstrating how GPCR ligands affect GPCR response. The blue line demonstrates 
basal activity of a receptor without the presence of ligands. A full agonist shifts the receptor to an active 
conformation, producing a positive response. A partial agonist also produces a positive response upon 
binding, however the efficacy of GPCR activity is not as high as what a full agonist could achieve. 
Antagonists competitively inhibit a GPCR, preventing agonist binding, however the equilibrium of the 
receptor would not be altered. An inverse agonist opposes a full and partial agonist, producing a negative 









1.3: Introduction into G protein-coupled receptors 
1.3.1: Overview of GPCRs 
GPCRs are the largest protein superfamily and are expressed on the cell surface of many different cell 
types. They are characterised by their seven -helical transmembrane domains, which are arranged in 
an anti-clockwise bundle (Hu et al., 2017). Over 800 GPCRs have been identified in mammalian 
organisms, however there are orphan receptors which are yet to be assigned (Sato et al., 2016; Ngo et 
al., 2017; Wootten et al., 2018). The diversity of GPCRs is augmented by transcription and translational 
mechanisms, such as: alternative splicing, post-translational modifications and protein-protein 
interactions (Wootten et al., 2018). The functional purposes of GPCRs are also varied and numerous, 
where they are involved in physiological responses such as olfactory senses, secretion, 
neurotransmission, metabolism, cellular growth and differentiation, inflammatory and immunological 
responses (Hu et al., 2017). The molecules GPCRs interact with vary in their properties and structure, 
where molecules can be photons, ions, odorants, neurotransmitters, hormones, peptides and small 
molecule ligands (Wootten et al., 2018). Even though each GPCR has a distinct purpose, the functional 
response can differ for a single GPCR, which is determined by: the different types of ligands a GPCR 
interacts with, allosteric modulators that associate with the receptors as and the signalling molecules 
found in the tissue a GPCR is expressed in (Wootten et al., 2018). Abnormalities and mutations of 
GPCRs are associated with human diseases such as: cancer, diabetes, cardiac and central nervous system 
dysfunction (Hu et al., 2017). Due to the growing research in GPCR signalling and pharmacology and 
the diseases GPCRs are associated with, the receptor superfamily has become a huge target for 
pharmaceutical companies to manufacture drugs against. Approximately 30-40% of approved 
pharmaceutical drugs target GPCRs, however only 10% of total GPCRs are deemed ‘druggable’ (Hu et 
al., 2017. Wootten et al., 2018). Some GPCRs interact with peptide ligands,which can be over 30 amino 
acid residues in size, making synthetic drug development difficult (Wootten et al., 2018). This has often 





Figure 8| Diagram illustrating the downstream signalling pathways of different G proteins. Upon GPCR 
activation, the G protein becomes active. The Gα- subunit dissociates from the Gβγ-subunits and GDP 
of the Gα- subunit is displaced by GTP. Depending on the type of Gα- subunit, different downstream 
processes are initiated (pink boxes). The Gβγ-subunits are also capable of signalling. Abbreviations: 
GTP, guanosine triphosphate; GDP, guanosine diphosphate; RGS, regulator of G protein signalling; 
cAMP, cyclic adenosine monophosphate; PKA, protein kinase A; PKC, protein kinase C; PLC,  
phospholipase C beta; PI3K, phosphoinositide 3-kinase; Pi, inorganic phosphate. Diagram obtained 
from (Jo and Jung, 2016). 
 
Agonist binding to GPCRs leads to the activation of downstream signalling processes, such as: cyclic 
adenosine monophosphate (cAMP) accumulation, calcium (Ca2+) release and inositol 1,4,5-
trisphosphate activity (Wootten et al., 2018). GPCRs interact with G proteins, which in turn activate 
effectors to transduce signalling cascades. All GPCRs interact with intracellular, heterotrimeric GTPases 
known as guanine nucleotide-binding proteins (G proteins) (Jo and Jung, 2016), which are 
approximately 90 kDa in size as a heterotrimer (Milligan and Kostenis, 2006). The protein consists of 
an  and  subunit. There are 16 subunits, 5 subunits and 13-14 subunits in humans, where each 
,  subunit can potentially combine with each other to form a certain type of G protein (Wootten et 
al., 2018. Milligan and Kostenis, 2006). Upon GPCR activation via agonist binding, the coupled G 
protein becomes active. Guanine triphosphate (GTP) replaces guanosine diphosphate (GDP) residing 
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within the GTP-binding pocket of the subunit, resulting in the subunit dissociating from the 
subunits (Wootten et al., 2018. Sato et al., 2016). The subunit is capable of signalling 
independently from the subunits as shown above in figure 8 (Jo and Jung, 2016. Sato et al., 2016. 
Wootten et al., 2018). GPCRs also signal through the -arrestin signalling pathway by interacting with 
-arrestin. There are two forms of β-arrestin, termed β-arrestin 1 and β-arrestin 2, which can interact 
with GPCRs (Ma and Pei, 2007) They are around 45 kDa in size, and are typically associated with the 
ablation of GPCR signalling, as well as functioning as scaffolds for mitogen-activated protein (MAP) 
kinase activation (Ma and Pei, 2007; Wootten et al., 2018). 
There are three superfamilies of GPCRs: family A, family B and family C. Each family differ in the 
structure of the GPCRs and their conserved sequences as well as the type of ligands which interact with 
them, varying from small molecules to hormones to large peptides. Family A GPCRs are also termed 
the ‘rhodopsin-like’ family of GPCRs due to their sequence and structural homology to rhodopsin (Hu 
et al., 2018). This family holds 80% of the total GPCRs discovered, being the largest family known with 
over 800 members (Fredriksson and Schioth, 2005; Hu et al., 2018). Their ligands include hormones 
and neurotransmitters. They have an eighth helix and sometimes a C-terminal cysteine, which is 
palmitoylated (Hu et al., 2018). Family B consists of approximately 70 receptors and is subdivided into 
secretin-like receptors, with 15 members, and adhesion receptors (Poyner and Hay, 2012; Hu et al., 
2018). The characteristic feature of this family is the large N-terminal extracellular domain, consisting 
of around 120 residues, stabilised by disulphide bonds (Hu et al., 2018). Family C GPCRs include the 
metabotropic glutamate family of receptors, GABA receptors, calcium-sensing receptors and taste 
receptors. Their N-terminal domain can be around 600 residues in size, which can act as a ligand binding 
site (Hu et al., 2018). Family C GPCRs are also obligate dimers (Wootten et al., 2018). 
As my project involves receptors from family A and family B GPCR, these two families will be the 





1.3.2.: Family A GPCRs 
Family A GPCRs are also known as the rhodopsin family of GPCRs due to their homologous sequences 
to the rhodopsin receptor (the first family A GPCR structurally characterised). Due to the nature of 
sequences being conserved amongst family A GPCRs, the Ballesteros-Weinstein numbering can be used 
to label residues based on the transmembrane domain (TMD) on which they are located and how 
conserved the residue is amongst the family A GPCRs. It consists of two numbers; the first number is 
the helix the residue is located in and the second number represents the position of the residue, which is 
relative to the most conserved residue (Isberg et al., 2016).This numbering system is useful to study 
GPCRs in relation to highly converved residues of the family A receptors (Isberg et al.,. 2016).  An 
essential conserved sequence found in family A GPCRs is the E/DRY sequence located between 
intracellular loop (ICL) 2 and TMD3 and is important in G protein coupling (Rovati et al,. 2007; Hanlon 
and Andew, 2015). The ionic lock is a feature found in a third of family A GPCRs where the E/DRY 
residue R3.50 and D/E6.30 form a salt bridge, locking the receptor in an inactive state (Schneider et al. 
2010). Upon ligand binding, the GPCR changes conformation, breaking the ionic lock thus allowing the 
receptor to become active (Schneider et al. 2010. Tehan et al. 2014). Other conserved sequences include 
GN in TMD1, LXXXD in TMD2, CWXP in TMD5 and the NPXXY motif, which links TMD7 to helix 
8 (Urizar et al. 2005). X represents variable amino acids. 
1.3.3: Common mechanisms of family A GPCR activation 
Understanding the concepts of the conformational changes which occur upon GPCR activation is 
essential for the development of drugs. In this project, the A2AR was used as a model to test the suitability 
of SMALPs in discovering nanobodies which target extracellular epitopes of the receptor. 
Upon agonist binding to family A GPCRs, structural changes occur within the transmembrane domains 
and the intracellular and extracellular loops. A feature important for GPCR activation is the movement 
of TMD3 and TMD6 upon agonist binding (Venkatakrishnan et al. 2013). When superimposing inactive 
and active conformations of GPCRs, common movements include the movement of TMD5, the upward 
movement of TMD3, TMD6 rotation and the inward movements of TMD1 and TMD7 (Tehan et al. 
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2014). This is summarised in figure 9 (Tehan et al. 2014). Once the TMs have been rearranged, a 
binding crevice becomes available for the Gsubunit to bind to via its 5 helix. This in turn leads to G 










Figure 9| Diagram showing basic conformational changes leading to the activation of family A GPCRs. 
Illustration obtained from (Tehan et al. 2014). 
 
Although the TMs are conserved in structure amongst family A GPCRs, the extracellular loops can vary 
in structure and size (Wheatley et al., 2012). ECL1 and ECL3 are involved in ligand binding, orientation 
of the TMs and affects the functional response of a GPCR (Wheatley et al., 2012). ECL2 is generally 
the largest and most diverse extracellular loop within this family of receptors, however there are 
exceptions such as the melanocortin receptor which has short ECL2 made of a few residues (Wheatley 
et al., 2012).  The ECLs are also involved in conformational rearrangements of a GPCR to transition 
from an inactive to active conformational state. ECL1 is formed between TM2 and TM3 whilst ECL3 
tethers TM6 and TM7 (Wheatley et al., 2012). ECL1 and ECL3 are responsible for ligand binding, 






1.3.4. The adenosine 2a receptor and its pharmacology  
The adenosine 2a receptor (AR) is heavily studied amongst the family A GPCRs and has been used 
for solubilisation, purification and biophysical experiments within this project. Many ligands with 
different pharmacological effects have been developed against the A2AR, allowing the characterisation 
of active, inactive and partially active conformations of the receptor. Furthermore, A2AR crystal 
structures are available, with different ligands attached to the receptor as well as different conformations. 
The structure of the A2AR complexed with the endogenous ligand, adenosine, is shown in figure 10. 
Within the field of SMALPs, the A2AR has been well characterised in a SMALP (Jamshad et al. 2015). 














Figure 10| Crystal structure of the adenosine-bound A2AR (PDB ID: 2YD0). The N to C terminus of the 
A2AR is coloured from blue to red. The chemical structure of the adenosine agonist is coloured in pink. 







Adenosine receptors are purinogenic GPCRs where its natural ligand is adenosine. Adenosine is a potent 
ligand for adenosine receptors and is essential for cytoprotection, metabolism and cardiovascular 
regulation (Vecchio et al. 2017). Adenosine acts on various cell types including neurones, neutrophils, 
platelets and smooth muscle cells (Ruiz et al. 2013). Common functions of adenosine receptors are: to 
increase oxygen supply, to condition the cells against ischaemic damage, to initiate angiogenesis and to 
trigger anti-inflammatory responses (Jacobson and Gao. 2006). Four subtypes of the adenosine receptor 
have been identified, which are: A1, A2A, A2B and A3 receptors. Each subtype differ in their 
pharmacology, tissue distribution and the G protein they couple to (figure 11) (Jacobson and Gao. 2006). 
 
Figure 11| Diagram illustrating the four subtypes of adenosine receptors and their signalling pathways. 
Abbreviations: A1R/ A2AR/ A2BR/ A3R, adenosine receptor subtypes; ATP, adenosine triphosphate; 
ADP, adenosine diphosphate; AMP, adenosine monophosphate; Ado, adenosine; Ino, inosine; s/ 
G protein subunits; cAMP, cyclic adenosine monophosphate; PKA, protein kinase A; PKC, 
protein kinase C; PLC,  phospholipase C beta; PI3K, phosphoinositide 3-kinase; PLD, phospholipase 
D; PKB/AKT, protein kinase B; CREB, cAMP response element-binding protein; NF-B, nuclear factor 
kappa B; DAG, diacylglycerol; PIP2, phosphatidylinositol 4,5-bisphosphate; IP3, inositol triphosphate. 
Diagram taken from (Jacobson and Gao. 2006).  
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 The A2AR is involved in many important processes, such as the vasodilation of coronary arteries in 
order to regulate myocardial blood flow. This in turn increases blood flow in the myocardium however 
abnormal regulation can lead to hypotension (Ruiz et al., 2013). The regulation of adenosine production 
is essential for the cardiovascular system as it acts upon the receptor to regulate vasodilation. Within the 
brain, the secretion of glutamate and dopamine is regulated by the A2AR. The A2AR can also dimerize 
with the dopamine D2 receptors to regulate its affinity for dopamine (Ruiz et al., 2013). As the A2AR is 
essential for the regulation of dopamine release and dopamine D2 receptor affinity, targeting the A2AR 
can impact the striatal dopaminergic neurotransmission. Parkinson’s disease is associated with the 
dysfunction of dopaminergic neurotransmission and drugs against the A2AR have been studied to see its 
effect on dopamine D2 receptors. The ligand, SCH58261, has been shown to bind A2AR, which leads to 
the potentiation of dopamine D2 receptors (Ruiz et al., 2013). The A2AR is distributed in a wide range 
of cell types and is associated with numerous bodily functions (figure 12) (Ruiz et al., 2013). 
Figure 12| Diagram showing the distribution of A2AR (black text), its function within certain tissues/ 
cells (red text) and diseases arising from A2AR abnormalities within certain tissues/ cells (blue text) 




As the A2AR is a heavily studied amongst family A GPCRs, many ligand types have been developed 
against the receptor. The endogenous agonist is adenosine and synthetic ligands such as 5’-N-
ethylcarboxamidoadenosine (NECA) have been made to activate the receptor (Lebon et al., 2011). 
Structural data have shown that both adenosine and NECA bind to A2AR almost identically. 4-(2-[7-
amino-2-(2-furyl)-1,2,4-triazolo[1,5-a][1,3,5]triazin-5-ylamino]ethyl)phenol (ZM241385) is a 
commonly used inverse agonist to study the inactive conformation of A2AR. Structural data identified 
some similarities with the binding of ZM241385 and the agonists. ZM241385 has a triazolotriazine ring 
structure, similar to the adenine-like ring of the agonists, which binds to the same site in the A2AR (Lebon 
et al., 2011). A structural difference between ZM241385 and the agonists is the triazolotriazine ring of 
ZM241385 has a furan substituent, whereas the adenine-ring like structure of the agonists contain a 
ribose substituent (Lebon et al., 2014). The difference in chemical structure between inverse agonist, 







Figure 13| Structures of NECA and ZM241385, compared with the endogenous agonist, adenosine. 







Many ligands have been created against A2AR to pharmacological characterise the receptor, which are 
listed in table 1. 
 
Table 1| The types of ligands which bind to adenosine receptors A1, A2A, A2B and A3. pKi is the negative 
logarithmic Ki value, which is the inhibition constant of a ligand and can be used to measure binding 
affinity. A higher the pKi value, the higher the affinity of a ligand binding to its receptor. pKi values for 
the table were obtained from Guide to Pharmacology  (Armstrong et al., 2019) 
 
In this project, the A2AR was used as a model to assess the efficiency of SMA solubilisation of the 
receptor, into a SMALP. Various techniques were implemented in this project to assess the 
pharmacology and biophysical properties of the receptor within a SMALP. Radioligand binding and 
molecular techniques were implemented to observe the solubilisation and purification of the receptor-
SMALP, as well as to test the binding capability of the receptor throughout the solubilisation and 
purification processes. Various techniques were implemented in this project to study novel properties of 
the A2AR, when incorporated into a SMALP. Such techniques include: fluorescence correlation 
spectroscopy (FCS), which observed the pharmacodynamics a single ligand and a single receptor-
SMALP; and x-ray radiolytic footprinting (XRF), which highlighted the residues of the SMA-
solubilised receptor that were exposed to water. The A2AR-SMALP was also used in phage display, to 






1.3.5: Family B GPCRs 
The calcitonin gene-related peptide receptor (CGRPR) is a family B secretin-like GPCR and was used 
in this project to identify residues of the ECL which interact with CGRP using photoaffinity cross-
linking. The receptor was also modified with fusion tags and expressed in mammalian cells for SMA 
solubilisation and phage display. 
Within the family B GPCRs, there are 15 secretin-like receptors which have been discovered with a 
sequence homology of 30-50% (Karageorgos et al., 2018. Fredriksson and Schioth, 2005). These 
receptors differ from the family A counterparts through their elongated extracellular domain (ECD), 
which is made up of around 150 amino acids (Gingell et al., 2016). Family B ligands are often peptides, 
which are considerably larger in size when compared with family A ligands and also make more 
chemical contacts. Manufacturing pharmaceutical drugs against family B GPCRs has been a challenge 
due to the native ligands being larger than a small molecule drug. Therefore drug design methods involve 
mimicking the large peptides interacting with a receptor (Karageorgos et al., 2018). Monoclonal 
antibodies have recently been developed to target family GPCRs, where the antibody, Erenumab, has 
been made to target the calcitonin gene-related peptide receptor (CGRPR) to prevent migraine 
(Karageorgos et al., 2018). Allosteric ligands are currently being investigated as a non-peptidic ligand 
to alter the pharmacology of a family B GPCR, as with the case of the glucagon-like peptide 1 receptor 
(GLP1R) (Zhao et al., 2020). Family B GPCRs are involved in homeostasis, where they regulate 
endocrine signalling, the central nervous system and the cardiovascular system. Pathophysiological 
conditions arise when there are alterations in family B signalling and receptor mutations, which can be 
life-threatening (Karageorgos et al., 2018). Like family A GPCRs, there are highly conserved residues 
found amongst family B GPCRs, however the conserved residues differ from motifs seen in family A 
GPCRs. A numbering scheme called the ‘Wootten numbering system’ can be applied to family B 




Although there are 15 secretin-like receptors within family B GPCRs, many can interact with receptor 
activity-modifying proteins (RAMPs), which can alter their pharmacology as well as traffic the receptor 
to the cell surface (Hay and Pioszak, 2016; Gingell et al., 2016). RAMPs are present in the plasma 
membrane and consist of one transmembrane domain, an ECD made of around 100 amino acids, and an 
intracellular C terminus (Karageorgos et al., 2018. Booe et al., 2015). Three RAMPs have been 
discovered in the human genome, termed: RAMP1, RAMP2 and RAMP3. They differ in their amino 
acid sequence as shown in figure 14 (McLatchie et al., 1998).  
Figure 14| Amino acid sequence of the three human RAMP isoforms. Boxed residues are conserved 
amino acids. Amino acids labelled with an asterix (*) indicate the conserved cysteine residues. Diagram 










The secondary structure of the ECD of RAMPs is conserved due to the four cysteine residues being 
present, which can form two disulphide bonds (figure 15) (Liang et al., 2018; Kusano et al., 2012; 
McLatchie et al., 1998). Most of the research on RAMPs has been conducted on the calcitonin receptor 
(CTR) and the CGRPR. Experiments have demonstrated that RAMPs are essential for the cell surface 
expression of some family B GPCRs, where the GPCR calcitonin-like receptor (CLR), requires coupling 
to a RAMP in order to be expressed on the cell surface (Weston et al., 2016). RAMPs can also alter 
ligand selectivity and pharmacology of the receptor, where CLR/RAMP1 can bind to CGRP with high 
affinity and is therefore termed the CGRPR (Weston et al., 2016). However when CLR is coupled with 
RAMP2 or RAMP3, the affinity for CGRP declines, whilst the affinity for adrenomedullin increases 
(Weston et al., 2016). CTR can also interact with RAMPs, however unlike CLR, it can be expressed by 
itself. CTR has a high affinity for calcitonin, however once expressed with the RAMPs, its affinity for 
amylin increases (Karageorgos et al., 2018). RAMPs therefore impact the signalling process of GPCRs 







Figure 15| Superimposed structures of the ECD of RAMP1 and RAMP2. RAMP1 (PDB ID: 6E3Y) is 
shown in red and the cysteine residues are shown as red sticks. RAMP1 (PDB ID: 3AQE) is shown in 
blue and its cysteine residues are shown as blue sticks. N is the N terminus and C is the C terminus. The 
structures were superimposed by their sequence, using Swiss PDB viewer. PDB files were obtained 







1.3.6: Common mechanisms of family B GPCR activation upon peptide binding 
In order to generate conformation specific nanobodies against the CGRPR and to determine ligand 
binding to the ECL residues of the receptor, understanding the conformational changes occurring upon 
receptor activation is important, with a main focus on the extracellular region of the receptor. 
The family B GPCR ligands are peptides, which make more chemical contacts with a target receptor 
than family A GPCR ligands. The endogenous peptides are around 25-114 residues in size, which 
include secretin, glucagon, calcitonin, parathyroid hormone (PTH), CGRP and amylin (Wheatley et al., 
2012. Culhane et al., 2015). The N terminus of a peptide interacts with the juxtamembrane domain of a 
GPCR (which includes the TM bundle and the ECLs), whilst the C terminus makes contact with the 
ECD (Karageorgos et al., 2018. Culhane et al., 2015; Liang et al., 2018). Deletion studies have shown 
that removing the termini residues of the CGRP reduces the binding affinity to its target receptor, 
demonstrating that both the N terminus and C terminus of a peptide are capable of making molecular 
contacts (Watkins et al., 2013). The positioning of a peptide ligand within a receptor has been identified 













Analysis of different family B GPCR structures have also informed the process of ligand binding. 
Studies with the glucagon-like peptide 1 (GLP-1) receptor have shown that the hydrophobic motif of 
the C-terminus of the peptide ligand makes contact with the ECD of the receptor.  The ECD reorientates 
itself, to allow the peptide to interact with the TM bundle. The middle of the peptide interacts with the 
stalk and ECL1, which has been confirmed in Liang et al., (2018) and the ECL1 photoaffinity cross-
linking experiment in Chapter 8. The ECL2 of the receptors also makes contact with a peptide ligand, 
where CRF1 receptor studies have demonstrated that Lys257 of ECL2 is in close proximity to the N-
terminal domain of CRF (Karageorgos et al., 2018). The closeness between the peptide and ECL2 can 
also be observed in the full length cryo-EM structure of the CGRPR, where the loop is orientated towards 
the N terminus of the CGRP and residue (figure 16) (Liang et al., 2018). The N terminus of the peptide 
akso forms interactions within the TM bundle, leading to receptor activation (Hollenstein et al., 2014; 
Underwood et al., 2010; Zhao et al., 2020).   
Figure 16| Cryo-EM structure of the CGRPR:CGRP complex (PDB ID: 6E3Y). RAMP1 is not shown 
in the figure. Ser286 of ECL2 forms a hydrogen bond with the backbone of His10 of the peptide. Bond 







The ECD of family B GPCRs consists of a conserved structural motif (alpha helices and beta 
sheets). The N-terminus is alpha helical, followed by two anti-parallel -sheets, which are known as β1-
β2 and β3-β4, followed by an alpha helical structure (Karageorgos et al., 2018). The two anti-parallel   
 sheet structure is also termed the sushi domain, which is essential in protein-protein interactions.  
Family B GPCRs are configured into an open V-shape formation, where the open end is at the 
extracellular surface of the GPCRs, as shown with the superimposed structures of the CRF1 receptor 
and the glucagon receptor figure 17A (Bortolato et al., 2014) and the more recent cryo-EM structure of 















Figure 17| A) Superimposed structures of the CRF1 receptor (PDB ID: 45KY) and the glucagon 
receptor (PDB ID: 4L6R). Receptors shown in rainbow coloration to denote sequence polarity from blue 
to red (N-C terminus). Receptor is viewed from the membrane point-of-view. The TM helices form a 
characteristic V shape formation. Diagram taken from (Bortolato et al., 2014). B) Structure of the 
CGRP-bound CGRPR, without the RAMP1 (PDB ID: 6E3Y). Structure in red marks TMs 1, 6 and 7 
and the ECD of CLR. Structure in orange marks TMs 2, 3, 4 and 5. The CGRP ligand is shown in purple. 





1.3.7: The calcitonin gene-related peptide receptor 
CGRPR is a complex of two proteins, CLR and RAMP1. It is a heavily studied receptor amongst the 
family B GPCRs and was the first to be identified to interact with a RAMP (McLatchie et al., 1998). 
The RAMPs are essential for transporting CLR to the cell surface, as well as allosterically altering ligand 
selectivity to favour the peptide, CGRP (Simms et al., 2019). It was hypothesised that the three RAMPs 
compete with each other to form a complex with CLR in the Golgi apparatus (Russel et al., 2014). Co-
expression experiments have shown that the CLR has a preference for RAMP1 (Buhlmann et al., 1999). 
Although CLR/RAMP1 has been the consensus complex for CGRP binding, the peptide can also interact 
with CLR/RAMP2 and CLR/RAMP3 although to a lower extent (Russel et al., 2014). The CGRP 
receptor is expressed in different tissue types with many roles.  
The CGRPR is important for many biological processes and is an important drug target. In the 
cardiovascular system, CGRP can act as a potent microvascular vasodilator upon binding to CGRPR 
(Russel et al., 2014). Upon inhibition by antagonists, the vasodilatory effects of CGRP become reduced. 
Studies have shown that the application of CGRP to the endothelium increases cAMP accumulation 
through the adenylate cyclase pathway upon G protein activation (Russel et al., 2014). CGRP has been 
shown to be essential for regulating blood pressure, where pathogenesis of hypertension occurs through 
reduced CGRP activity, as demonstrated by knockout CGRP mice (Russel et al., 2014). Migraine is a 
complex condition involving the neurovascular system. It is a disease affecting 8% of males and 18% 
of females (Russel et al., 2014). These symptoms include: a painful headache, high photosensitivity, 
sensitivity to sound, vomiting, nausea and fatigue (Russel et al., 2014). Studies have shown that the 
intravenous administration of CGRP in patients elevates the onset of migraine (Lassen et al., 2008). To 
combat the effects of migraine, many antagonists have been made to prevent CGRP binding to CGRPR 
in the neurovascular system. Antagonists include: Olcegepant and telcegepant, which bind the 
extracellular domain of the CLR:RAMP1, preventing important contacts being made between the CGRP 
and its receptor (Russel et al., 2014; Charles and Pozo-Rosich, 2019; ter Haar et al., 2010; Warfvinge 
et al., 2019). Efforts have been made to target the receptor to prevent the onset of migraine, including 
the generation of CGRPR antagonists, olcegepant and telcegepant. Unfortunately hepatotoxicity was 
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associated with their administration (Charles and Pozo-Rosich, 2019; Hay et al., 2017; Akhtar, 2019). 
Due to the difficulties associated with generating small molecule antagonists against the CGRPR, an 
antibody-based alternative approach is being investigated to target the receptor (Charles and Pozo-
Rosich, 2019). Galcanezumab, fremanezumad, erenumab and eptinezumab are antibodies which have 
entered clinical trials to prevent onset of migraine, with erenumab targeting the receptor and the rest 
targeting the peptide ligand (Akhtar, 2019). Out of the four monoclonal antibodies, eptinezumab 
demonstrated the best results in reducing migraine. The antibodies were deemed generally safe in the 
clinical trials, with a slight risk of adverse effects (Akhtar, 2019). Using phage display to generate 
CGRPR-specific nanobodies will therefore lead to the discovery of safer, therapeutic drugs to relieve 
migraine. 
The peptide for CGRPR exists as two isoforms, termed CGRP and CGRP. In chromosome 11, two 
different genes are transcribed and translated into the two isoforms which are 37 amino acids in size 
(Russel et al., 2014; Kee et al., 2018). Human CGRP and CGRP have 90% sequence similarity, 
where three amino acids differ between each other (Russel et al., 2014). CGRP is mainly found in the 
central and peripheral nervous system, whilst the isoform is involved in enteric transmission (Russel 
et al., 2014; Kee et al., 2018). The isoforms have similar roles to each other however the CGRP has 
been most heavily studied. Both isoforms consist of four domains.  
As the CGRPR is composed of the CLR and RAMP1, it is fundamental to understand the molecular 
contacts made between the two proteins as well as the peptide, The recent cryo-EM structure provides 
valuable insight on how family B GPCRs function as well a structure of the CLR, in complex with 
RAMP1, which will be useful for drug discovery (figure 18) (Liang et al., 2018). The TM of RAMP1 
resides between TMs 3-5 of CLR, which forms an interface for RAMP1 (Liang et al., 2018). A majority 
of the TM interactions are formed between the TM5 of CLR and the TM of RAMP1 (Liang et al., 2018), 
Mutagenesis of the RAMP1 interface of CLR reduces binding of CGRP (Liang et al., 2018). Residues 

















Figure 18| Crystal structure of the CGRPR (PDB ID: 6E3Y). The CLR is shown in orange and RAMP1 
is shown in red. Structure was made using BIOVIA Discovery Studio. 
 
1.3.8. Allosteric modulation of GPCRs 
GPCRs contain allosteric binding sites as well as the orthosteric ligand binding site. Orthosteric ligand 
binding sites are sites where orthosteric ligands bind and are often exploited by pharmaceutical 
companies for drug development (Jakubik et al., 2019). An example of an orthosteric ligand would be 
adenosine and CGRP binding to the orthosteric site in the A2AR and the CGRPR respectively. An 
allosteric site is positioned away from where endogenous orthosteric ligand binds to, where molecules 
binding to the allosteric site are termed allosteric ligands or modulators (Digby et al., 2010; Jakubik et 
al., 2019). The addition of multiple binding sites of a receptor makes their pharmacology more complex. 
RAMPs, G proteins and arrestin, which have been mentioned in previous sections, are examples of 
endogenous allosteric modulators which affect GPCR pharmacology. However there are many 
additional protein and non-protein components which can alter a receptors behaviour. These can either 
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be positive allosteric modulators which influence the receptor to be in an active state, or a negative 
allosteric modulators which push a receptor into an inactive conformation. Neutral allosteric modulators 
do not influence receptor pharmacology however they may compete with other allosteric modulators 
(Wold et al., 2019). As this project involves the use of SMALPs to solubilise GPCRs with the 
surrounding lipid bilayer, which can act as an allosteric modulator, understanding allosteric effects of 
GPCRs was fundamental to this project. 
In the A2AR, a sodium ion binding pocket was discovered within the ZM241385-bound A2AR structure 
(figure 19) (PDB ID 4EIY, Liu et al., 2012). A sodium ion binding region was detected around the 
highly conserved Asp522.50 (Massink et al., 2015). There are four residues in the TM bundle which form 
a water network with water molecules. The residues are Ser913.39, Trp2466.48, Asn2807.45, and Asn2847.49 
(Massink et al., 2015). The water network coordinates the sodium ion into the allosteric site of A2AR. 
Upon transitioning to an active state, the sites which interact with structural waters change (Massink et 
al., 2015). This indicates that water molecules as well as ions can act as allosteric modulators, interacting 
with GPCRs and stabilising their conformation. From molecular dynamic simulations and wet lab 
experiments, increasing the sodium ion concentration promotes the receptor to transition into an inactive 











Figure 19| Crystal structure of the ZM241385-bound A2AR (PDB ID: 4EIY) with the sodium ion present 
within the TM bundle of the receptor. The sodium ion is shown as a green sphere. The blue spheres 
represent water molecules. The red dashed line marks an electrostatic interaction between Na+ and 
Asp522.50. The blue dashed lines indicate hydrogen bonds formed between the water molecules and 
Asp522.50. The pink chemical structure is the ligand, ZM241385. The black stick chemical structure is 
the highly conserved Asp522.50. The red ribbons represent the A2AR. The structure was analysed using 
BIOVIA Discovery Studio.  
 
Lipids also impact the pharmacology of receptors. The use of detergents to solubilise proteins often 
removes the allosteric effects of a native lipid on its target protein. The phospholipids within the lipid 
bilayer have shown to affect GPCR ligand binding, stability of receptor conformation and receptor 
dimerization (Song et al., 2019). Radioligand binding experiments with 2 adrenergic receptor have 
shown the impact lipids can have on a receptor. 1,2-Dioleoyl-sn-glycero-3-phosphoglycerol (DOPG) is 
a negatively charged lipid which stabilised the active conformation of the receptor. Replacing 
surrounding lipids with 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), which has no net 
charge, pushes the conformation of the receptor to an inactive state, as shown by a reduced displacement 
of [3H]-DHAP by isoproterenol (Dawaliby et al., 2016). Cholesterol is also an important allosteric 
modulator that binds to GPCRs such as the A2AR. Seven cholesterol binding sites were discovered in 
the hydrophobic regions of the TM bundle (Song et al., 2019). Experiments involving the depletion of 
membrane cholesterol using methyl--cyclodextrin reduced downstream accumulation of cAMP 
through adenylyl cyclase (McGraw et al., 2019). Both lipids and cholesterol therefore have an impact 
on GPCR pharmacology, and should therefore be considered when generating membrane protein 
structures and drugs. 
Drugs which allosterically modulate GPCRs are a recent trend, as recent allosteric drugs have been 
approved by the Food and Drug Administration (FDA) (Wold et al., 2019). Allosteric binding sites 
between GPCRs show less homology, which can be exploited by pharmacologist to design subtype 





1.4: The use of the styrene-maleic acid copolymer to solubilise receptors 
1.4.1: How detergents are used to solubilise membrane proteins 
As mentioned previously, in order to generate crystal structures of a membrane protein, solubilisation 
of the protein must occur in order for the protein to be successfully purified and crystallised. However, 
many classes of detergents with different properties have been used for solubilisation. Detergents are 
amphipathic molecules with a hydrophobic tail and a hydrophilic headgroup (Moraes et al., 2014). Due 
to the amphipathic nature of detergents, they are expected to disrupt the lipid bilayer without degrading 
the protein. Detergents can form a micellar structure around the protein and mimic the lipid bilayer in 
an attempt to retain protein structure, rendering the protein soluble (Moraes et al., 2014). When the 
protein-detergent micelle is in solution, the polar headgroups of the detergent can form hydrogen bonds 
with water molecules, whilst the hydrophobic tails complex together to form the micellar structure 
(Moraes et al., 2014). The micelles have a weight of less than 100 kDa, depending on the type of 
detergent used (Seddon et al., 2004). There are different classes of detergents to choose from, each with 
different properties.  
Ionic detergents contain an anionic/ cationic headgroup. They are capable of disrupting the 
hydrophobicity of a protein, causing its distortion, therefore this class of detergent is not generally 
applicable to solubilise proteins in a biologically relevant conformation (Moraes et al., 2014). Ionic 
detergents can also be applied when less harsh methods of solubilisation do not work with a particular 
protein.  
Non-ionic detergents consist of a hydrophilic headgroup and therefore possess no net charge (Moraes et 
al., 2014). They are ubiquitously used to solubilise and purify membrane proteins for characterisation 
and crystallisation for structural studies. Compared to ionic detergents, non-ionic detergents are mild 
due to their properties in disrupting protein-lipid and lipid-lipid interactions without affecting protein-
protein interactions (Moraes et al., 2014). This class of detergents also come in different sizes, where 
short length varieties are often used for solubilisation and crystallography, whilst larger variants are 
used for reconstitution studies (Moraes et al., 2014). Another advantage of using non-ionic detergents 
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is that UV measurements are not skewed after solubilisation and purification, with exception to Triton 
due to its impurities (Moraes et al., 2014). Maltosides and glucosides belong to the non-ionic class of 
detergents such as n-Dodecyl β-D-maltoside (DDM), which is a mild and non-denaturing detergent 
(Moraes et al., 2014). Zwitterionic detergents are milder than ionic detergents, containing ionic and non-
ionic properties (Moraes et al., 2014). They have been used in crystallisation and NMR studies.  
1.4.2: The use of styrene-maleic acid copolymers as an alternative to detergents in solubilising 
membrane proteins 
Progress in resolving structures of membrane proteins has been hindered due to the use of detergents to 
isolate membrane proteins. Detergents are capable of removing some or all of the surrounding lipid 
bilayer, potentially disrupting the folding of the protein, such as the lipophilic membrane-spanning 
protein domains (Jamshad et al. 2015; Lee et al., 2016). Crystal structures of receptors therefore may 
not reflect a native conformation of a protein. Detergents are often made fresh for each time it is being 
used and finding a suitable detergent for a particular protein can be tedious to identify (Moraes et al., 
2014). The limitations associated with some detergents can be alleviated by using SMA copolymers. 
In the year 2000, an organic polymer was discovered, which can solubilise proteins with the lipid bilayer 
intact (Knowles et al. 2009). The copolymer is styrene-maleic acid (SMA) which can form SMALPs 
when applied to a membrane. SMA is formed upon the hydrolysis of the styrene-maleic anhydride co-
polymer, which is formed through the copolymerization of styrene and maleic anhydride, as shown in 
figure 20 (Dorr et al. 2016). Within life sciences, SMA copolymers can be used to treat cancer by 
encapsulating anti-cancer drugs for drug delivery (Tsukigawa et al., 2015; Xian et al., 2015). Tighe and 
Tonge discovered that the SMA copolymer can interact with phospholipids and solubilise lipid bilayers 
(Dorr et al. 2016). SMA can form a ringed structure on a membrane, which can be released from the 
membrane to form a discoidal structure containing lipid and protein (figure 21) (Dorr et al. 2016). 
Different styrene to maleic acid ratios in SMA copolymers can lead to different disc sizes when applied 
to the membrane, where SMA2000P (the most commonly used SMA copolymer) can form a ring shape 
that is 10nm in diameter (Dorr et al. 2016). The styrene component of SMA can be altered to increase 
the ratio, where SMA2000P consists of a 2 styrene: 1 maleic acid ratio (Dorr et al., 2016). SMALPs are 
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therefore a useful tool to solubilise receptors and to keep then in a native conformation surrounded by a 
phospholipid bilayer. 
 
Figure 20| Diagram showing the conversion reaction of styrene maleic-anhydride to SMA in a 1:1 ratio. 
Reaction 1 demonstrates the polymerization of styrene and maleic anhydride to form styrene maleic-
anhydride. Reaction 2 demonstrates the conversion of the anhydride to an acid. Diagram taken from 







Figure 21| A) Illustration showing a membrane protein solubilised using detergents (red). The lipid has 
been stripped away by the detergents. B) Illustration showing a membrane protein solubilised using 
SMA. The protein is surrounded by a lipid bilayer (green head groups). The SMA (yellow) forms a ring-











The A2AR was previously expressed in human embryonic kidney cells (HEK293T) and Pichia pastoris, 
where SMA2000 was used to solubilise the receptor into SMALPs (Jamshad et al., 2015). Different 
aspects of the A2AR-SMALP was tested, such as the thermostability of the copolymer, where the 
SMALPs were more stable than DDM micelles as the temperature increased (Jamshad et al., 2015). 
Circular dichroism (CD) spectroscopy has also shown that the stability of the A2AR helix content was 
intact at 65°C (Jamshad et al., 2015) demonstrating the better stability of the A2AR within a SMALP, 
than DDM. Radioligand binding experiments have also confirmed that the receptor was functional 
within a SMALP when the temperature was pushed to 65°C, albeit some loss of binding (Jamshad et 
al., 2015). SMALPs were also proven resilient over time when compared with DDM, where binding 
experiments with the A2AR showed no loss of binding after 16 days of incubation at 37°C (Jamshad et 
al., 2015). DDM-solubilised A2AR however lost binding after 2 days of incubation at 37°C. From the 
data gathered by Jamshad et al (2015), SMALPs showed superiority over the commonly used detergent, 
DDM, in keeping the protein stable and functional over a long period of time. 
As SMALP research is a new field in membrane protein biology, the understanding of how SMA 
interacts with the lipid bilayer is somewhat limited. In 2018, molecular dynamic simulations and 
analysis have suggested how SMA interacts with the membranes to solubilise proteins (Xue et al., 2018). 
SMA copolymers in solution formed a disordered configuration, where aggregation could occur through 
the hydrophobic regions of the copolymer (Xue et al., 2018). Once the copolymer was applied to a lipid 
environment, the hydrophobic styrene embeds itself between the acyl tails of the lipid bilayer at a 20 ns 
time point (Xue et al., 2018). After 400 ns, the copolymer fully immersed itself into the lipid bilayer, 
where electrostatic interactions between the SMA carboxyl group and phospholipid head groups were 
mediated by sodium ions (Xue et al., 2018). The structure of SMA changed into a stretched 
conformation. The copolymer, once absorbed into the lipid, caused membrane bending, lipid tilting, 
lipid extraction and water infiltration, according to the simulations (Xue et al., 2018). The stability of 
the lipid bilayer became disrupted, where water infiltration enlarged the pores of the lipid bilayer (Xue 
et al., 2018). The SMA copolymers formed disc shapes around the lipid, between the phospholipid head 
groups of the bilayer to form SMALPs through self-assembly of the copolymers (Xue et al., 2018).  
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1.5: Characterisation of the SMA-solubilised A2AR and CGRPR. 
As SMALPs have been shown to retain a GPCR in its native, functional conformation with the lipid 
bilayer intact, assessing further characteristics of the receptor-SMALP would provide new information 
on the pharmacology of the A2AR (Jamshad et al., 2015). In this project, different techniques were used 
to assess the pharmacology and properties of the A2AR and the CGRPR within a SMALP. 
Radioligand binding assays were used to compare the ligand binding affinity of ZM241385 to the A2AR 
in membranes and in SMALPs, to observe whether the GPCR retains its pharmacology after 
solubilisation (Uddin et al., 2018; Jamshad et al., 2015). Once the binding capability of the receptor was 
confirmed, additional techniques were used to identify novel features of the SMA-solubilised receptor. 
Fluorescence correlation spectroscopy applied the confocal microscope to observe the 
pharmacodynamics of a single fluorescent ligand and a single receptor-SMALP (Briddon et al., 2018). 
The technique was used to observe the the pharmacodynamics of the A2AR-SMALP, as well as the 
lipophilicity of ligands, to see how they non-specifically interact with the SMALP. Water-exposed 
residues of the A2AR-SMALP were analysed using X-ray radiolytic footprinting. The technique involved 
the irradiation of water molecules, to observe which regions of the SMA-solubilised A2AR interacts with 
water, which can be compared with the distribution of water networks in existing crystal structures 
(Gupta et al., 2016; Gupta, 2019). Changes in water exposure of the A2AR can be observed by applying 
agonists and antagonists, which will inform how water networks may change when a GPCR transitions 
between an active and an inactive state, as observed with rhodopsin (Orban et al., 2010). 
The A2AR-SMALP was also used as a drug discovery target, to test whether phage display would be 
applicable in a SMALP context, in order to develop A2AR-specific nanobodies. Phage display applies 
phage technology to express nanobodies onto the coat protein during phage assembly (Hoogenboom, 
2005). The phage used for nanobody generation were conjugated with a nanobody to the coat protein of 
the phage (figure 22) (Wesolowski et al., 2009). A naïve phage library, was used to isolate the phage 








Figure 22| Illustration of an M13 bacteriophage, with a VHH nanobody fused to the gIIIp coat protein. 
The genome encoding the VHH nanobody can be digested and cloned into a phagemid vector, from the 
Camelidae genome. Within the phagemid, the VHH gene was fused to the gIIIp coat protein. The 
phagemid can then be transfected into E.coli, alongside a helper phage to assemble VHH-conjugated 
phage. Diagram taken from (Wesolowski et al., 2009). 
 
Photoaffinity cross-linking was also incorporated into this project to identify the ECL residues of the 
CGRPR, which interact with the fluorescein-conjugated CGRP. The experiments were conducted on 
detergent-solubilised receptors, however the technique could be transferrable to SMA-solubilised 
receptors. The technique is also beneficial in locking an SMA-solubilised GPCR in an active or an 
inactive state, which could be applied in drug discovery techniques such as phage display, to discover 











1.6: Project aims 
As SMALPs are becoming increasingly popular in membrane protein research, the characteristics and 
pharmacology of GPCRs in SMALPs must be understood, to ensure their binding capability and 
functionality is retained after solubilisation. Previous research with the A2AR has demonstrated 
successful SMA solubilisation, however further experimental techniques can be implemented to 
understand the properties and pharmacology of the receptor in a SMALP context (Jamshad et al., 2015). 
In this project, the first aim was to characterise the A2AR and the CGRPR in SMALPs, using a range of 
techniques, such as x-ray radiolytic footprinting, fluorescence correlation spectroscopy, cyclic AMP 
accumulation and radioligand binding. This is to ensure the receptors are binding capable and to discover 
properties, such as water-exposed residues of an SMA-solubilised receptor. The second objective was 
assess the applicability of using SMALPs as a drug discovery tool, using the phage display technique. 
SMALPs were used as a platform for phage display nanobody discovery due to their ability to retain the 
native conformation of a GPCR, therefore allowing nanobody-conjugated phage to bind conformational 
epitopes of the receptor within the SMALP. (Wheatley et al., 2016; Jamshad et al., 2015). Finally, the 
photoaffinity cross-linking assay was used to covalently lock the CGRPR into an active state in order to 
discover nanobodies which are conformationally selective against the active GPCR and to study whether 
the technique is applicable with SMALP GPCRs.  
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Chapter 2: Materials and methods 
2.1: Table of materials used in experimental procedures 
Table 2: Reagents for quick-change polymerase chain reaction (PCR) 
Enzyme/ Reagent  
PfuUltra II Hotstart PCR master mix   
 
Table 3: Restriction enzymes and buffers used for molecular biology experiments 
Buffers/ enzymes Company 
NotI  
EcoRI   
Pme1   
Dpn1   
NEBuffer 3.1   
Cutsmart buffer  
 
Table 4: Reagents for DNA electrophoresis 
Solutions/ reagents Components 
1 X TRIS-acetate-EDTA (TAE buffer) 20 ml 50 X TAE, pH 8.3 (from Merck) 
980 ml dH2O 
Hi-Res Standard agarose (from AGTC 
bioproducts). 
 
RedSafe nucleic acid staining solution- (from 
Intron) 
 
6 X Bromphenol blue loading dye 4 g sucrose (Sigma Aldrich) 
25 mg bromophenol blue powder (Sigma 
Aldrich 
Dissolved in dH2O until the final volume of 10 
ml was reached. 















Table 5: Solutions and reagents for competent E. coli cell generation, transformation and 
growth. 
Solutions/ reagents Components 
Transformation buffer 1 (pH 5.8) 6 g RbCl (from Sigma-Aldrich) 
5 g MnCl2-4H20 (from Sigma-Aldrich) 
15 ml 1 M Potassium acetate (pH 7.5) (from 
Sigma-Aldrich) 
0.75 g CaCl2-2H20 (from Sigma-Aldrich) 
75 ml glycerol (from Fisher Bioreagents) 
Dissolved in 500 ml dH20 
Transformation buffer 2 (pH 6.8) 10 ml 0.5 M 3-(N-morpholino)propanesulfonic 
acid (MOPS) (pH 6.8) (from Sigma-Aldrich) 
0.6 g RbCl 
5.5 g CaCl2-2H20 
75 ml glycerol 
Dissolved in 500 ml dH20 
Lennox Broth (LB) media 20 g LB dissolved in 1 L dH20 
LB agar 5 g LB (from Fisher Bioreagents) 
5 g agar (from Becton, Dickinson) 
Dissolved in 250 ml dH20 
50 μg/ml ampicillin (from Sigma-Aldrich) 
 
 
Table 6: Solutions and reagents for competent Pichia pastoris generation and electroporation 
Solution/ reagents Components 
Yeast extract, peptone, dextrose (YPD) media 10 g yeast extract (from Becton, Dickinson) 
20 g peptone (from Becton, Dickinson) 
Dissolved in 900 ml dH2O 
After sterilising, 100 ml of 10 X dextrose (from 
Sigma-Aldrich) was added. 
BEDS solution  10 mM bicine- NaOH, pH 8.3 (from Sigma-
Aldrich) 
3% (v/v) ethylene glycol (from Sigma-Aldrich) 
5% (v/v) dimethyl sulfoxide (DMSO) (from 
Thermofisher Scientific) 
1 M sorbitol (from Sigma-Aldrich) 
DTT solution 1 M dithiothreitol (DTT) (from Sigma-Aldrich) 
YPD, sorbitol (YPDS) agar plate 5 g yeast extract 
10 g peptone 
91.1 g sorbitol 
10 g agar 









Table 7: Solutions and media for Pichia pastoris growth and expression 
Buffer/ reagent Components 
0.02 % Biotin 20 mg Biotin (from Supelco) 
Dissolved in 100 ml dH2O 
Filter sterilised and stored at 4°C 
20 % Dextrose 200 g D-glucose  
Dissolved in 1 L dH2O 
Autoclaved and stored at room temperature 
(RT) 
5 % Methanol 50 ml methanol (from Fisher Scientific) 
Up to 1 L in dH20 
Filter sterilised and stored at 4°C 
10 % Glycerol 100 ml glycerol 
Dissolved in 1 L in dH2O 
10 X Yeast nitrogen base extract (YNB) With ammonium sulphate 
Without amino acids 
Dissolve YNB (according to suppliers 
instructions) in dH2O to 500 ml to obtain 10 X 
YNB 
Filter sterilised and stored at 4°C 
1 M Potassium phosphate buffer (pH6) 132 ml 1M K2PO4 (pH6) 
868 ml 1M KH2PO4 (pH6) 
Autoclaved and stored at RT 
Yeast extract peptone dextrose (YPD) agar plate 
+ zeocin 
1 % yeast extract 
2 % peptone 
2 % dextrose 
2 % agar 
100 μg zeocin (from Thermofisher) 
Dissolved in dH20 
Filter sterilised and stored at 4°C 
Buffered glycerol-complex medium (BMGY)  1 % yeast extract 
2 % peptone 
100 mM potassium phosphate (pH6) 
1.34 % YNB 
4 x 10-5 % biotin 
1 % glycerol 
Dissolved in dH2O 
Autoclaved and stored at 4°C 
Buffered methanol-complex medium (BMMY) 1 % yeast extract 
2 % peptone 
100 mM potassium phosphate (pH6) 
1.34 % YNB 
4 x 10-5 % biotin 
0.5 % methanol 
dissolved in dH2O 
Autoclaved and stored at 4°C 
Breaking buffer (pH8) 50 mM sodium phosphate (pH8) (from Sigma-
Aldrich) 
2 mM ethylenediaminetetraacetic acid (EDTA) 
(from Sigma-Aldrich) 
100 mM NaCl (from Sigma-Aldrich) 
5 % glycerol 




Table 8: Solutions and reagents for mammalian cell culture and growth. 
Solutions/ reagents Components 
Dulbecco’s modified eagle media (DMEM), 
Glutamax, high glucose and pyruvate (from 
Thermofisher scientific) 
Standard DMEM components 
25 mM glucose 
1 mM pyruvate 
Fetal bovine serum (FBS), Gibco (from 
Thermofisher scientific) 
 
Opti-MEM, reduced DMEM, Gibco (from 
Thermofisher scientific) 
 




Poly-D-lysine hydrobromide (from Sigma-
Aldrich) 
Lyophilized poly-D-lysine reconstituted in 
sterilised dH20 to 50 mg/ml 
100 X Penicillin Streptomycin (from Generon)  
 
Table 9: Buffers for SMA solubilisation 
Buffer Components 
Buffer A 50 mM HEPES 
150 mM NaCl 
10 % Glycerol 
 
Table 10: Buffers and reagents for general deca-his-tagged protein purification 
Buffers/reagents Components 
Nickel-nitrilotriacetic acid agarose (Ni2+-NTA) 
(from Qiagen) 
Stored in 100 % ethanol (from Fisher Scientific) 
Wash buffer (pH8) 50 mM TRIS (from Sigma-Aldrich) 
300 mM NaCl 
10-20 mM imidazole (from Sigma-Aldrich) 
Elution buffer (pH8) 50 mM TRIS 
300 mM NaCl 
250 mM imidazole (but can vary depending on 
experiment) 
Dialysis buffer (pH8) 50 mM HEPES 
150 mM NaCl 
 
Table 11: Buffers and reagents for deca-his-tagged protein purification for X-ray radiolytic 
footprinting. 
Buffers/reagents Components 
Nickel-nitrilotriacetic acid agarose (Ni2+-NTA) 
from Qiagen 
Stored in 100 % ethanol 
Wash buffer (pH8) 50 mM NaH2PO4 (from Sigma-Aldrich) 
300 mM NaCl 
20 mM imidazole 
Elution buffer (pH8) 50 mM NaH2PO4 
300 mM NaCl 
250 mM imidazole  
Dialysis buffer (pH8) 20 mM NaH2PO4 




Table 12: Radioligand binding buffers and reagents 
Buffers/reagents/ligands Components 
Binding buffer 50 mM HEPES 
150 mM NaCl 
5 % Glycerol 
DMSO (Dimethyl sulfoxide)  




Table 13: Buffers and reagents for sodium dodecyl sulfate (SDS)- polyacrylamine gel 
electrophoresis (PAGE) 
Buffers/reagents Components 
12 % Separating gel For 1 gel: 
1.9 ml 30 % Protogel polyacrylamide (from 
National Diagnostics) 
2.2 ml dH20 
1.5 ml 1.5 M TRIS-HCL (pH8.8) (from Sigma-
Aldrich) 
60 μl 10% Sodium dodecyl sulfate (SDS) (from 
Sigma-Aldrich) 
20μl 20% Ammonium persulphate (APS) (from 
Sigma-Aldrich) 
4.5 μl TEMED 
4 % Stacking gel For 1 gel: 
300 μl 30 % Polyacrylamide 
600 μl dH20 
1.5 ml 0.5 M TRIS-HCL (pH6.8) 
25 μl 10 % SDS 
10 μl 20 % APS 
2.5 μl TEMED 
Running buffer 100 ml TRIS/glycine/SDS mixed with 900ml 
dH20 
5 X Lamaelli sampling buffer 4 ml 1.5 M TRIS-HCL pH 6.8 
10 ml glycerol 
5 ml -mercaptoethanol (from Sigma Aldrech) 
2 g SDS 
1 ml 1% bromophenol blue (from Sigma 
Aldrech) 
His ladder protein standard (from ProtoMetrics)  
PageRuler Prestained protein ladder, 10-180 











Table 14: Buffers for western blotting 
Buffers/antibodies Components 
Transfer buffer 200 ml 100 % Methanol 
100 ml TRIS/glycine (from Geneflow) 
Mixed with 700 ml dH2O 
Blocking buffer 2.5 g non-fat milk powder (from BIORAD) 
dissolved in 50 ml PBS 
Electrophoresis buffer 100 ml 10 X TRIS/glycine/SDS (from 
Geneflow) 
900 ml dH2O 
Phosphate buffer saline (PBS) + Tween 1 X PBS dissolved in 1 L dH2O 
0.2 % Tween-20 (from Sigma-Aldrich) 
EZ-ECL Solutions A and B (from Geneflow)  
 
Table 15: Reagents for Coomassie staining 
Reagents Components 
Instant Blue protein stain (from Expedeon)  
 
Table 16: Buffers and reagents used for biotinylation of avi-tagged proteins 
Buffers/ reagents Components 
Biotin ligase reaction buffer 2.5 mM MgCl (from Sigma-Aldrich) 
10 mM Adenosine triphosphate (ATP) 
Bir500 biotin ligase - volume depends on protein 
concentration. (from Avidity) 
0.3 mM D-Biotin (from Sigma-Aldrich) 
1X PBS 
Dissolved in 500 μl dH2O 
Bir500 biotin ligase (from Avidity)  
 
Table 17: Reagents used for biotin quantitation 
Reagent Components 
HABA/avidin reagent (from Sigma Aldrich) Lyophilised HABA/avidin reagent was dissolved 
in 10 ml deionized water, yielding a solution at 
pH 7.3 with components: 
0.3 mM HABA 
0.45 mg/ml avidin 
0.3 M NaCl 
0.01 M HEPES 
0.01 M MgCl2 









Table 18: Buffers and reagents used for indirect enzyme-linked immunosorbent assays (ELISA). 
Buffers/ reagents Components 
Dilution buffer 1 X PBS (pH 7.4) 
0.15 μg/ml Bovine serum albumin (BSA) (from 
Sigma-Aldrich) 
Dissolved in dH2O 
Blocking buffer 1% BSA 
1% non-fat milk powder 
1 X PBS 
Dissolved in dH2O 
Streptavidin-alkaline phosphatase solution 40 μg/ml streptavidin-alkaline phosphatase 
(from Sigma-Aldrich) 
1 X PBS 
Dissolved in dH20 
Streptavidin solution 1 mg/ml streptavidin (from Sigma-Aldrich) 
Dissolved in dH2O 








Table 19: Buffers, reagents and media for phage display and phage ELISA 
Buffers/reagents/media Components 
Naïve llama VHH-expressing phage library IP protected by UCB 
Wash buffer PBS (pH7.4) + 0.1 % Tween 
Blocking buffer PBS (pH7.4) + 3 % Bovine serum albumin 
(BSA) 
Milk buffer PBS (pH7.4) + 3 % BSA + 3 % skimmed milk 
Elution buffer 0.1 M HCl 
Neutralization buffer 1 M TRIS (pH8) 
PEG solution 20 % Polyethylene glycol + 2.5 M NaCl 
2TY media 100 μg/ml carbenicillin 
50 μg/ml Kanamycin 
1 % Glucose 
LB agar plates LB agar (manufactured by UCB) 
100 μg/ml carbenicillin 












Table 20: Buffers and reagents used for photoaffinity cross-linking 
Buffers/ reagents Components/ properties 
DDM solubilisation buffer 1% (w/v) dodecyl-beta-maltoside (from 
Anatrace) 
10 mM TRIS-HCL (pH6.8) 
50 mM NaCl 
1 mM CaCl2 
0.1 mM phenylmethylsulfonyl fluoride (PMSF) 
Roche protease inhibitor cocktail (1 tablet/ 10 
ml). 




Table 21: List of antibodies and phage for recombinant protein detection 
Antibody Company Product code Epitope 






7076 Mouse IgG 
Anti-FLAG rabbit IgG Neo Biotech NB-22-8776 DYKDDDDK 
Anti-avi-tag mouse 
IgG 
Neo Biotech NB-22-15720 GLNDIFEAQKIEWHE 
Anti-HA mouse IgG Cell Biolabs AKR-006 YPYDVPDYA 
HRP-linked goat anti-
rabbit IgG 
Southernbio 4030-05 Rabbit IgG 
HRP-conjugated anti-
His mouse IgG 
N/A (Given by UCB) N/A HHHHHH 
Anti-phage (M13) 
mouse IgG 
N/A (Given by UCB) N/A M13 bacteriophage 
Fab2838-conjugated 
M13 phage 
Made in UCB N/A A2AR 
ScFv2838-conjugated 
M13 phage 
Made in UCB N/A A2AR 
Helper (control) M13 
phage 













Table 22: List of ligands and their properties  






A2AR Stock is in 50 % ethanol 




ZM241385  TOCRIS 
Bioscience 






























CGRPR Made stock concentration in DMSO at 10-3 M. 















2.2.1: Plasmid constructs 
The deglycosylated human adenosine 2a receptor (dghA2AR) gene construct was obtained from Fraser 
et al. 2006. Expression of dghA2AR was done similarly to Fraser (2006). A mutation was induced to 
replace Asparagine154 to Glutamine to prevent hyperglycosylation, without affecting receptor 
pharmacology, when expressing the construct in Pichia pastoris (Jamshad et al. 2015). The construct 
was ligated into pGEM-T Easy Vector (Promega) using EcoRI and NotI restriction enzymes and was 
amplified in Escherichia coli (DH5-alpha). The construct was excised out of pGEM-T Easy Vector 
using the same restriction enzymes and was inserted into an upstream 10x His tag (Fraser 2006), using 
the primer 
‘CGAGAAAAGAGAGGCTGAAGCTCATCATCATCATCATCATCATCATCATCATGAATTCAT
GCCCATCATGGGC’. The pPICZα A-dghA2AR construct was expressed in X33 Pichia pastoris.  
pPICZα A consists of an alcohol oxidase (AOX1) promoter region which is induced by methanol for 
gene expression.  A stop codon was incorporated downstream the hA2AR construct to prevent 
incorporation of downstream c-myc and polyhistidine. A modified version of the dghA2AR, containing 
a C terminal linker glycine-serine (GS) and an avi-tag was made, which was termed dghA2AR-A. The 
cDNA sequence was obtained from Fraser (2006) and was modified in the software ‘Gene designer’ and 
was translated in ‘Expasy translate’. ‘Gene designer’ was also used to confirm the sequence being in the 
correct frame upon expression. The sequence was sent to Genscript for codon optimization. The gene 
construct was ligated into pPICZα A, using EcoRI and NotI restriction sites, by Genscript and was 
sequenced by the company. Human CD81 tetraspanin was also expressed in Pichia pastoris. The protein 
construct was the same construct used in Jamshad et al. (2008) and was provided by Hoor Ayub. Human 
CD81 was ligated into the pPICZB vector, which also allowed protein expression via AOX1 













Figure 23| A) cDNA sequence of the deglycosylated human A2AR (dghA2AR) construct, made by Fraser 
(2006). Text highlighted in red are the EcoRI and NotI restriction sites. The cDNA was sequenced by 
Dr Sarah Routledge prior to use. B) cDNA sequence of the deglycosylated, avi-tagged human A2AR 
(A2AR-A) construct. Text highlighted in red are the EcoRI and NotI restriction sites. Text highlighted in 
blue represents the decahistidine-tag sequence. Text highlighted in purple represents the TEV cleavage 
sequence. Text highlighted in green represents the 15 amino acid linker (GS) sequence. Text highlighted 
















































Figure 24| A) Plasmid map of the pPICZ A vector. EcoR1 and NotI were the restriction sites used to 
ligate the dghA2AR and A2AR-A cDNA sequences into the vector. The PmeI restriction site was used to 
linearise the vector for genome integration into Pichia pastoris. Zeocin resistance is encoded by the 
BleoR sequence of the vector. Snapgene viewer was used to illustrate the pPICZ A vector.  B and C) 
Illustrations of the A2AR constructs which were ligated into the vector backbone. EcoRI and NotI were 
the restriction site added to the 5’ and 3’ positions of the cDNA construct. His represents the deca-his-
tag. GS is the 15 amino acid linker sequence composed of glycine and serine. Avi is the avi-tag. Panel 






The pcDNA3.1- T8-HA-CLR construct was provided by Dr. S. M. Foord (from Glaxo-Smith Kline, 
Stevenage UK). The vector pcDNA3.1- was modified to containing the T8 signal peptide, taken from 
the T-cell surface glycoprotein CD8 alpha  chain (T8) signal peptide sequence, and the hemagglutinin 
(HA)-tag sequence (Wootten et al., 2013). The CALCRL DNA sequence, encoding the CLR, was 
ligated into the vector using EcoRI and NotI restriction enzymes (Wootten et al., 2013). The signal 
sequence of the CALCRL was removed prior to ligation in order to incorporate the upstream T8 signal 
peptide sequence and the HA-tag. This was to increase surface expression of the CGRPR. The T8-HA-
CLR construct was used for mutagenesis experiments and was sequenced by Eurofins Genomics, using 
primers targeting the T7 and BGH sequences of the vector backbone. A modified version of the T8-HA-
CLR, containing a C terminal strep II-tag and an avi-tag was made, which was termed CLR-A. The wild 
type CALCRL gene sequence was modified in the software ‘Gene designer’ and was translated in 
‘Expasy translate’. ‘Gene designer’ was also used to confirm the sequence being in the correct frame 
upon expression. The sequence was sent to Genscript for codon optimization. The gene construct was 
ligated into pcDNA3.1+, using EcoRI and NotI restriction sites, by Genscript and was sequenced within 
the company. The pcDNA3.1+-RAMP1 contained the RAMP1 cDNA sequence with an upstream N 





Figure 25| cDNA sequence of A) T8-HA-CLR and B) CLR-A. Sequences highlighted in red indicate 
the EcoRI and NotI restriction sites. Sequences highlighted in green indicate the 24 amino acid cleavable 
T8 signal peptide. The T8 signal peptide replaced the endogenous signal peptide of the CLR. Sequences 
highlighted in pink indicate the hemagglutinin (HA) tag sequence. The sequence highlighted in blue 
represents the strep II tag sequence. The sequence in yellow is the avi-tag sequence. Sequences were 























































Figure 26| The cDNA sequence of the FLAG-tagged RAMP1. The FLAG-tag sequence is highlighted 
in yellow. The start codon is highlighted in green and the stop codon is highlighted in red. Sequence 




































Figure 27| A) Plasmid map of the pcDNA3.1+ vector. EcoR1 and NotI were the restriction sites used 
to ligate the CLR-A sequence into the vector. Ampicillin resistance is encoded by the AmpR sequence 
of the vector. Snapgene viewer was used to illustrate the pcDNA3.1+ vector.  B-D) Illustrations of the 
constructs which were ligated into the vector backbone. T8 represents the signal peptide. HA represents 
the HA-tag. Avi is the avi-tag. ST is the streptavidin II tag. FLAG represents the FLAG-tag Panel B 







2.2.2: Diagnostic restriction digest using DNA electrophoresis 
Purpose of the methodology 
To confirm the presence of a recombinant gene construct within a plasmid vector, a diagnostic digest 
can be performed to separate the gene construct from the vector using two restriction sites. The digested 
DNA can be separated on an agarose gel, based on the size of the DNA fragments and the electrical 
charge applied to the gel. The ribose-phosphate backbone of DNA gives the molecule a net negative 
charge, allowing the DNA fragments to migrate down the agarose gel, towards the positively charged 
electrode (Lee et al., 2012).As the DNA mass to charge ratio is the same amongst different sized 
fragments, the digested DNA can be separated based on its size, where smaller fragments move faster 
than larger fragments (Lee et al., 2012). The RedSafe nucleic acid staining solution can be applied to 
the gel, which binds to the DNA similarly to ethidium bromide, in order to detect the DNA fragments 
using excitation at 514 nm. Ethidium bromide can insert itself between adjacent nucleotide base pairs 
of a DNA strand, therefore migrating with the DNA fragments for visualisation. The RedSafe variant 
has a lower mutation rate than ethidium bromide, according to the manual supplemented by the kit. 
Procedure 
A restriction digest was set up using: 1 l of the restriction enzymes in table 3, 2 l NEB buffer 3.1, 
500 ng of the DNA construct. The digestion reaction was topped up to 20 l using dH2O. The digestion 
was incubated at 37°C for 1 hour. After the reaction, 4 l of the digested DNA was mixed with 12.5 l 
1 X TAE buffer and 3.5 l 6 X bromophenol blue loading die. 
 A 1% agarose gel was made by dissolving 0.5 g of Hi-res Standard Agarose in 50 ml 1 X TAE buffer. 
The solution was heated in a conical flask until all the agarose particles were dissolved. The agarose gel 
was cooled down to approximately 50°C.  2.5 l of RedSafe was pipetted into the agarose solution, 
which was subsequently poured into a gel casting tray. A comb was inserted into the gel to create wells 
for loading the digested DNA. Once the gel was solidified and the comb was removed, the gel was 
placed into a benchtop electrophoresis tank. 1 X TAE buffer was used to fill the tank, submerging the 
agarose gel. The digested DNA: loading dye mixture and 10 l of the DNA ladder was pipetted into the 
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wells of the agarose gel, which was ran at 80 volts and 60 amps until the dye reached the end of the gel. 
The gel was visualised in the Syngene G:Box, using UV light to highlight the positioning of the digested 
bands in relation to the size of the DNA ladder.  
2.2.3: Competent E.coli generation and transformation. 
Purpose of methodology 
In order to expand clones of DNA constructs, E.coli was used to generate a sufficient amount of DNA 
for studies involving cell transfection. E.coli can also be transformed with PCR products to increase the 
yield of DNA as well as to ligate the linear PCR products into a circular structure via DNA ligase (Adam 
et al., 1999; Sriskanda and Shuman, 2001). Another useful feature of E.coli is their ability to methylate 
chromosomal and plasmid DNA (Marinus and Lobner-Olesen, 2014). This feature is useful for PCR-
based experiments, where methylated template DNA, obtained from transformed E.coli, can be digested 
using DpnI, leaving the unmethylated PCR products intact (Li and Mullins, 2002). 
Prior to transforming E.coli with DNA, the cells must be made competent. In this project, chemically 
competent E.coli cells were generated using a rubidium and calcium based method, similarly to Green 
and Rogers (2002) protocol. Both rubidium and calcium have been shown to enhance the transformation 
efficiency of bacteria due to their physiochemical properties affecting the membrane of E.coli, as well 
as the temperature imbalances during the process (Asif et al., 2017). Once made competent, the cells 
were transformed with DNA constructs, where heat shocking the bacteria in a calcium rich environment 









E.coli strain, XL Gold, was streaked onto an LB agar plate without antibiotics. The plate was left to 
incubate at 37°C overnight. A single colony of E.coli was grown overnight in a starter culture of 5 ml, 
in LB broth, at 37°C in a shaking incubator, shaking at 200 rpm. 1 ml of the starter culture was 
transferred to a flask containing 30 ml of LB at the same conditions overnight. 8 ml of the culture was 
transferred to a 2 L flask containing 200 ml LB and was incubated at 37°C , shaking at 200 rpm until an 
OD550 of 0.6 was achieved. The culture was decanted into 50 ml Falcon tubes, which was chilled at 4°C 
for 15 minutes. The tubes were spun down at 3000 g for 20 minutes at 4°C, in a pre-cooled centrifuge. 
The supernatant was drained from the cell pellet, which was resuspended in transformation buffer 1 (16 
mls per 50 ml Falcon tube). The cell pellet was resuspended by repeated pipetting. The tubes were 
incubated for 1 hour, followed by centrifugation at the same settings. The transformation buffer 1 
supernatant was removed from the cell pellet. All the cell pellets were resuspended in transformation 
buffer 2, where the total volume of the buffer and cell pellet was 6 ml. 50 μl aliquots were made using 
the cell-transformation buffer 2 mixture. The aliquots were stored in -80°C until they were ready for 
transformation. 
For transformation, the competent cell aliquots were thawed on ice. 1pg-100ng of plasmid DNA was 
mixed with a competent cell aliquot via repetitive pipetting. The tubes were left on ice for 30 minutes. 
The DNA-cell mixture was then heatshocked at 42°C for 45 seconds. The tubes were then placed on ice 
for 2 minutes. 1 ml of LB was added to the tubes, which were incubated at 37°C on a roller for 1 hour. 
The transformed bacteria were plated out onto LB agar with ampicillin to select for transformants. The 
transformants were grown in LB media with ampicillin at 37°C shaking at 200 rpm . The cells were then 







2.2.4: Expressing the A2AR and CD81 in Pichia Pastoris 
Purpose of methodology 
To generate a high yield of recombinant protein for downstream experiments, the P.pastoris expression 
system was used. Prior to introducing exogenous DNA to P.pastoris, the yeast cells were made 
electroporation-competent by weakening the cell wall, using the methodology derived from Lin-
Cereghino et al. (2005). The pPICZA vector containing the gene construct was also linearized at the 
PmeI restriction site in order for the exogenous plasmid to integrate into the genome of the yeast cells 
(Vogl et al., 2018). Multiple casettes of the gene construct can be integrated into P.pastoris to increase 
the yield of protein upon yeast expression in methylotrophic conditions (Vogl et al., 2018). Once the 
exogenous plasmid has been linearised, electroporation was used to quickly insert and integrate the DNA 
into the yeast genome.  
In order to express the protein in the yeast expression system, the cells were subjected to media 
containing methanol in order to induce the expression of the protein via induction of the AOX1 promoter 
(Chang et al., 2018). After growing the cells to an adequate amount, with the recombinant protein 
expressed, the cells were homogenized to obtain the membrane containing the membrane proteins. The 
cell wall of the yeast must first be broken in order the harvest the membranes, requiring the C3 
homogenizer to apply a high pressure to the cells (Routledge et al., 2016). Homogenization using the 
C3 homogenizer has a cell wall breaking efficiency of over 90% when applying 30,000 psi of pressure 









2.2.4.1: Creating competent Pichia pastoris cells for transformation 
A 20 ml starter culture was prepared in YPD media in a baffled flask, with one colony of a Pichia 
pastoris strain, plated on YPD agar without antibiotics. The starter culture was grown overnight at 30°C 
in a shaking incubator, rotating at 220 rpm. 3 ml of the starter culture was incubated into 500 ml of YPD 
media, which was incubated at 30°C at the same rotation speed until an OD600 of 0.8-1 was achieved. 
The culture was centrifuged at 3000 g for 10 minutes; the supernatant was removed and the cell pellet 
was resuspended in 100 ml of YPD + 0.02 M HEPES. 2.5 ml of 1 M DTT (filter sterilised) was applied 
to the culture slowly. The culture was then incubated at 30°C at 220 rpm. 400 ml of autoclaved dH2O 
(kept on ice) was added to the culture until 500 ml of total volume was reached. The cell culture was 
then centrifuged for 10 minutes at 3000 g, 4°C. The supernatant was removed and 500 ml of ice cold 
dH2O was used to resuspend the cell pellet.  The cells were centrifuged again at the same speed, 
temperature, time and the supernatant was removed and replaced with 250 ml of ice cold dH2O. The 
culture was centrifuged again at the same conditions, however the supernatant was replaced with 20 ml 
of 2 M sorbitol. The sorbitol-yeast culture was centrifuged at 3000 g, 10 minutes at 4°C. The supernatant 
was replaced with 1 ml of sorbitol. The cell pellet was also resuspended in solution and aliquoted into 
sterile 1.5 ml Eppendorf tubes. The tubes were stored in -80°C. 
2.2.4.2: Pichia pastoris transformation and growth 
pPICZα A protein constructs were linearized using PmeI. The reaction was done in multiple 1.5 ml 
Eppendorf tubes to achieve 10000 ng of linearized plasmids for transformation. The reaction conditions 
for each tube was: 20 μl cutsmart buffer, 4 μl PmeI, 30 ul DNA (4000 ng of DNA), dH2O. The reaction 
was incubated at 37°C for one hour. The linearized plasmid was then purified using the DNA mini-spin 
purification kit (from Qiagen).  The plasmid was then transformed into competent X33 wild type Pichia 
pastoris. 100 ng of the purified, linearized plasmid construct were mixed with 40 μl of competent yeast 
cells on ice. The mixture was transferred to a 0.4 mm electroporation cuvette and were left to incubate 
on ice for 5 minutes. The cell-DNA mixture was electroporated at 1800 v and 1 ml of cold 0.5 M sorbitol. 
The cell-DNA mixture was left to incubate for 1 hour at 30°C. The cells were then plated in YPD + 
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sorbitol plates with increasing concentrations of zeocin to select colonies with a high copy number of 
the plasmid. 
A single colony of transformed Pichia pastoris, expressing the A2AR construct, was incubated in a 
baffled flask containing 50ml of BMGY overnight at 30°C and shaking at 220 rpm within an incubator. 
After overnight culture, the yeast were pelleted and reincubated in BMMY, which contained methanol 
to induce hA2AR expression. The incubation was at 30°C in a shaking incubator set at 220 rpm. The 
yeast were grown in BMMY for 48 hours where at 24 hours, methanol was added to the culture at a 
final concentration of 2%. Once the 48 hour growth was complete, the culture was decanted into 500ml 
centrifuge tubes. The Pichia were pelleted down and were decanted into sterile plastic bags, which were 
then stored in -80°C. 
2.2.4.3: Extracting Pichia pastoris membranes 
In order to extract the membrane, containing the A2aR, the cell wall had to be broken. The Avestin 
EmulsiFlex C3 homogenizer was used to break the cell wall using high pressure. Prior to operating the 
C3 homogenizer, the extracted yeast pellet was thawed. An equal weight to volume ratio of breaking 
buffer was added to the yeast pellet and Roche protease inhibitor cocktail tablets were applied to the 
sample to prevent A2aR degradation. The sample was stored and mixed in 4°C for 30 minutes. More 
breaking buffer was applied to the sample if the sample remained viscous. Meanwhile, the C3 was 
washed and primed using 70% ethanol, 0.5M sodium chloride and breaking buffer. The sample was then 
cracked in the C3 homogenizer for 20 minutes. The oxygen tank was set to 80 psi and the air regulator 
was set to 40 psi. Around 22000-25000 bar pressure was used to crack the yeast cell walls. After 20 
minutes, the samples were decanted into centrifuge tubes. 
The cracked Pichia pastoris was spun down at 5000 RPM (or 3000 g) for 20 minutes using a JA 25.50 
rotor. The supernatant was decanted into Beckman coulter centrifuge tubes and were spun down at 
100,000 g for 1 hour at 4°C in rotor type Ti70. The membrane was pelleted at the bottom of the tube 
and the supernatant was removed. The pellet was homogenized with buffer A to yield a final 
concentration of 40 mg/ml. The reconstituted pellet was kept in -80°C. 
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2.2.5: Mammalian cell culture and transfection 
Procedure 
Human embryonic kidney (HEK) 293T cells were stored in liquid nitrogen in 90% DMEM, 10% DMSO 
in 500 μl aliquots. An aliquot was thawed at room temperature and was inserted into a T-25 flask with 
5 ml DMEM, 10% FBS, 1 X penicillin streptomycin (complete DMEM). Once the cells were 80-90% 
confluent, normally taking two days to reach high confluency, the cells were passaged into new flasks 
at a 1:5 or a 1:10 dilution, depending on when the cells were being used for an assay. The instructions 
supplied in the Thermofisher Lipofectamine 3000 kit were followed to transiently transfect the cells. 
2.2.6: SMA copolymer preparation and membrane solubilisation 
Procedure 
The SMA copolymer was prepared by hydrolysing styrene-maleic anhydride under refluxing conditions, 
as described in Lee et al. (2016). The SMA buffer was prepared using 5% (w/v) SMA, dissolved in 
Buffer A. 
The homogenized yeast membranes were solubilised using the 5% SMA buffer at a 1:1 ratio, where the 
final concentration of the membrane was 40 mg/ml and the final concentration of the SMA copolymer 
was 2.5% (w/v). The sample was vortexed and inverted until the polymer was dissolved. The sample 
was mixing on a shaker at room temperature for 2 hours for SMALP solubilisation. Once the 
solubilisation process was complete, the sample was sonicated for three 15 second pulses. The sample 
was then spun down at 100,000 g for 45 minutes to pellet the membrane. The SMALP proteins remain 
in the supernatant due to their solubility and were separated from the un-solubilised membrane pellet. 
The HEK293T cells expressing the CGRPR were homogenized using the Polytron tissue-grinder 
homogenizer. The cell suspension was placed on ice and homogenized at 15 second bursts, 6 times with 
a 10 second rest interval. After homogenization, the cell suspension was centrifuged at 100,000 g to 
pellet the cell membrane and the supernatant was removed. The membrane was resuspended in Buffer 
A, with the concentration of the membrane being 80 mg/ml. The membrane solution was solubilised 
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using the 5% SMA buffer at a 1:1 ratio, where the final concentration of the membrane was 40 mg/ml 
and the final concentration of the SMA copolymer was 2.5% (w/v). The membrane was solubilised for 
2 hours at room temperature on a shaker. The sample was centrifuged at 100,000 g for 20 minutes. The 
SMALP supernatant was separated from the un-solubilised membrane pellet. 
2.2.7: Protein purification, dialysis and concentration 
Purpose of methodology 
In order to separate the non-specific, SMA-solubilised membrane proteins from the A2AR and CD81, 
the histidine-tags fused to the recombinant membrane proteins were isolated using nickel-nitrilotriacetic 
acid agarose (Ni2+-NTA) resin. The nickel ions are captured onto the chelating nitrolotriacetic acid 
agarose beads (Spriestersback et al., 2015). The Ni2+-NTA can be applied to the SMALP samples in 
order to bind the deca-histidine-tagged protein SMALPs to the resin. The thin membrane of the benchtop 
columns can capture the protein-bound Ni2+-NTA whilst allowing the unbound and washed material to 
flow through the column. Although Ni2+-NTA purification is a popular purification strategy, non-
specific protein binding can occur on the resin itself; however this can be eliminated by including low 
concentrations (10-50 mM) of imidazole in the washing buffers (Bornhorst and Falke, 2000). After 
washing the resin, the specific SMALPs can be eluted by increasing the concentration of imidazole 
above 100 mM, where imidazole competes against the his-tag to bind the nickel ions (Bornhorst and 
Falke, 2000). 
Procedure 
Ni2+-NTA was used to purify the A2AR through the decahis-tag, fused to the receptor. Ni2+-NTA (from 
Qiagen) was supplemented in ethanol at a 1:1 ratio. Ni2+-NTA was spun down at 1000 g for 1 minute 
and the supernatant was aspirated off. Washing buffer was applied to the Ni2+-NTA in order to remove 
residual ethanol and to prime the gel beads for A2AR binding. The Ni2+-NTA was centrifuged at 1000 g 
for 1 minute and the washing buffer was removed. This was repeated three times. After washing, the 
Ni2+-NTA was applied to the yeast membrane SMALP sample, which was left to incubate at 4C on a 
plate shaker overnight. 
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The next day, benchtop purification columns were equilibrated using 2 column volumes of wash buffer 
and the flow-through was discarded. The Ni2+-NTA SMALP sample was poured into the purification 
column. The flow-through was collected and labelled as unbound. 20 column volumes of washing buffer 
was used to wash the Ni2+-NTA SMALP to remove non-specific Ni2+-NTA protein interaction. The 
flow-through was collected for analysis. 1 ml of elution buffer was used 10 times to elute the A2aR-
SMALP from the nickel resin. Elutions were collected in ten 1.5ml Eppendorf tubes or one universal 
25ml tube. The A2aR-SMALP was then centrifuged in vivaspin columns, molecular weight cut off 
(MWCO) 30000 (from GE healthcare life sciences) at 2500 RPM for 20 minutes to remove the imidazole 
from the sample. Dialysis buffer was applied to the A2AR-SMALP and the sample was centrifuged again 
at the same speed. This was repeated three times in order to remove the imidazole. After the third dialysis 
round, the sample was spun down to obtain the appropriate concentration of protein. 
For X-ray radiolytic footprinting, the TRIS and HEPES based buffer systems were replaced by a sodium 
phosphate based buffer system. The dialysis buffer contained a low salt concentration in order for a 
successful protein irradiation and mass spectrometry. 
2.2.8: Identifying recombinant proteins via SDS-PAGE 
Purpose of methodology 
SDS-PAGE was used to detect proteins based on their molecular weight and the tags fused to them. The 
initial step was to make the polyacrylamide gel. The 30% Protogel acrylamide was stocked in liquid 
form prior to casting the gels. When preparing the stacking and separating gels, the polyacrylamide was 
polymerised when the redox initiators, TEMED and APS were applied to the gel mixtures (Abu-Thabit, 
2017). APS initiations the polymerization reaction of acrylamide and bis-acrylamide whilst TEMED 
lowers the activation energy of APS decomposition for the reaction to occur at room temperature (Abu-
Thabit, 2017). As the migration of proteins through the polyacrylamide gel requires an electric field, the 
net charge of the protein molecules must be uniform and of the same charge if they were to be separated 
based on size only. SDS is therefore an essential component of SDS-PAGE, where it carries a highly 
negative charge and can coat the proteins (Jensen, 2012). SDS also acts as an anionic detergent, 
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denaturing the protein tertiary structure, rendering the proteins linear (Jensen, 2012). The resulting 
linearised, negatively charged proteins can travel in a cathode-to-anode direction. As proteins differ in 
their size, they can be separated by the speed of their migration (Jensen, 2012). 
Once the electrophoresis was completed, the gel can be subjected to western blotting to identify the 
A2AR and CD81 in the membrane and SMALP samples. The migrated proteins can be transferred onto 
an activated membrane made of polyvinylidene difluoride (PVDF). A primary antibody can be used to 
target the fusion tags of the protein and a second antibody, such as the HRP-linked secondary antibodies, 
can be used to target the primary antibody. The HRP enzyme can be used to catalyse the oxidation of 
luminol into the chemiluminescent product, which can be detected by a low-intensity light emission 
(Yang et al., 2015) The blocking buffer is essential in western blotting to remove non-specific binding 
sites, which may be present on the membrane (Jensen, 2012).  
InstantBlue coomassie staining can be used to detect the purity of the purified SMALP samples. The 
gels, post electrophoresis, were stained in InstantBlue staining solution in order to detect all the proteins 
in a sample. The coomassie dyes, R-250 and G-250, interact with the proteins in a polyacrylamide gel, 
however the exact interactions between the dye and protein is not fully elucidated. It is thought that the 
dyes interact with the proteins through van der Waals and hydrophobic interactions (Chevalier, 2010). 
Once the gel has been stained, the gel can be washed and the bands are visible without the requirement 
of a light source. A disadvantage of coomassie staining is its low sensitivity when compared with 
western blotting and silver staining (Chevalier, 2010). However the stained samples can be recovered 







The 12% separating and 4% stacking gels were made according to table 14. The 12% separating gel was 
loaded into a 1.0 mm gel cassette until ¼ away from the top. 1 ml of 100% isopropanol was added to 
the top of the separating gel to help settle the gel. The gel was left to set for 20 minutes. After 20 minutes, 
isopropanol was washed off the gel using dH20. The 4 % stacking gel was loaded into the cassette. A 
1.0 mm comb was inserted into the cassette to form the wells. The gel was left to set for 15 minutes. 
Meanwhile, 5 μl of 5X Lamaelli sampling buffer was added to 15 μl of protein samples. After gel was 
set, the cassette was inserted into buffer tank. Running buffer was poured into the chamber of the cassette 
until full. Running buffer was also poured around the cassette. The comb was removed from the cassette 
and samples were loaded into the wells, as well as the his-ladder and protein ladder (10-180 kDa). 120V 
was used to run samples down the gel for approximately 1 hour. 
2.2.8.1: Western blotting 
Procedure 
Whilst samples were running down an SDS-PAGE gel, PVDF membrane (0.2mm) were dipped in 100% 
methanol and were then washed in transfer buffer for 30 minutes. After 1 hour of running samples, the 
gel was placed on top of four filter cards and afiber pad. The PVDF membrane was placed on top of the 
gel and four more filter cards and another fiber pad was placed on top of the membrane to form a 
sandwich. The sandwich was placed in a transferring cassette, which was placed in a buffer tank. 
Transfer buffer was poured into the tank until full. 100 V was used to transfer proteins and ladders from 
the gel to the membrane for 1 hour. After 1 hour, membrane was placed in 2.5% blocking buffer 
overnight at 4°C. The next day, the milk buffer was removed from the membrane. Anti-his mouse IgG 
antibody was pipetted into fresh 2.5% blocking buffer at a 1/5000 dilution. The antibody-blocking buffer 
solution was poured onto the membrane, which was then placed on a shaking incubator for 1 hour at 
room temperature. After an hour, the antibody solution was removed from the membrane. The 
membrane was washed in PBS + 0.2% Tween for three minutes, three times. An anti-mouse HRP-linked 
goat IgG antibody was prepared in blocking buffer at 1/5000 dilution. After the final wash, PBS + Tween 
was removed from the membrane. The HRP-linked goat anti-mouse antibody milk solution was poured 
onto the membrane, which was then placed on a shaking incubator for 1 hour at room temperature. The 
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membrane was washed with PBS + 0.2% Tween three minutes three times. EZ-ECL solutions A and B 
were mixed at a 1:1 ratio and was poured onto the membrane. The membrane was shaken on a shaker 
for 10 minutes. Membranes were visualised in Syngene G:Box. 
2.2.8.2.: Instant Blue (Coomassie) staining of SDS-PAGE gel. 
Procedure 
After samples ran down the SDS-PAGE gel, 20 ml of Instant Blue staining solution was pipetted onto 
the gel. The gel was shaken on shaker for 30 minutes. Residual Instant Blue staining solution was 
washed off with dH20. The gel was visualised in Syngene G:Box. 
2.2.8.3: Determining the concentration of a receptor-SMALP sample 
Procedure 
The concentration of a purified protein-SMALP sample was determined by electrophoresis of increasing 
concentrations of bovine serum albumin (BSA) (0.125-1.25 mg/ml) and 15 ul of the protein-SMALP.  
5 ul of lamelli sampling buffer was added to the BSA concentrations and the protein-SMALP sample to 
achieve a final volume of 20 ul. The sample and the BSA concentrations was loaded into the SDS-PAGE 
gel, which ran at 120 v for approximately one hour. The gel was then stained with Instant Blue coomassie 
stain for 30 minutes. Once bands were visible, an image was taken, which was uploaded onto the 
software ‘Image J’. The density of the BSA concentrations were analysed and a linear line of best fit 









2.2.9: Radioligand binding assay 
2.2.9.1: Competitive radioligand binding 
Procedure 
Various concentrations of ZM214385 were made up in DMSO. The concentration range was between 
0.001 μM to 1 mM. 100% DMSO was also used as a control to identify maximum A2aR binding when 
using radioligand. The radioligand [3H]ZM214385 was made up at a concentration of 100 nM.. Prior to 
the ligand binding reaction, adenosine deaminase was added to the A2AR sample to remove adenosine 
from the A2AR binding site. 
For membrane radioligand binding, 5 μl of different concentrations of ZM214385 and DMSO were 
pipetted into respective assay tubes. 5 μl of 100 nM [3H]ZM214385 was pipetted into all assay tubes. 
500 μl of membrane (at 1mg/ml) containing A2AR were pipetted into each tube. The tubes were vortexed 
and were left to incubate at 30°C for 30 minutes in order for ligands to bind A2AR. After 30 minutes, the 
assay tubes were spun down at 14000RPM on a benchtop centrifuge for 7 minutes to pellet the 
membrane. The supernatant was washed away with water to remove unbound ligands. Assay tubes were 
left to air dry for 1 hour. After drying, 100 μl of soluene was added to each assay tube to solubilise the 
membrane pellet overnight. The next day, assay tubes were vigorously vortexed to dislodge and 
homogenize the pellet. 1 ml scintillant was added to each assay tube and the solution was shaken. Assay 
tubes were analysed in a scintillation counter. 
For soluble protein samples; experiments were done in a similar way to membrane proteins. The 
difference being the use of P-30 desalting columns (MWCO 30000) from Biorad to separate the unbound 
ligands from the protein. Columns were washed three times in dH20 and equilibrated once with binding 
buffer. 50-75 μl of soluble protein sample was loaded on to the desalting columns and were spun at 1000 
g for 4 minutes to remove unbound ligands. 1 ml scintillant was added to each assay tube and the solution 




The Cheng-Prusoff equation: Ki = IC50 / 1 + ([R] / KdR) was used to calculate the pKi of ZM241385 
(Cheng, 2001). Ki is the dissociation equilibrium constant of an inhibitor/antagonist, which was 
converted to a negative logarithm (pKi). The logIC50 was obtained by identifying the log concentration 
(M) of ZM241385 to occupy half of the receptors (half of Bmax). [R] represents the concentration of 
the radioligand and KdR represents the Kd affinity of the radioligand. 0.34 nM was the Kd of ZM241385, 
when binding to the dghA2AR construct expressed in Pichia pastoris (Fraser, 2006).   
2.2.9.2: Calculating the recovery of ZM241385-binding dghA2AR-SMALPs 
A single point concentration radioligand binding assay was used to assess the binding in membranes 
and SMALPs, using 1 nM [3H]ZM241385 and either 10 M ZM241385 or DMSO, to identify total and 
non-specific binding. The binding methodology for membranes and SMALPs is the same as chapter 
2.2.9.1. To calculate the recovery of ZM241385-binding dghA2AR-SMALPs, the specific binding of the 
SMALPs was compared to the specific binding of the receptor expressed in yeast membranes. The 
concentration of membranes used for SMA-solubilisation or radioligand binding were kept the same, in 
order to assess the proportion of active receptors recovered after solubilisation. The equation in figure 
28 was used to calculate recovery.  
 
 
Figure 28| Equation to calculate the recovery of ZM241385-binding dghA2AR-SMALPs after 








2.2.10: cAMP detection assay 
Purpose of methodology 
The LANCE cAMP detection kit (from Perkin Elmer) was used to determine whether the CGRPR and 
the CGRPR-A produced cAMP upon CGRP stimulation. This would demonstrate whether the receptors, 
transfected in the HEK193T cells, were functional. The kit utilises a FRET-based approach in 
determining the level the cAMP accumulation (Perkin Elmer [online], last accessed 23.11.2019). Alexa 
Fluor 647-conjugated anti-cAMP antibodies are occupied by either the intracellular cAMP produced by 
receptor stimulation or by the competitive Europium-labelled cAMP (Eu-cAMP) tracer complex, as 
shown in figure 29 (Perkin Elmer [online], last accessed 23.11.2019). The Eu-cAMP complex is 
composed of the biotin-cAMP and Europium-labelled streptavidin, which form a tight complex. When 
the Eu-cAMP complex is in contact with the anti-cAMP fluorescent antibody, a signal will be detected. 
However when the intracellular cAMP levels out-compete the Eu-cAMP complex, the signal will 
decrease (Perkin Elmer [online], last accessed 23.11.2019). For Gs-coupled GPCRs like the CGRPR, 
agonist stimulation will lead to a decrease in the fluorescent signal due to intracellular cAMP occupying 
the antibody binding site, instead of the Eu-cAMP complex (Liang et al., 2018; Perkin Elmer [online], 
last accessed 23.11.2019). This would suggest that upon agonist stimulation, the Gs-coupled GPCR 












Figure 29| An illustration demonstration the principle of the LANCE cAMP detection assay. When the 
Eu-cAMP complex, composed of biotin-cAMP and Europium-streptavidin, occupied the Alexa Fluor 
647-conjugated antibody, a fluorescent signal will be obtained upon light excitation. The Europium-
labelled cAMP tracer complex can be excited at 320 or 340 nm, resulting in an energy transfer from the 
europium, to the Alexa-conjugated antibody. The fluorescence emission can then be detected from the 
antibody, using a 665 nm emission filter. Intracellular cAMP can compete against the Eu-cAMP 
complex for the antibody binding site, where no energy transfer occurs between the intracellular cAMP 
and the antibody, resulting in no fluorescence emission. Diagram taken from (Perkin Elmer [online], 
last accessed 23.11.2019) 
 
Procedure 
The methodology was derived from the LANCE cAMP detection kit and Weston et al. (2015). The 
assay kit was used to analyse cAMP production in T8-HA-CLR and CLR-A transfected cells.  HEK293T 
cells were transiently transfected in six-well cell culture plates, using RAMP1 and either T8-HA-CLR 
or CLR-A. Control cells transfected with empty vector pcDNA3.1+ was prepared as a control. The 
lipofectamine 3000 kit (from Thermofisher) was used to transfect the cells. Two days post-transfection, 
the LANCE cAMP 384 kit was used to detect cAMP accumulation in the cells. A standard curve was 
generated by following the instructions provided by the kit. CGRP was the ligand used in the assay at 
different concentrations. Forskolin was used to assess the maximum production of cAMP from the cells 
of each condition, acting as a positive control and to normalize the data. The white 384-well Optiplate 
was used to analyse cAMP accumulation, using the Mithras plate reader with a 340 nm excitation filter 
and a 665 nm emission filter. 
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2.2.11: Fluorescence correlation spectroscopy 
Purpose of methodology 
FCS is a developing technique to study ligand-receptor interactions at a single molecule level and has 
recently been used to study pharmacodynamics in SMALPs (Kilpatrick and Hill, 2016). Traditional 
binding techniques, such as competitive radioligand binding, often study a population of receptors 
within a sample, where receptors can exist in multiple conformations and can oligomerize, impacting 
the pharmacological profile of the receptor. (Kilpatrick and Hill, 2016). FCS avoids the issue of studying 
a population of receptors by observing the pharmacology of a single ligand binding to a single receptor. 
The technique is also useful to study the pharmacology of receptors in a SMALP context, such as looking 
at the lipophilicity of a ligand and its non-specific interaction with the lipid bilayer. 
The procedure was in the optimization stage whilst studying CA200645 binding to the A2AR-SMALP, 
therefore the methodology will include the priming of the confocal microscope and related parameters 
to study the diffusion of SMALPs. The confocal microscope was placed on a shock absorbent desk and 
the room temperature was controlled, to prevent movement of the microscope and a change in 
temperature influencing the assay. The microscope was aligned and calibrated using the Cyanine-5 dye, 
which emitted a similar fluorescent wavelength as the CA200645 ligand. After the microscope was 
optimised for single molecule detection, the SMALPs were loaded into the coverslip, with the addition 
of the ligands. The data was recorded in real-time to observe the changes in the displacement of the 
CA200645 fluorescent ligand by ZM241385. 
Procedure 
Prior to FCS analysis, the room was set at a constant temperature of 25°C. The confocal microscope 
was calibrated prior to experimentation in order to align the machine to detect a specific detection 
volume. Stocks of the Cyanine-5 (Cy5) (from Amersham Biosciences) dye were made at 10 mM, (for 
calibration) and 500 nM (for alignment) concentrations, using 1 X HBSS buffer. The 633 laser of the 
ZEISS LSM510 Confocor2 confocal microscope was used to analyse the Cy5 fluorophore and the 
fluorescent ligand, CA200645. A 500 nM concentration of the Cy5 dye was made up using the 10 mM 
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stock solution with 1 X HBSS, in a final volume of 500 μl and 200 μl of the diluted dye was pipetted 
onto a coverslip, within a Nunc Lab-Tek 8-well chambered cover-glass (from Thermo Scientific, UK). 
The coverslip was 150 microns thick, so the bottom and the top of the coverslip was detected using the 
reflection of the laser beam path and the confocal volume was positions 200 m above the coverslip 
surface. A 10 nM concentration of the Cy5 dye was made using the 10 mM stock concentration, in 1 X 
HBSS in a total volume of 500 μl. 200 μl of the 10 nM Cy5 was pipetted onto a coverslip within a glass 
chamber and was used to adjust the parameters for FCS. The beam path was finely adjusted until 30000-
40000 photons was reached, representing counts per molecule. The structural translation parameter was 
checked to see if the value was 7. Once the microscopy was calibrated and adjusted, 180 μl of the 
SMALP samples were pipetted onto a coverslip within a glass chamber. 20 μl of the 500 mM stock 
CA200645 was pipetted onto the SMALP samples, which was then measured using the adjusted 
parameters for FCS. The cold ligand was added at an equal final concentration to observe displacement 
of CA200645. The Zeiss AIM 4.2 software was used to analyse the data. 
2.2.12: The biotinylation and immobilisation of avi-tagged SMALPs 
Purpose of methodology 
In order to produce antibody-based drugs using phage display on SMA-solubilised GPCRs, the SMALPs 
must be immobilised onto an ELISA plate to behave as a target antigen. NUNC maxisorp plates are 
routinely used in UCB to generate phage libraries against target antigens. The plates consist of a 
polystyrene surface, which is highly charged, having a high affinity for polar and hydrophilic proteins 
(ThermoFisher Scientific [online] last accessed: 25.11.2019). SMALPs were directly immobilised onto 
the NUNC maxisorp plates for phage display, however the immobilisation of the SMALPs was 
inefficient. In order to solve this problem, avi-tagged GPCR-SMALPs were made. Biotin ligase was 
used to biotinylated the avi-tag of the GPCR-SMALPs, in order to immobilise them onto streptavidin-
coated NUNC maxisorp plates (Li and Sousa, 2012). The BirA500 biotinylation kit from Avidity was 
used for avi-tag biotinylation, however the buffers provided by the kit were replaced by buffers which 
were suitable for GPCR-SMALP biotinylation, without causing SMA precipitation. The Biomix B 
component consisted of 100 mM ATP, 100 mM MgOAc and 500 M D-Biotin. Solutions of each 
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individual component of Biomix B were prepared so the magnesium concentration can be reduced and 
the ATP and Biotin content can be increased.  
Once the samples were biotinylated, ELISA assays were conducted to determine whether the 
biotinylated A2AR-A-SMALP can interact with streptavidin and to see whether the biotinylation of the 
A2AR-A-SMALP affected its immobilisation onto streptavidin-coated NUNC maxisorp plates. For the 
pNPP assay, the alkaline phosphatase-conjugated streptavidin catalyses the colourless pNPP into p-
nitrophenol, which produces a yellow colour, and a phosphate (Behera et al., 2017). For the OPD assays, 
the protein-SMALPs were immobilised onto streptavidin-coated ELISA plates, with the primary and 
secondary antibodies targeting the protein. The HRP component of the secondary antibodies oxidised 
the OPD, in the presence of H2O2 (Cao et al., 2017). The oxidised OPD produced a detectable yellow 
colour. 
The HABA/avidin biotin quantitation assay was used to determine how many biotin molecules were 
present per protein molecule. HABA and avidin form a complex, which forms an orange colour. In the 
presence of biotin, the HABA molecules dissociate from avidin, which forms a complex with biotin. 
The displacement of HABA reduces the absorbance at 500 nm and produces a yellow colour (figure 
30). The lower the absorbance, the more biotin molecules are present to outcompete HABA for avidin 







Figure 30| Principle of the HABA/avidin biotin quantitation assay. The HABA component of the 
HABA/avidin complex is displaced by biotin, reducing the absorbance of the solution at 500 nm. The 
reduction in absorbance correlates with the presence of biotin in the sample.  
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2.2.12.1: Biotinylation of receptor-SMALPs 
Procedure 
The Bir500 biotinylation kit was from Avidity. The instructions for biotinylation were performed with 
slight alterations to the biotinylation reaction buffer, as shown in table 16. Once the purified SMALP 
sample was pipetted into the biotinylation reaction buffer, the sample was left to incubate at 4°C, 
overnight.  
2.2.12.2: Indirect ELISA to determine receptor-SMALP biotinylation and streptavidin-biotin 
interaction using pNPP. 
Procedure 
For streptavidin binding detection, A2AR-A-SMALP-biotin, myelin basic protein-biotin (MBP) and 
myelin basic protein-non-biotinylation (MBP-non-biotinylation) were diluted in dilution buffer (PBS + 
0.15 l/ml BSA) to achieve various concentrations. MBP was loaded onto an NUNC maxisorb 96-well 
plate, with an amount of 1-45 ng loaded into the wells. 45 ng of non-biotinylated MBP was loaded into 
empty wells and served as a negative control. 5-200 ng of A2AR-A-SMALP was loaded into empty wells. 
The total volume in each well was 50 l. The proteins were absorbed into the plate for 1 hour with gentle 
rotational shaking. Plates were subsequently washed four times with 200 ul of PBST (PBS + 0.05% 
tween). The plate was then incubated with 200 l of blocking buffer (PBS + 40 g/ml BSA) at room 
temperature. The plate was then washed four times with PBST. 50 l of streptavidin-alkaline 
phosphatase (40 g/ml) was pipetted into each well with sample and two empty wells as a background 
control. The plate was left to incubate at room temperature for 1 hour with gentle shaking. The plate 
was again washed four times with PBST. The plate was then washed twice with TBS (10 mM Tris, pH 
7.5, 150 mM NaCl). 200 ul of p-nitrophenyl phosphate (pNPP) developing solution was applied to each 





2.2.12.3: Biotin quantitation using HABA/avidin. 
Procedure 
The A2AR-A-SMALP, CD81-SMALP, MBP-biotin and MBP were diluted to 100 g/ml, prior to biotin 
quantitation. 1 ml of HABA/avidin solution was pipetted into a cuvette and was read at A500. 100 l of 
each protein sample was pipetted into cuvettes containing 900 l of the HABA/avidin solution and was 
mixed via inversion. The cuvettes were read at A500. The HABA calculator by Thermofisher Scientific 
was used to calculate the ratio of biotin per mole of protein, using the absorbance readings of 
HABA/avidin and HABA/avidin/protein samples.  
2.2.13: Nanobody generation using phage display 
Purpose of methodology 
The A2AR-SMALP was used as a drug discovery platform to identify A2AR-specific monoclonal 
nanobodies using phage display. The filamentous M13 bacteriophage, containing the nanobody genes 
in its phagemid, was used to generate A2AR-specific nanobodies (Ledsgaard et al., 2018). The general 
procedure involved the identification of target-specific phage by incubating the phage with the A2AR-
SMALPs, eluting the phage and expanding monoclonal phage from colonies of bacteria. An ELISA test 
was used to identify the phage specific to the A2AR. 
For the phage display selection biopanning rounds, the A2AR-SMALPs and the Fab positive control were 
immobilised onto the NUNC maxisorp ELISA plates. The M13 phage library expressing the naïve VHH 
were incubated with 1,2-dimyristoyl-sn-glycero-3-phosphorylcholine (DMPC)-SMALPs, which was 
used for negative pre-selection to isolate the lipid and SMA binding phage. The phage-DMPC-SMALP 
mixture was added to the immobilised A2AR-SMALP in order for the VHH expressed on the phage to 
bind the epitopes of the A2AR. The plate was washed to remove non-specific phage from the assay 
(Ledsgaard et al., 2018). The acidic elution buffer, containing 0.1 M HCL, was used to elute the phage 
from the A2AR-SMALP by breaking the interaction between the target-specific phage and the A2AR (Wu 
et al., 2016; Ledsgaard et al., 2018). For phage expansion, the eluted phage were transfected into phage-
94 
 
competent TG1 cells E.coli, which can tolerate multiple freeze-thaw cycles (Carmen and Jermutus, 
2002). Once the phagemid has been inserted into the TG1 E.coli, the helper phage were transfected into 
the bacteria. The helper phage contained the complete M13 genome which was essential for phage 
assembly, capsid production, chromosome replication and budding (Ledsgaard et al., 2018). Once the 
A2AR-specific phage was expanded, PEG (a non-denaturing water-soluble polymer), was used to 
precipitate the phage (Castro-Mejia et al., 2015; Ingham, 1984). The process was repeated two more 
times to remove the non-specific and background binding phage from the A2AR-specific phage 
(Ledsgaard et al., 2018).   
2.2.13.1: Generating A2AR-specific phage using phage display 
Procedure 
To generate the A2AR specific phage, three rounds of biopanning was used to select the phage, as shown 
in figure 52 in chapter 5. In day 1, 50 μl of approximately 5 μg/ml of target protein (A2AR) was pipetted 
into 8 wells of a NUNC Maxisorb ELISA plate. Fab fragments at approximately 5 μg/ml were also 
pipetted into another 8 wells of the ELISA plate to serve as a positive control. The plate was incubated 
overnight at 4°C. In day 2, the supernatant was removed from the immobilised target proteins on the 
ELISA plate. 200 μl of blocking buffer was added to each well containing target proteins. The ELISA 
plate was incubated for 1 hour at room temperature. A naïve llama VHH expressing bacteriophage 
(containing ~1012phages) was removed from -80°C and left to thaw at room temperature. The phage 
stock was mixed with DMPC-SMALPs at a 3 (phage):1 (DMPC-SMALPs) ratio. The DMPC-SMALP 
served as negative selection to remove SMALP-binding phage. The phage-DMPC-SMALP mixture was 
diluted in dried milk buffer at a 1:1 ratio. 10 ml of TG1 bacteria was prepared as a starter culture in 2TY 
media, which was incubated at 37°C in a shaking incubator. After 1 hour incubation, the ELISA plate 
was washed 4 times with wash buffer. 50 μl of the phage mixture was pipetted onto each well containing 
target protein and the plate was incubated for another hour at room temperature on a shaker. Once the 
TG1 starter culture reached an OD600 of 0.4, 2 ml of the culture was transferred to a flask containing 
50ml 2TY media, which was then incubated at 37°C in a shaking incubator. The ELISA plate was 
washed 4 times in wash buffer. The plate was then dried by tapping it onto tissue paper. 50μl of elution 
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buffer was added to each well containing target solution. The plate was left to incubate for 10 minutes 
at room temperature. The supernatant from each well containing a target protein was transferred to 400 
μl of the neutralisation buffer. Once the TG1 culture reached an OD600 of 0.4-0.6, the neutralised phage 
was transferred to 10ml of the TG1 culture. The culture was incubated at 37°C without shaking. 200 μl 
of culture was used for Phage tittering. The rest of the culture was spun down for 10 min at 3500 RPM. 
The supernatant was removed from the bacterial pellet. The pellet was spread on a 15cm plate containing 
2YT carbenicillin + 1% glucose agar plates. The plate was incubated at 30°C. On day 3, 5 ml of 2YT + 
15% glycerol was added to the 15 cm plate. Cells were scraped from the plate and transferred to 
cryovials. The vials were dipped in liquid nitrogen and stored at -80°C, which concluded the first round 
of biopanning.  
The second and third rounds of biopanning was similar to the first round. The differences were: the 
phage library being more specific to the immobilised target proteins, the increase in wash cycles from 4 
to 12 to 20 and the use of helper phage, incubated with the stock phage mixture to help form the A2AR 
specific phage when extracted from TG1 bacteria. At the start of the second and third rounds, an aliquot 
of bacteria + phage was thawed and diluted in 11 ml of 2TY + 200 l carbenicillin + 1% glucose until 
an OD600 of 1 was achieved. The culture was then grown at 37°C in a shaking incubator until the culture 
reached an OD600 of 0.4. 100 μl of helper phage (containing ~1012phages) was added to the culture to 
rescue the bacterial clones. The culture was incubated for 60 minutes at 37°C without shaking, followed 
by spinning the culture for 10 minutes at 3500RPM to pellet the bacteria. The pellet was resuspended in 
10 ml 2TY + 200 μl carbenicillin + 200 μl kanamycin (both antibiotics from 1000X stock). The culture 
was grown in a shaking incubator overnight at 30°C. The next day, the cells were centrifuged for 15 
minutes at 4700RPM. The supernatant was transferred to a 50 ml Falcon tube and 2.5ml of PEG solution 
was applied to the supernatant, which was left on ice with shaking at 15 minute intervals. The 





2.2.13.2: Phage tittering 
During the phage display protocol, 200 μl of TG1-phage culture was used for phage tittering. The 200 
ul of culture was pipetted into two wells of a 96-well plate. A serial dilution using 180 μl of 2TY media 
and 20 μl of culture was created in the empty well, with a total of 6 dilutions. The dilutions were done 
in duplicate. 10 μl of the dilutions were spotted onto an LB agar plate containing carbenicillin + 1% 
glucose. The spots were left to dry and grow overnight at 30°C. The next day, colonies were counted to 
identify the efficiency of TG1 transfection with A2AR-binding phage. 
2.2.13.3: Detecting phage specificity to A2AR using phage ELISA 
After the third phage display biopanning round, spots of bacteria were plated for phage tittering. A single 
colony from the plate was streaked onto another LB agar plate (carbenicillin + 1% glucose), which was 
incubated overnight at 37°C. 
 The next day, 1 ml of 2TY (carbenicillin + 1% glucose) was pipetted into each well of a 96 well 2 ml 
plate. Single colonies were picked from the LB plate and placed into wells of the 96 well 2ml plate. 
Each well therefore contained a single clone of TG1 bacteria, harbouring monoclonal phage. A 
breathable foam lid was placed onto the 96 well 2ml plate, which was then stored in a 37°C shaking 
incubator for 4 hours. 100 μl of culture from each well was pipetted into a new 96 well 2 ml plate. A 
1/10 dilution of helper phage was prepared in 2TY media (carbenicillin + 1% glucose). 50 μl of diluted 
helper phage was pipetted into each well containing 100 μl culture. The plate was incubated at 37°C for 
1 hour, followed by spinning the plate at 3500RPM for 7 minutes. The supernatant was removed from 
each well of the plate and 100 μl of 2TY media (carbenicillin + 1% glucose) was pipetted into each well. 
The 96 well 2ml plate was placed on a shaker at room temperature at high speed to resuspend cell pellet. 
800 μl of 2TY media (carbenicillin + 1% glucose) was applied to each well. The plate was incubated at 
37°C shaking overnight. A NUNC Maxisorb 96 well ELISA plate was prepared with 50 μl of either 
target solution (A2AR-SMALP or Fab fragment), DMPC-SMALP and PBS for control. The ELISA plate 
was left to incubate at 4°C overnight. 
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The next day, the 96 well 2 ml plate which was left to incubate overnight was spun down at 4700RPM 
for 7 minutes. The supernatant from wells containing the immobilised A2AR-SMALP, DMPC-SMALP 
and control was replaced with 200 μl blocking buffer. The ELISA plate was placed on a shaker at room 
temperature for 1 hour. After the 2 ml plates were centrifuged, 200 μl of the supernatant containing the 
phage were placed in new 96 well 2 ml ELISA plates and 200 μl of milk buffer was applied to each 
well. Plates containing the phage were placed on a shaker for 1 hour at room temperature. The ELISA 
plates were washed four times with 200 μl of wash buffer. 50 μl of phage solution from the 2 ml plates 
were pipetted to wells containing either A2AR-SMALP, DMPC-SMALP or control wells. For the 
positive control, A2AR-SMALP was replaced by Fab and phage against Fab was pipetted instead of 
Phage against A2AR.The ELISA plate was placed on a plate shaker for 1 hour at room temperature. 
1/5000 dilution of anti-phage antibody was prepared in blocking buffer. The ELISA plate was washed 
four times with 200 μl of wash buffer and was tapped to dry. 50μl of diluted anti-phage antibody was 
pipetted into each well of the ELISA plate, which was then placed on a plate shaker for 1 hour at room 
temperature. The supernatant was aspirated and the plate was washed again with 200 μl of wash buffer, 
four times. 100 μl of 1 step ultra XMB-ELISA substrate was applied to each well and the plate was read 












2.2.14: Photoaffinity cross-linking F-CGRP to CGRPR ECL mutants 
Purpose of methodology 
The photoaffinity cross-linking assay was used to map the residues of the extracellular loops of the 
CGRPR which interact with the CGRP. The residues of ECL1 and ECL3 were mutated to AzF, which 
is a photo-crosslinkable unnatural amino acid. The fluorescent CGRP was used to bind the mutant 
receptors to detect cross-linking after UV exposure. 
Quick-change PCR was used to generate the AzF CLR mutants. The pCDNA3.1- -T8-HA-CLR 
construct was used as a template to generate the mutants. The primers were complementary to the 
template, with exception of the site of mutation, which was replaced by the amber stop codon. The Pfu 
Hotstart master mix contained all the components necessary for the PCR reaction, including: PfuUltra 
II Fusion HS DNA polymerase, PCR buffer, magnesium and dNTPs. The quick-change PCR protocol 
was used to synthesize the mutants. DpnI digested the methylated template DNA, so the mutant PCR 
products remain. 
The mutant CLR constructs were co-transfected with the RAMP1 construct to express mutant CGRPR 
in HEK293T cells. The F-CGRP was cross-linked to the receptors using UV light. The cells were spun 
down and washed three times to remove the F-CGRP which has not formed cross-links with the 
receptors. DDM was then used to solubilise the receptors from the cell membrane. The solubilised 









2.2.14.1: Primer design and mutagenesis of the T8-HA-CLR construct using quick-change PCR 
Procedure 
The FASTA DNA sequence of the CLR construct was obtained from Uniprot. The CALCRL gene 
encodes the CLR and was used to create mutations. Primers were 35 bases long and a forward and 
reverse primer sequence was generated (Appendix). A single amber stop codon (tag) mutation was 
inserted into the primer, whilst the rest of the sequence complements the CALCRL DNA. The website 
‘Netprimer’ was used to calculate the melting temperature (tm) of the primer, where the average tm was 
between 75-85°C. The site ‘Expasy translate’ tool was used to confirm the amino acid sequence of the 
primers. The web tool ‘reverse complement’ was used to generate the reverse primer, using the forward 
primer as a template. Primers were ordered from ‘Eurofins genomics’. The lyophilised primers were 
reconstituted to 100 pmol/μl. Complementary forward and reverse primers were mixed and diluted with 
dH2O, where each primer was at 10 pmol/μl. 
Quick-change PCR was used to create CLR mutants with the amber stop codon. The reaction conditions 
were: 25 μl pfu ultra II hotstart mastermix, 2 μl 10 pmol/ μl primer mix, 1 μl pCDNA3.1-CLR template 
(at 30 ng/μl) and 22 μl dH2O. The PCR tube containing the reaction ingredients were placed in a PCR 
machine. The reaction was proceeded with the instructions: 1) 95°C for 30 seconds (melting), 2) 95°C 
for 30 seconds (melting), 3) 55°C for 1 minute (annealing), 4) 68°C for 7 minutes (extension), 5) 4°C 
until ready to use. Steps 2-4 were repeated for 16 cycles. Once the reaction was complete, 1 μl dpnI was 
used to digest methylated template DNA. 1 μl of the PCR product was used for bacterial transformation 
to confirm dpn1 digestion (no colonies on an ampicillin LB agar plate) and presence of mutant constructs 
(colonies on ampicillin LB agar plate). The transformed bacteria were grown and lysed to obtain a high 
concentration of plasmid construct, which were then sequenced by Eurofins Genomics using primers: 






2.2.14.2: Photoaffinity cross-linking of F-CGRP to the mutant CGRPR 
Procedure 
HEK293T cells were seeded into six-well plates (from NUNC) at 8 x 105 cells per well and were 
incubated at 37°C, 5% CO2 overnight. The cells were approximately 70% confluent the next day. The 
lipofectamine 3000 transfection kit was used to transfect the HEK293T cells according to the 
instructions providing by the kit. The DNA mixture used to transfect the cells consisted of: 0.5 μg 
pCDNA3.1+- RAMP1, 0.5 μg pCDNA3.1-CLR, pSVBpUC-Yam (the suppressor tRNA, recognising 
the ‘tag’ amber stop codon), pcDNA3.1+-RS-V1 (the aminoacyl-tRNA synthetase for AzF 
incorporation). The total volume of the transfection mixture was 200 μl, which was left to incubate for 
15 minutes. 800 μl of opti-MEM was pipetted into the transfection mixture to achieve a total volume of 
1 ml.  
Once the transfection was completed, p-azido-L-phenylalanine (AzF) was incorporated into the receptor 
structure, as shown in the schematic in Chapter 8, figure 60 (Nodling et al., 2019). The complete 
DMEM was removed from the adherent HEK293T cells and the 1 ml transfection mixture was added to 
the wells. AzF was prepared in a 25 mM stock. Initially, the lyophilised AzF was dissolved in 0.2 M 
NaOH, which was added to DMEM, 1 X penicillin streptomycin. Droplets of 20% (v/v) HCL, dH2O 
was added to the soluble AzF until pH 7.4 was reached. The 25 mM AzF was diluted in DMEM, 20% 
FBS, 1 X penicillin streptomycin, to achieve a 1 mM AzF concentration. 1 ml of 1 mM AzF was added 
to each well of the six-well plates containing the transfected HEK293T cells, which were subsequently 
left overnight at 37°C, 5% CO2 overnight. 10-8 M CGRP-carboxyfluorescein (F-CGRP) was prepared 
by diluting the stock F-CGRP (10-5 M) in binding buffer. The supernantant from the transfected 
HEK293T cells was removed from the wells, where each well was washed using 1 X HBSS, followed 
by aspiration of the washing solution. 1 ml of 10-5 M F-CGRP was added to each well and the cells were 
incubated at 37°C, 5% CO2 for 15 minutes. The cells were then placed on ice and a scraper was used to 
resuspend the cells in the binding buffer. 450 μl of cells were placed in 1.5 ml tubes, wrapped in 
aluminium foil and were termed the control conditions. 450 μl of cells were also placed in tubes, 
however they were exposed to ultraviolet (UV) light (254 nm wavelength) for crosslinking. The control 
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and assay tubes were placed in an ice slurry bath and were exposed to UV light for 30 minutes. The 
tubes were then centrifuged at 3000 g for 10 minutes to pellet the cells, where the supernatant was 
aspirated. The cell pellet was resuspended in PBS via vortexing, and were centrifuged using the same 
conditions. This was repeated three times. In the final centrifugation process, the supernatant was 
drained so the cell pellet only remained. The pellet was solubilised using 100 μl DDM solubilisation 
buffer. The cells were left on ice for 1 hour. The solubilised cells were centrifuged at 15000 g for 15 
minutes at 4°C. The supernatant was pipetted into black ELISA plates. The Mithras plate reader was 
used to read fluorescein absorbance, using a 485 nm excitation filter and a 535 nm emission filter.  
2.2.15. Statistical analysis 
The analysis of variance (ANOVA) tests were used to compare the means of three or more groups of 
data (Kim., 2017). The one-way ANOVA test compares the means of three or more independent groups 
with only one independent variable (Mishra et al., 2019). The two-way ANOVA test is an extension of 
the one-way ANOVA test, in which an additional independent variable is being analysed (Mishra et al., 
2019). Once a significant difference is observed by the ANOVA tests, a post-hoc test is used to compare 
the means. The Tukey’s multiple comparisons test compares the mean of each group with every other 
mean (Graphpad [online] last accessed: 19.03.2020). The Dunnett’s multiple comparison test compares 
a control mean with every other mean (Graphpad [online] last accessed: 19.03.2020). The Sidak’s 
multiple comparisons test functions similarly to the Tukey’s test albeit more powerful in making 
independent comparisons and was used alongside the two-way ANOVA test (Graphpad [online] last 
accessed: 19.03.2020).  
Non-linear regression was used to analyse competitive radioligand binding data. Regression analysis is 
the correlation between a dependent (Y) variable and independent variables. Linear regression compares 
the two variables with the y= mx + c equation, normally generating a straight line. Non-linear regression 
assumes that the dependent variable is random, with the line being curved and is useful to determine the 




Chapter 3: Solubilisation of recombinant membrane proteins from Pichia pastoris using SMA. 
3.1: Introduction 
Yeast cell expression systems have been favoured by scientists due to the low cost of growing cells, 
which can be grown in large cultures and can generate a high yield of recombinant protein (Byrne, 
2015). The methylotrophic yeast species, Pichia pastoris, can use methanol as a carbon source and 
contains eukaryotic post-translational modification machinery, making it a useful alternative to 
mammalian cells (Byrne, 2015). The alcohol oxidase (AOX1) promoter present in the genome of Pichia 
can be induced by methanol, in absence of the inhibitory glucose and glycerol (Byrne, 2015). The 
induction process can be taken advantage of, where plasmid-protein constructs containing the AOX1 
promoter can be integrated into the genome of Pichia. The pPICZ series of plasmids are often used as a 
vector for recombinant protein expression, as the plasmids contain the AOX1 promoter sequence 
upstream of the multiple cloning site. Pichia pastoris has successfully expressed over 100 GPCRs and 
can yield double the amount of receptors when compared with E. coli, making the yeast strain an 
effective cell expression system for GPCRs. The deglycosylated A2AR construct has been successfully 
expressed in the wild type Pichia strain, X33, retaining its pharmacological characteristics and has been 
studied in SMALPs (Fraser, 2006; Jamshad et al., 2015).  
The SMA copolymer has been used to solubilise the deglycosylated human A2AR and the A2AR-A, where 
previous research with the A2AR has demonstrated successful solubilisation of binding-capable receptors 
(Jamshad et al., 2015; Wheatley et al., 2016). The SMA copolymer has been studied instead of 
detergents due to its ability to solubilise receptors in a nanodisc, with the native lipid bilayer intact (Dorr 
et al., 2016). This is important for downstream applications, particular experiments involving drug 
discovery. Receptors need to be in a stable and functional conformation, which lipids have been proven 
to stabilise, in order to discover drugs that bind an active target (Neale et al., 2015). Recent molecular 
dynamic simulations and mass spectrometry analysis have shown phospholipid interaction sites on the 




Replacing the lipids with detergent micelles will alter the allosterism and structural stability the lipids 
provide to the receptors and can potentially distort the GPCR structure (Wheatley et al., 2016; Dorr et 
al., 2016; Song et al., 2019). Within this chapter, the expression, solubilisation and purification of the 
A2AR-SMALP was confirmed, using molecular techniques. The confirmation of the presence of the 
receptor within a SMALP is essential for downstream applications. 
3.2: Results 
3.2.1: Growth of X33 yeast expressing A2AR. 
The growth of the X33 Pichia pastoris strain was analysed using a spectrophotometer, measuring light 
absorbance, to assess the growth rate of the yeast in glycerol and methanol conditions. Yeast expressing 
the recombinant A2AR construct was compared with X33, containing no recombinant gene construct, in 










Figure 31| X33 Pichia pastoris cells expressed the dghA2AR and the A2AR-A pPICZA constructs. 
A) A line graph illustrating the percentage growth of dghA2AR-expressing X33 cells over time in media 
(10% yeast extract, 20% peptone and 0.02% biotin). 8 Samples were taken from the culture for OD 
analysis. Arrow 1 represents the start of the glycerol feed (BMGY), arrow 2 indicates the stoppage of 
glycerol feed arrow 3 represents start of methanol feed (BMMY) and arrow 4 indicates the point of 
harvest. The OD595 values for the samples were converted to percentages, with the highest growth point 
being 100%. B) Exponential growth curve comparing the growth of X33-pPICZα-A dghA2AR cells and 
wild type X33 cells. The cells were cultured in BMGY for 54 hours at 30°C in baffled flasks. The OD595 
readings for each sample was converted to a percentage value, relative to the maximum growth point 
(100%) of the X33 yeast strain. Experiment was repeated three times. Error bars represent the standard 
error of the mean. C and D) Western blot showing the expression of: C) the dghA2AR and D) the A2AR-
A, in X33 cells. 15 l of an 80 mg/ml dghA2AR-expressing X33 membrane was mixed with 5 l LSB 
and was loaded into a well. Anti-his mouse IgG bound the his-tag of the dghA2AR. HRP-linked goat 
anti-mouse IgG bound the anti-his mouse IgG. EZ-ECL was the chemoluminescent substrate for the 
HRP-linked goat anti-mouse IgG. ‘mem’ was the 80 mg/ml sample of X33-dghA2AR membranes, ‘PL’ 






X33 cells were transfected with the pPICZα-A vector containing the dghA2AR construct, using 
electroporation at 1800V. Cells were grown in a bioreactor at 30°C for 72 hours (figure 31A). Cells 
were initially growing slowly between 0 and 20 hours. Upon glycerol induction, the cells grew rapidly 
as they used glycerol as a carbon source. Cells were still growing rapidly after stopping the glycerol 
feed for one hour. At 24 hours, cells were fed with methanol to induce the expression of dghA2AR, where 
methanol activates the AOX1 promoter upstream the dghA2AR construct. The growth rate decreased 
slightly, when compared to the glycerol feed, however cells were still growing rapidly. At around 42 
hours onwards, the cells stopped growing (figure 31A). The exponential growth rate of X33-pPICZα-A 
dghA2AR cells was compared with X33 wild type cells, which were grown in BMGY at 30°C in baffled 
flasks. Growth rate of X33-pPICZα-A dghA2AR was slightly slower than X33 wild type cells however 
both cells types continued to grow (figure 31B). Western blotting was used to confirm the presence of 
the dghA2AR in X33-pPICZα-A dghA2AR cell membranes (figure 33C) and the A2AR-A in X33 pPICZα-
A A2AR-A cell membranes (figure 31D). For both membrane receptor samples, a band was located 
between 35-40 kDa, which was close to the 34 kDa band observed in Fraser et al. (2006). However 
multiple bands were detected above 40 kDa. The his molecular ladder was used to confirm the viability 
of the primary and secondary antibodies used for the western blot. 
3.2.2: The use of SMA to solubilise A2AR receptors from the P. pastoris membranes 
Different SMA copolymers were tested to select the copolymer which solubilised the most receptors 
from an 80 mg/ml sample of membranes expressing A2AR. The SMA copolymers differ from each other 
through their styrene to maleic acid ratio, which affects the diameter of the SMALP as shown in table 
23.  The four copolymers were selected due to their availability at the time. SMA2000 was previously 
used with the A2AR and has demonstrated successful solubilisation of the receptor as well as retaining 
ligand-receptor binding (Jamshad et al., 2015). SMA2000 is made of a 2:1 ratio of styrene to maleic 
acid and forms a 10 nm diameter nanodisc upon membrane solubilisation (Stroud et al., 2018). From 
literature, Xiran SZ30010 achieved similar membrane protein solubilisation, yield of purified protein 
and protein thermostability to SMA2000 (Gulamhussein et al., 2019). The Xiran SZ25010 copolymer 
demonstrated successful solubilisation, although the purified SMALPs showed less stability than 
106 
 
SMA2000 and SZ30010, according to previous research (Gulamhussein et al., 2019). SZ25010 consists 
of a 3:1 styrene to maleic acid ratio, which can cause a decrease in the strength of the acidic component 
of the SMA, slightly increasing the pH tolerance of the copolymer (Scheidelaar et al., 2016). The Xiran 
SZ42010 contains a higher percentage of maleic acid, 42%, than SMA2000, which has a maleic acid 
content of 33% (Stroud et al., 2018; Morrison et al., 2016). The solubilisation efficiency of the Xiran  
SZ42010 copolymer was not as efficient as SMA2000, which may be due to the higher acidity content, 
preventing lipid insertion of the copolymer (Morrison et al., 2016). 
 
SMA copolymer Mw (g/M) Disc diameter (nm) Styrene: maleic acid 
ratio 
SMA2000 (from Cray 
Valley) 
7500 10 2:1 
Xiran SZ30010 (from 
Polyscope) 
6500/ 10000 N/K 2.3:1 
Xiran SZ25010 (from 
Polyscope) 
10000 N/K 3:1 
Xiran SZ42010 (from 
Polyscope) 
10000 N/K N/K 
 
Table 23| The SMA copolymers used to solubilise A2AR receptors from yeast membranes and their 









Figure 32| The solubilisation efficiency of different SMA copolymers used to solubilise dghA2AR-
expressing yeast membranes. 40 mg/ml X33 membranes expressing the dghA2AR was solubilised for 
20 hours at room temperature, using 2.5% (w/v) of SMA copolymers: SMA2000, SZ30010, SZ25010, 
SZ42010. The resulting SMALPs were separated from the unsolubilised pellet by centrifugation at 
100,000 g. The supernatant was extracted and the pellet was suspended in buffer A at the same volume 
of SMA buffer used for solubilisation. A) Western blot showing the density of bands of SMALPs and 
the resuspended membrane pellet. 15 l of the SMALP and pellet samples were mixed with 5 l LSB 
and were loaded into an SDS-PAGE gel for electrophoresis and western blotting. Anti-his mouse IgG 
bound the his-tag of the dghA2AR. HRP-linked goat anti-mouse IgG bound the anti-his mouse IgG. EZ-
ECL was the chemiluminescent substrate for the HRP-linked goat anti-mouse IgG. The arrow points to 
the position of the dghA2AR. The blot represents one experiment. B) Bar chart illustrating solubilisation 
efficiency of each copolymer by using densitometry analysis of panel A. The band between the 35-40 
kDa region, representing the dghA2AR, was compared between all the copolymers. ImageJ was used to 
obtain the arbitrary density values of each band. The percentage of dghA2AR in the supernatant reflects 
the density of the bands in panel A. Graph represents one experiment. 
 
Multiple bands were detected for each copolymer condition, however a band between 35-40 kDa was 
the densest, representing the dghA2AR (figure 32A). For the SMALP conditions for each copolymer, 
the bands were denser than the bands in the pellet condition. The programme, ImageJ, was used to detect 
the density values of each dghA2AR band. A densitometry bar chart was made using the data in figure 






3.2.3: Recovery of binding-capable A2AR-A after solubilisation at different time periods 
The solubilisation times for the best recovery of binding-capable receptors was investigated, using the 
SMA2000 copolymer. A single point, saturation radioligand binding assay was used to detect binding 
of the ligand, [3H]ZM241385, to the A2AR-A after solubilisation. Figure 33 shows the time point where 












Figure 33| Solubilising membranes for 2 hours using SMA2000 yielded the most 
pharmacologically stable A2AR-A-SMALPs. Histogram displaying the percentage of binding-capable 
A2AR-A-SMALPs recovered from the A2AR-expressing X33 membranes after SMA solubilisation. 1nM 
of the radioligand, [3H]ZM241385 and 10-5 M of ZM241385 were used to calculate specific binding. 
The percentage values were obtained by dividing the cpm of the A2AR-A-SMALPs by the cpm observed 
from the A2AR-A-membranes prior to solubilisation, followed by converting the values to percentage 
(chapter 2.2.9.2). The geometric mean of three independent experiments was calculated from the 
binding data. The error bars represent the standard error of the mean. The one-way ANOVA statistical 
test, followed by Tukey’s multiple comparison test was used to compare the differences between the 








X33 membranes expressing A2AR-A were solubilised for 1 hour, 2 hours, 4 hours and 20 hours, using 
SMA2000. The receptors in the membrane and the SMALPs were pharmacologically tested, using the 
radioligand binding assay. [3H]ZM241385 was used as the radioligand. To assess total binding of the 
radioligand, the membrane and SMALP samples were incubated with the radioligand and DMSO. To 
assess the non-specific binding of the membranes and SMALPs, the samples were incubated with the 
radioligand and the cold ligand, ZM241385. The specific binding values of the SMALPs were converted 
into a percentage value, based on the proportion of binding-capable receptors solubilised from the 40 
mg/ml membrane sample, using the methodology is chapter 2.2.9.2. The percentage recovery was 
compared between the solubilisation time periods, in order to identify the most efficient solubilisation 
time length (figure 33). The 2 hour solubilisation time demonstrated a significantly higher percentage 
recovery of active receptors between the four conditions (figure 33). The percentage recovery of 
solubilisation for 2 hours was two-fold higher than the 1 hour, 4 hours and 20 hours solubilisation times. 
There was no significant different in the recovery of active receptors between the 1 hour, 4 hours and 
20 hours solubilisation time, where the percentage recovery was around 10% (figure 33). The receptor 
occupancy equation: [L] / ([L] + Kd) was used to assess whether the experiment was conducted in 












3.2.4. Overview of Ni2+-NTA purification of histidine-tagged proteins 
The purification of the his-tagged receptors in SMALPs was achieved using the Ni2+-NTA affinity resin 
(from Qiagen). Histidine tags have been a popular choice for protein purification as the hexahistidine 
tag is 0.84 kDa in size, is uncharged at pH 7.4, it does not interfere with the folding of a protein and has 
low immunogenicity (Spriestersbach et al., 2015). The purification procedure was done through binding 
the protein-SMALPs to the Ni2+-NTA, followed by a series of washes to remove non-specifically bound 
protein and elution of target SMALPs. Ni2+-NTA resins have been widely used to purify his-tagged 
proteins (Spriestersbach et al., 2015). NTA consists of 4 metal-chelating sites, which stably bind Ni2+ 
(Spriestersbach et al., 2015). The his-tag sequence of a fusion protein can bind the Ni2+ portion of Ni2+-














Figure 34| Illustration demonstrating the interaction between a his-tagged protein and the Ni2+-NTA 













Figure 35| dghA2AR-SMALP purification from contaminating SMALPs. 40 mg/ml of the X33-
dghA2AR cell membranes was solubilised for 20 hours using 2.5% (w/v) SMA2000, at room 
temperature. Membranes were spun down at 100,000 g to separate the membranes from SMALPs. The 
A2AR-SMALPs were purified using nickel affinity chromatography A) Instant Blue staining of an SDS-
PAGE gel showing the elution of purified dghA2AR-SMALPs, using different imidazole concentrations 
(50-600 mM) in elution buffer. Unbound flow through (UB) and wash flow throughs (W1 and W2) were 
analysed. 2 column volumes of wash buffer, containing 20 mM imidazole, were used to remove non-
specific protein. PL represents the protein ladder. Blot is representative of one experiment. B) Instant 
Blue staining of an SDS-PAGE gel showing the elution of purified dghA2AR-SMALPs. Unbound 
flowthrough (UB) was analysed. 20 column volumes of wash buffer (~300 ml), containing 20 mM 
imidazole, was used to remove non-specific protein. Each wash (W1, W2, W3 and W4) represents 5 
column volumes of washes. 1ml elution buffer containing 250mM imidazole was used 10 times to elute 
the A2AR-SMALP (e1-e10). Conc. represents the purified, concentrated and dialysed dghA2AR-SMALP 
sample, using the 10 collated elution fractions, which were concentrated and dialysed to remove 
imidazole in Vivaspin 20 centrifugal concentrators. Gel is representative of two experiments. C) 
Western blot demonstrating the presence of dghA2AR-SMALPs in the 10, 1 ml elution fractions (e1-
e10) and after concentration and dialysis of the pooled elution fractions. The Elution buffer contained 
250mM imidazole. Anti-his mouse IgG was used to label the his-tag, fused to the dghA2AR. HRP-linked 
goat anti-mouse IgG was used to label the anti-his mouse IgG. EZ-ECL solutions A and B were mixed 
together at 1:1 ratio and was used as the substrate for the HRP attached to the goat antibody. UB was 
the unbound flowthrough, WF was the wash flowthrough, His was the molecular histidine marker and 
PL was the protein ladder. Blot is representative of two independent experiments. The arrowheads on 
panels A-C indicate the position of the dghA2AR. D) A densitometry graph based on panel C, illustrating 
the elution peak when fractions e1-e10 were used to elute the target A2AR-SMALP. ImageJ was used to 













The nickel affinity resin was used to purify the dghA2AR-SMALPs from contaminants in the SMALP 
sample (figure 35). 40mg/ml of dghA2AR-expressing X33 yeast membranes were solubilised using 2.5% 
(w/v) SMA2000. Solubilisation was done for 18 hours followed by sonication. Membranes were 
separated from SMALPs by centrifuging at 100,000 g. 1 ml of nickel resin (without ethanol) was used 
per 10 ml of SMALP sample. SMALPs were incubated with the nickel-NTA resin for 24 hours at 4°C. 
The 10 ml of nickel resin-SMALP sample was loaded into one benchtop chromatography column to 
remove all contaminating protein during chromatography as well as to elute the dghA2AR-SMALP, with 
the flow rate being determined by gravity. Initially, the imidazole concentration was optimised to elute 
as much of the SMALPs from the resin (figure 35A). The flow through, containing unbound protein, 
was obtained and analysed using SDS-PAGE and Instant Blue Coomassie staining, revealing multiple 
bands which could not be distinguished in the SDS-PAGE gel (UB) (figure 35A). The wash buffer, 
containing 20mM imidazole, was used to wash away any non-specific proteins which may have bound 
to the columns. The flow through was collected and analysed after each wash cycle. From the first wash, 
multiple bands were detected in the SDS-PAGE, which decreased after the second wash. After washing, 
the elution buffer containing imidazole was used to break the interaction between the his-tagged receptor 
from the nickel resin. Elution buffers with different imidazole concentrations were used to elute the 
dghA2AR-SMALP, where the 150mM imidazole elution buffer eluted the highest amoung of receptor-
SMALPs (figure 35A). 
Once, the optimal imidazole concentration was identified, the yield of eluted SMALPs was analysed 
from each elution cycle, where an increase in wash cycles was used to remove all the non-specific 
protein bound to the column during purification (figure 35B). Again, multiple bands which could not 
be distinguished were detected in the unbound flow through lane of the coomassie stained SDS-PAGE 
gel. No clear bands were detected in the wash lanes, W1-W4. Once the resin was washed, the dghA2AR-
SMALP was eluted, with the flow rate determined by gravity. The elution buffer containing 250mM 
imidazole was used to elute the dghA2AR-SMALP where 1 ml of elution buffer was pipetted onto the 
resin, ten times where ten fractions were collected and analysed (e1-e10). From the first elution, a band 
could be detected at the 35-40 kDa region. From the second to fifth elution, the bands reached their 
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highest density. After the fifth elution the density of the bands decreased. No bands were detected in 
elution fractions e8-e10 (figure 35B). After collating the elutions, the pooled sample was concentrated 
and dialysed to replace the elution buffer with the dialysis buffer containing no imidazole. The 
coomassie stained gel showed one dense band at the 35-40 kDa region (figure 35B). 
The samples used for the coomassie gel in figure 35B were ran through an SDS-PAGE gel for western 
blotting (figure 35C). Western blotting detected the presence of the his-tagged dghA2AR. A faint band 
at the 35-40 kDa region was detected in the unbound and wash lanes of the blot. However the bands 
became dense at the start of eluting the dghA2AR-SMALP (figure 35C). The densest band was detected 
at the second elution lane (e2). The density of the band at 35-40 kDa declined after the second elution 
(figure 35C). No bands were visible after elution 5 (e6-e10). There was also a band located underneath 
the 35 kDa marker which was not present in the coomassie stained SDS-PAGE gels (figure 35C). The 
band representing the dghA2AR was still present after western blotting when the elution fractions were 
collated, dialysed and concentrated (figure 35C). A his-ladder was used to confirm whether the anti-his 
















Figure 36| A2AR-A-SMALP and CD81-SMALP purification from contaminating SMALPs. 40 
mg/ml of the X33-A2AR-A and X33-CD81 cell membranes was solubilised for 2 hours at room 
temperature, using 2.5% (w/v) SMA2000. The membranes were spun down at 100,000 g to separate 
them from the SMALPs. The A2AR-A-SMALPs and CD81-SMALPs were purified using nickel affinity 
chromatography A) Western blot, showing the elution of purified A2AR-A-SMALPs, using different 
imidazole concentrations (50-600 mM) in elution buffer. Unbound flow through (UB) and wash flow 
throughs (W1 and W2) were analysed. 20 column volumes of wash buffer, containing 10 mM imidazole, 
were used to remove non-specific protein, where W1 is a mixture of wash cycles 1-5 and W2 is a mixture 
of wash cycles 6-10. PL represents the protein ladder. His represents the molecular his ladder. Anti-his 
mouse IgG was used to label the his-tagged A2AR-A. HRP-linked goat anti-mouse IgG was used to label 
the anti-his mouse IgG. EZ-ECL solutions A and B were mixed together at 1:1 ratio and was used as the 
substrate for the HRP attached to the goat antibody. Blot is representative of one experiment. B) Instant 
Blue coomassie staining of an SDS-PAGE gel showing the elution of purified A2AR-SMALPs. Unbound 
flowthrough (UB) was analysed. 20 column volumes of wash buffer (~300 ml), containing 10 mM 
imidazole, was used to remove non-specific protein. Each wash (W1, W2, W3 and W4) represents 5 
column volumes of washes. 1ml elution buffer containing 250mM imidazole was used 10 times to elute 
the A2AR-A-SMALP (e1-e10). PL represents the protein ladder. Gel is representative of one experiment. 
C) A densitometry graph based on panel B, illustrating the elution peak when fractions e1-e10 were 
used to elute the target A2AR-A-SMALP. ImageJ was used to analyse the density of the bands at the 35-
40 kDa region of panel C. D and E) Instant Blue coomassie staining of SDS-PAGE gels, illustrating the 
presence of the purified A2AR-A-SMALP and CD81-SMALP, which were concentrated and dialysed 
using Vivaspin 20 centrifugal concentrators. PL represents the protein ladder. Gels are representative of 
three independent experiments. F) Western blot comparing the presence of purified, concentrated and 
dialysed A2AR-A-SMALPs and CD81-SMALPs. Anti-his mouse IgG was used to label the his-tag, fused 
to the A2AR-A and CD81. HRP-linked goat anti-mouse IgG was used to label the anti-his mouse IgG. 
EZ-ECL solutions A and B were mixed together at 1:1 ratio and was used as the substrate for the HRP 
attached to the goat antibody. His was the molecular histidine marker and PL was the protein ladder. 
Blot is representative of three independent experiments. For all gels, the black arrowhead indicates the 
band representing the A2AR-A and the red arrowhead indicates the band representing the CD81. 
 
The nickel affinity resin was used to purify the A2AR-A-SMALP and the CD81-SMALP from 
contaminants in the SMALP samples (figure 36). CD81 was SMA-solubilised, purified and analysed as 
a negative control to confirm the expression of the A2AR constructs in A2AR-transformed yeast. 40mg/ml 
of X33 yeast membrane expressing either A2AR-A or CD81 were solubilised using 2.5% (w/v) 
SMA2000. Solubilisation was done for 2 hours followed and the membranes were separated from 
SMALPs by centrifugation at 100,000 g. 1 ml of nickel resin (without ethanol) was used per 10 ml of 
SMALP sample. SMALPs were incubated with the Ni2+-NTA resin for 24 hours at 4°C. The 10 ml of 
nickel resin-SMALP sample to wash and elute the protein-of-interest, with the flow rate being 
determined by gravity. 20 column volumes of wash buffer was used to wash the resin, where non-
117 
 
specific proteins were removed from the resin, which can be seen as an undistinguishable smear in W3 
(figure 36B). Western blot analysis showed no band representing the A2AR-A (35-40 kDa) being present 
in the first ten wash cycles (figure 36A), therefore only the non-specific protein was eluted from the 
column during the wash cycles. Initially, different concentrations of imidazole (50-600 mM) were used 
to identify the best concentration to elute the A2AR-A-SMALP from the resin. The 100 mM imidazole 
elution buffer demonstrated the highest yield of A2AR-A-SMALP from the nickel resin column, 
followed by the 150 mM concentration elution buffer, as shown by the density of the bands representing 
the A2AR-A (figure 36A). The bands became fainter as higher concentrations of imidazole were applied 
to the column after a 100 mM concentration. 250 mM imidazole elution buffer was used as the standard 
elution buffer for further purification processes. After washing the resin, 10 ml of elution buffer was 
used to elute the A2AR-A-SMALP, which was collected in 1 ml fractions (e1-e10), as seen in the 
coomassie gel (figure 36B) and its complementary densitometry graph (figure 36C). The peak elution 
was in fraction 3, with nothing seen after fraction 8 (figure 36B and C). No additional bands, besides 
the band representing the A2AR-A, could be seen in the coomassie gel (figure 36B). 
After purifying the A2AR-A-SMALP and collating the 10 elution fractions, the sample was concentrated 
and dialysed using the dialysis buffer. This was also done with the CD81-SMALPs, which have been 
purified the same way as the A2AR-A-SMALP, using the same buffer system. The SMALP samples 
were loaded into an SDS-PAGE gel for electrophoresis. The gel was stained with Instant Blue to detect 
the purified A2AR-A and CD81 bands (figure 36D and 36E). A dense band was located between 35-40 
kDa, which indicated the presence of the A2AR-A as it was similar to the size of the dghA2AR (Fraser et 
al., 2006). There were five additional bands present in the purified sample, which were not present in 
other purification procedures involving the dghA2AR-SMALP (figure 36B and 36D). The CD81-
SMALP sample showed a dense band at the 35 kDa region, where literature has demonstrated a tagged 
CD81 band positioned at around 27 kDa (Clark et al., 2001). There was a fainter band (indicated by the 
red arrowhead) below the dense band, which is positioned closer to the 27 kDa region of the gel (figure 
36E). Western blotting was used to confirm the presence of the membrane proteins using their his-tags 
(figure 36F). A dense band was detected at the 40 kDa marker, which suggests the presence of the 
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GPCR (figure 36B) similarly to the indicated band in the coomassie gel (figure 36A). There was a 
blurred band in the A2AR-A-SMALP sample between the 25-35 kDa region, which could be degraded 
receptors present within the sample.  The band representing the A2AR-A was not present in the purified 
CD81-SMALP sample and vice versa (figure 36F). Western blotting detected the band representing the 
CD81 to be positioned around the 27 kDa region, similarly to the arrowhead-indicated band in the 
coomassie gel (figure 36E and 36F).  
3.3: Discussion  
The dghA2AR and the A2AR-A construct was deglycosylated at residue N154 via mutagenesis to Q154. 
The deca-his-tag was fused to the N-terminus of the A2ARs by using the primer in chapter 2.2.1. The 
dghA2AR was kindly provided by Fraser et al. (2006), and its pharmacology was not affected upon 
deglycosylation (Fraser et al., 2006; Jamshad et al., 2015). The purpose of the deglycosylation in this 
project was to prevent full occupancy of glycosylation when the construct was expressed in P.pastoris 
(Jamshad et al. 2015). In human cells, the extent of glycosylation of the A2AR is not as high as when the 
receptor is expressed in Pichia pastoris. The N154 glycosylation site is positioned the middle of the 
ECL2, which may hinder the accessibility of a nanobody-expressing phage from binding the receptor 
(Fraser et al., 2006). The construct was ligated into a pPICZα-A vector, where the AOX1 sequence 
encodes an alcohol oxidase for methanol metabolism (Kupcsulik and Sevella, 2004), which was 
upstream the A2AR construct. Methanol is a toxic carbon source for yeast and without alcohol oxidase, 
methanol would not be metabolised which can harm the cell. Upon methanol induction, alcohol oxidase 
is activated, which leads to the downstream transcription and translation of the A2AR constructs. Figure 
31A demonstrates that upon starvation of glycerol and the application of methanol, the dghA2AR-
expressing yeast continued to grow rapidly until the 45 hour time point, where the yeast culture reached 
the lagging phase. This shows that the dghA2AR-expressing yeast is able to survive and use methanol as 
an alternative carbon source, which activates AOX1, leading to dghA2AR expression. When comparing 
the exponential growth rate of dghA2AR-expressing yeast and wild type yeast, the growth rate was almost 
identical, indicating that the transformation of the X33 yeast strain did not have an impact its growth. 
Western blot analysis against the his-tag of the A2AR constructs demonstrated that dghA2AR was present 
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in the membranes of the dghA2AR-expressing P.pastoris after the cell wall was broken through C3 
homogenization and membrane pelleting (figure 31C and 31D).  
After the expression of the A2AR constructs were confirmed in the X33 Pichia pastoris, the homogenized 
yeast membranes expressing dghA2AR were solubilised for 20 hours at room temperature, similarly to 
Jamshad et al. (2015). Different SMA polymers with different properties were used to solubilise the 
GPCR from the membranes (figure 32A). The preliminary data compared the proportion of soluble 
receptors with the total receptors expressed in the membrane, where all polymers showed a similar 
solubilisation efficiency of around 70% (figure 32B). The similarity in solubilisation efficiency between 
SMA2000 and SZ25010 was also observed with non-GPCRs in Morrison et al. (2016), however 
SZ42010 was less efficient than SMA2000 and SZ25010 when solubilising non-GPCRs. As the data in 
figure 32 was preliminary, SMA2000 was used for subsequent experiments as it is the most popular 
choice amongst the polymers for GPCR solubilisation (Jamshad et al., 2015; Wheatley et al., 2016; 
Morrison et al., 2016). Western blot analysis of the SMA-solubilised dghA2AR demonstrated a high 
solubilisation efficiency of the polymers, however the amount of pharmacologically active receptors 
within the SMALPs was much lower (figure 32).  
A solubilisation time course was conducted on the A2AR-A-expressing membranes for 1-20 hours, to 
measure the amount of binding-capable receptors solubilised for different time periods (figure 33). For 
the A2AR-A construct, a 2 hour solubilisation period showed the highest recovery of ZM241385-binding 
receptors, whilst the rest of the time periods demonstrated a 2-fold lesser solubilisation efficiency of 
binding-capable receptors (figure 33). The optimum solubilisation time period for the A2AR-A differed 
to the methodology presented in Jamshad et al. (2015), where the solubilisation period for the dghA2AR 
was 20 hours at room temperature. As the 2 hour solubilisation time at room temperature showed the 
highest recovery, subsequent solubilisation experiments with the A2AR-A were done with SMA2000 for 
2 hours. The highest receptor recovery was around 22% of ZM241385-binding A2AR-A, which was 
lower than the total amount of receptors solubilised in blot figure 32B. The recovery percentage differs 
from existing data with non-GPCRs, where solubilisation efficiencies of 70-90% were observed 
(Swainsbury et al., 2017; Hardy et al., 2019). Light scattering and western blotting methods were used 
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to assess solubilisation efficiency, which was similar to the 70-80% efficiency in figure 32B. However 
the techniques do not assess the amount of binding-capable receptors present in the SMALP sample. 
This demonstrated that the gel-based techniques do not take into account the amount of conformationally 
stable receptors in the SMALP sample, where binding assays proved to be a superior technique to 
demonstrate this. ZM241385 is highly specific to the adenosine receptors and can only bind the receptor 
if it was in its correct conformation.   
Once the dghA2AR constructs were solubilised into SMALPs, the Ni2+-NTA affinity resin was used to 
purify the receptor SMALPs via the deca-his-tags which were fused to the N terminus of the receptors. 
Initially, various concentrations of imidazole in elution buffer was used to identify whether the his-
tagged dghA2AR-SMALP can be eluted from the nickel affinity column. Coomassie staining 
experiments have identified the 150mM imidazole eluted the most, but not all, of the dghA2AR-SMALPs 
(figure 35A). From then on, 250mM of imidazole was chosen to elute all the dghA2AR-SMALP from 
the resin, as this concentration was used previously with success when purifying the dghA2AR (Jamshad 
et al., 2015). The 250mM imidazole elution buffer was used elute the dghA2AR-SMALP from the nickel 
resin, where 1 ml washes with elution buffer ten times eluted all of the A2AR-SMALP from the nickel 
resin in the benchtop column (figure 35B). Furthermore, wash cycles with the wash buffer was increased 
to 20 cycles to ensure all contaminating protein was removed from the sample. From each elution 
fraction in the coomassie stain, only one band was detected at 35-40 kDa, which is the size of A2AR 
(figure 35B). This showed that the purification method eluted all the dghA2AR-SMALPs from the nickel 
resin and the receptor-SMALP sample was pure. The elution fractions were collated and concentrated 
using vivaspin 20 centrifugal concentrators and the sample was still present as shown by coomassie 
staining (figure 35B). Furthermore, collation of the samples revealed one distinct band at the 35-40 kDa 
region, showing that the sample was pure. Dialysis was also used on the same day as purification and 
concentration to remove all the imidazole from the sample to prevent any degradative effects to the 
receptor. His-tag western blotting also showed that the dghA2AR-SMALP was present during the 
purification procedure and that all the dghA2AR-SMALP was eluted during the purification (figure 
35C). However, the coomassie gels detected the presense of protein up to elution fraction 8 (e8), whereas 
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the western blot did not detect bands between elution fractions e5-e10 (figure 35B-35C). As western 
blotting is a more sensitive technique than coomassie staining, bands should theoretically be present in 
elution fractions e5-e8 in figure 35C. Possible reasons as to why the bands were not detected in the blot 
could be due to faults with the anti-His tag antibody, or the coomassie gel may have detected a non-
specific protein. The western blot also detected a band between 25-35 kDa, which was not seen in the 
coomassie stained gels (figures 35B and 35C). 
 A similar purification optimization procedure was also performed on the A2AR-A-SMALPs, where the 
first step was to identify whether the receptor-SMALPs can be eluted from the nickel resin. The elution 
buffer containing 100 mM imidazole eluted the highest amount of A2AR-A-SMALPs from the 
chromatography column (figure 36A) where the rest of the SMALPs were eluted by using increasing 
concentrations of imidazole. For further purification procedures, elution fractions containing 250 mM 
imidazole was used for receptor elution. The 20 wash cycles, with the wash buffer containing 10 mM 
imidazole, removed non-specific protein-SMALPs from the column, without interfering with the 
captured A2AR-A-SMALP (figure 36B). An elution peak was created based on the density of the elution 
fractions of figure 36B, where all the A2AR-A-SMALPs were eluted from the column (figure 36C). The 
same purification steps done with the A2AR-A-SMALPs were also conducted with CD81-SMALPs, 
which was used as a negative control. The CD81 negative control was used to confirm that the A2AR 
constructs were only expressed in yeast that were transformed with either the dghA2AR gene construct, 
or the A2AR-A construct. From the coomassie stained gels (figures 36D and 36E), a dense band 
representing the A2AR-A was present between the 35-40 kDa marker, however there were 5 unknown 
bands present in the concentrated sample. The bands have not been characterised and were not always 
present in independent purification procedures with A2AR-A-SMALPs. The A2AR-A band was not 
present in the CD81-SMALP sample, indicating that the receptor eluted in figure 36D could be the 
receptor of interest. The band representing the A2AR-A differed in its molecular weight by approximately 
5 kDa, before and after purification (figure 36D and 36F). This could be differences in the migration 
of the protein during each SDS-PAGE experiment or an issue with the anti-His antibody. The SMA 
copolymer could also have an affect on SDS-PAGE, as it can be separated and possibly co-migrate with 
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the protein sample (Korotych et al., 2019). The CD81 sample also showed high purity, which was 
important for downstream experiments when used as a negative control. Western blotting against the 
his-tag also showed that the bands between the A2AR-A-SMALP and CD81-SMALP samples were 
distinct from each other. As there were a few additional bands in all the purified SMALP samples (figure 
35 and figure 36), an extra purification step would be beneficial to generate highly pure receptor-
SMALPs. The AKTA gel filtration system could be used to further purify the protein-SMALPs based 
on their molecular weight. Any additional bands after the gel filtration step can be analysed using mass 
spectrometry. 
Both the dghA2AR and the A2AR-A were successfully expressed in X33 Pichia pastoris, as shown by 
the bands in the western blot, positioned at approximately 37 kDa. This was similar to the bands 
representing the dghA2AR in Jamshad et al. (2015), which was positioned at the 37 kDa marker. The 
positioning of the A2AR bands observed in figures 35 and 36 and the dghA2AR band in Jamshad et al. 
(2015) are slightly higher than the band observed in Fraser et al. (2006). The difference may be due to 
the different speed of receptor migration through the polyacrylamide gel. The tetraspanin CD81 has also 
been successfully expressed in X33 cells, as a band between 25-35 kDa was detected in both the 
coomassie stained gel and the western blot (figures 36E and 36F), which was concordant with the bands 











Chapter 4: Biophysical characterisation of GPCR-SMALPs 
4.1: Introduction 
To establish the pharmacology of the SMA-solubilised A2AR, different experimental procedures have 
been implemented into this project to study how the receptor interacts with ligands within a SMALP. 
Applications have been used to study new properties of the A2AR within SMALPs, using techniques 
such as FCS and XRF. 
The radioligand binding assay has been used to observe the displacement of the radioligand, 
[3H]ZM241385, by the competitive ligand, ZM241385, from the SMALP solubilised A2AR. GPCRs 
need to be in their native conformation, which can be stabilised in SMALP (Dorr et al., 2016; Wheatley 
et al., 2016). Initially radioligand binding was used in this chapter to study the binding capabilities of 
the A2AR in the cell membrane, in SMALPs and after purification. The affinity of [3H]- ZM241385 was 
measured. This was to ensure that the functionality of the receptor was preserved throughout the 
membrane solubilisation and purification processes (Uddin et al., 2018).  The binding capability of the 
dghA2AR in SMALPs was compared with the diisobutylene-maleic acid (DIBMA) copolymer, which is 
an emerging polymer counteracting the limitations of the SMA copolymers, as described in chapter 
4.2.1.2. 
The use of fluorescent ligands is becoming widespread amongst pharmacology, replacing radioligands 
as a safer alternative. Fluorescent ligands can be used to measure pharmacological activity in real-time 
and can be used in imaging studies with the use of fluorescence microscopy. The diversity of the 
applications of fluorescent ligands is larger than radioligands, which are measured in a scintillation 
counter (Stoddart et al., 2016; Stoddart et al., 2015). Fluorescent ligands can be used in procedures such 
as FRET, BRET, flow cytometry and FCS (Stoddart et al., 2016; Stoddart et al., 2015). FCS has 
previously been used to study ligand-GPCR interactions in live cells and membrane microdomains, 
however there are currently no publications demonstrating the use of FCS to study GPCR-SMALPs 




yl)phenoxy]-acetamide (CA200645) and the competitive ligand, ZM241385, was used to assess the 
pharmacology of the dghA2AR-SMALP and the A2AR-A-SMALP. CA200645 is a xanthine amine 
congener (XAC)-based ligand, with the fluorophore BODIPY 630/650 attached via a -alanine linker 
(Stoddart et al., 2015). CA200645 binds non-specificly to the adenosine receptor subtypes and 
antagonises them (Stoddart et al., 2016; Stoddart et al., 2015).  
FCS was used to study the pharmacodynamics of ligand binding within a SMALP. It utilises confocal 
microscopy to identify ligand-receptor interactions. The technique can monitor the spatial and temporal 
differences in the intensity of fluorescent molecules as they move pass a given detection volume 
(Briddon et al., 2018). FCS can measure the speed of the molecules, moving through a given space, 
which is described using the diffusion coefficient (D). The technique also provides information on the 
brightness of fluorescent molecules as well as the concentration of the molecules. Fluorescent species 
can be observed through a pinhole within a confocal microscope to generate a detection volume at 
approximately 100 nm by 200 nm (Briddon et al., 2018). Fluctuations of fluorescence data can be 
observed as fluorescent molecules move through the detection volume (figure 37) (Briddon et al., 2018). 
When a fluorescent ligand forms a complex with a receptor-SMALP, the complex will have a slower 







Figure 37| Illustration of a confocal detection volume used in FCS. A point of interest is selected on a 
live cell or membrane, which is the confocal detection volume, used for data collection. The confocal 
lens produce a rugby-shaped detection volume, where fluorescent species can diffuse through. 
Illustration obtained from (Briddon et al., 2018). 
 
The structural water molecules of the dghA2AR-SMALP was also assessed, to see whether the 
rearrangement of water networks can be observed in the presence of different ligands, under SMALP 
conditions. In X-ray radiolytic footprinting (XRF), the combination of the synchrotron and mass 
spectrometry can identify protein sequences which are exposed to modification. The radiolysis of water 
molecules to form hydroxyl radicals provides an effective labelling technique to identify protein residues 
exposed to water (figure 38) (Gupta et al., 2016). The hydroxyl radicals interact with particular side 
chains of proteins, acting as a detectable label for mass spectrometry and altering the mass of the protein 
(Orban et al., 2010). Mass spectrometry is then used to highlight the residues of the receptor sequence 
which are exposed to hydroxyl modification. Rhodopsin is an example of a GPCR which has undergone 
radiolytic footprinting to identify a water network. Residue Phe116 of rhodopsin had a high modification 
rate, suggesting its exposure to water molecules (Orban et al, 2010). In crystallography studies, a water 
molecule was present near residue Phe116 (Okada et al., 2004). Upon activation of rhodopsin, the 
modification rate of Phe116 decreased, whereas modification rate of residue Met86 increased (Okada et 
al., 2004). This indicated that an inactive to active conformational transition of rhodopsin changed the 
exposure of certain residues to water.   This demonstrated the usefulness of X-ray radiolytic footprinting 













Figure 38| Schematic, illustrating the radiolysis of water molecules into hydroxyl radicals to label 
protein residues. Upon x-ray irradiation, hydroxyl radicals (.OH) and hydrogen peroxide (H2O2) are 
formed from the water molecules. The hydroxyl radicals, (red) interact with each other, buffer molecules 
(green) and interact with protein side chains (yellow). The hydroxyl radicals can also interact with 
electrons (blue) to form superoxide radicals. The kinetics are shown as ‘k’ values, representing the rate 
of various interactions. A short irradiation beam time is favoured as this will lead to fewer superoxide 
radicals and .OH-.OH recombination, which can scavenge the hydroxyl radicals, reducing protein 











Studying SMALPs using X-ray radiolytic footprinting will provide knowledge on how receptor 
dynamics may change, with the native lipid bilayer also being a factor to receptor conformation 
(Wheatley et al., 2016; Gupta et al., 2016; Gupta, 2019). The exclusion of the lipid bilayer in detergent 
solubilised receptors may provide misleading data on protein dynamics, especially when lipids and 
cholesterol are allosteric modulators of certain membrane proteins (Tschammer, 2016). Identifying 
water networks within the dghA2AR will provide useful information on the crevices of the receptor, 
which may give an understanding of how conformational changes occur and how complementary 
proteins, such as a G protein, may bind. Another important element of XRF is that the changes of protein 
conformation and solvent accessibility can be compared between active and inactive A2AR, in presence 
of different ligands. This may illustrate how different drugs change the shape of the receptor and which 
water networks may break or form. 
As SMALPs retain the lipid bilayer around the solubilised membrane protein, the impact of the lipid 
bilayer affects the conformation of the protein, as seen in GPCRs such as the 2AR (Dawaliby et al., 
2016), where phospholipids have altered the pharmacology of the receptor. The conformation of GPCRs 
are also affected by water molecules, which can stabilise an inactive or active conformation of a GPCR 
(Okada et al., 2014). As there are no XRF publications on SMALP proteins, discovering the water-
exposed residues of the dghA2AR-SMALP can provide new insights on the conformational dynamics of 
the receptor, which may be influenced by water. Furthermore, comparing the water-exposed regions of 
receptors in SMALPs and DDM micelles could provide a valuable insight on how the dynamics of the 









4.2.1: Assessing the pharamacology of the A2AR-SMALPs using radioligand binding 
4.2.1.1: Using competitive radioligand binding to characterise the pharmacology of the A2AR-
SMALPs. 
The binding profile of the inverse agonist, ZM241385 was compared between the A2AR-expressing 
membranes and purified A2AR-SMALPs. This was done to establish whether its affinity was the same 
for the receptors expressed in the yeast membranes and after purification of the SMALPs. The 
comparison of the ligand binding affinity was also made between the dghA2AR construct and the A2AR-










Figure 39| Competitive radioligand binding profile of the A2AR constructs in Pichia pastoris 
membranes and purified SMALPs. 1 nM [3H]ZM241385 was used as the radioligand and 10-11 – 10-5 
M ZM241385 was used to compete against the radioligand. The pseudo-concentration, 10-12 M, was 
100% DMSO, instead of ZM241385.  A) The binding curves of the A2AR in membranes and purified 
SMALPs. Graph represents four independent experiments for the A2AR, expressed in membranes and 
three independent experiments for the purified A2AR-SMALPs. B) The binding curves of the A2AR-A in 
membranes and purified SMALPs. Graph represents three independent experiments for the membrane 
and purified SMALP conditions. C) Table showing the average pKi values for membrane and purified 
SMALPs containing either the A2AR or the A2AR-A. The pKi values were calculated using the Cheng-
Prusoff equation. The pKi values of the individual repeats from panel A and B were used to compile the 
data table. A one-way ANOVA test, followed by the Tukey’s multiple comparisons test (Graphpad 
Prism 7) was used to compare the means of the pKi values with each other, which showed no significant 
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A B
C Receptor pKi
dghA2AR-membrane 8.72 +- 0.15
dghA2AR-SMALP 8.42 +-0.2
A2AR-A-membrane 9.05 +- 0.33
A2AR-A-SMALP 8.32 +- 0.5
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The A2AR expressed in membranes and as purified SMALPs showed a clear mass action displacement 
curve, where [3H]ZM241385 was displaced by increasing concentrations of the cold ligand, ZM241385 
(figure 39A). The hill slope was of unity and there was no shift in the slope before and after 
solubilisation. There was also no significant difference in the binding affinity (pKi) of the ligand to the 
A2AR expressed in membranes and solubilised in SMALPs (figures 39A and 39C). The same pattern 
was observed for the membrane A2AR-A (figure 39B), where there was no difference in ligand binding 
affinity prior solubilisation and after solubilisation with SMA2000 (figures 39B and 39C).  
4.2.1.2: Comparing the pharmacological activity of the A2AR solubilised using either SMA or 
DIBMA copolymers 
A novel copolymer is being testing on a variety of membrane proteins, named DIBMA (figure 40) 
(Oluwole et al., 2017). The copolymer is synthesised similarly to SMA. The DIBMA copolymer is 
theorised to be advantageous over SMALPs, which can alter lipid dynamics (Oluwole et al., 2017). The 
DIBMA copolymer does not drastically change the lipid-acyl chain order, retaining the phase behaviour 
of the lipids, similarly to a lipid vesicle preparation (Oluwole et al., 2017). Divalent cations such as 
Mg2+ and Ca2+ are tolerated by DIBMA, unlike SMALPs, where applying 10 mM of Mg2+ and Ca2+ into 
the solubilisation buffer speeds up lipid solubilisation by the DIBMA copolymer (Danielczak et al., 
2019). Exceeding 4 mM concentrations of Mg2+ in buffers containing protein-SMALPs, solubilised 
using a 2:1 copolymer will cause protein precipitation (Pollock et al., 2018). The tolerance to divalent 
cations would be advantageous to experiments performed in receptor biotinylation, where the biotin 
ligase enzyme optimally functions with concentrations of 10 mM magnesium present in the reaction 
mixture Chapter 6. The DIBMA copolymer has also shown similar solubilisation efficiency when 
compared to SMA (Oluwole et al., 2017). The current literature has demonstrated the advantages of 
replacing SMA with DIBMA for membrane protein solubilisation, however as research into DIBMA is 
new, there is a lack of information in protein conformational stability and functionality in DIBMALPs 












Figure 40| The structure of DIBMA and SMA copolymer. x represents the number of styrenes in SMA, 
1 = (1:1), 2 = (2:1), 3 = (2:1) styrene to maleic acid ratio. Structure taken from (Oluwole et al., 2017). 
 
The dghA2AR was solubilised from yeast membranes using either the SMA2000 copolymer or the 
DIBMA (tradename Sokalan CP9, BASF, Ludwigshafen, Germany) copolymer. The binding affinity 
and receptor stability post-solubilisation was measured using the competitive radioligand binding assay. 
The experiments were done in collaboration with Aiman Gulamhussein (Aston University, Birmingham, 
UK) and is published in Gulamhussein et al., (2020). I have conducted one repeat and Aiman 
Gulamhussein has repeated the experiment two more times with the same conditions. Data analysis was 









Figure 41| Competitive radioligand binding assay demonstrating the stability of the dghA2AR after 
solubilisation, using the copolymers SMA2000 and DIBMA. The dghA2AR was solubilised from X33 
membranes for 1 hour. 1 nM [3H]ZM241385 was used as the radioligand and 10-11 – 10-5 M ZM241385 
was used to compete against the radioligand. The pseudo-concentration, 10-12 M, was 100% DMSO, 
instead of ZM241385. ZM241385 binding to the dghA2AR was measured A) 1 hour B) 18 hours C) 6 
days post-solubilisation. The graphs represent three independent experiments. D) Table showing the pKi 
binding affinity of ZM241385 to the dghA2AR, solubilised using either SMA2000 or DIBMA. The 
affinity was measured 1 hour, 18 hours or 6 days post-solubilisation. The table represents the three 
independent experiments, shown in graphs A, B and C. The two-way ANOVA test, followed by Sidak’s 
multiple comparisons test was used to compare the pKi of SMA2000 and DIBMA for each time post-
solubilisation. There was no significant difference in the pKi for each copolymer used for solubilisation 








1 hour SMA2000 7.9 +- 0.1
DIBMA 8.3 +- 0.75
18 hours SMA2000 8.5 +- 0.1
DIBMA 8.5 +- 0.3
6 days SMA2000 8.4 +- 0.4
DIBMA 8.6 +- 0.2
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A mass action sigmoidal curve was observed for both the SMA2000 and DIBMA copolymers, which 
indicate the displacement of the radioligand by ZM241385 (figures 41A-C). The stability of the 
dghA2AR was measured over time when using either SMA2000 or DIBMA copolymers. The percentage 
of active dghA2AR-DIBMALP was compared to the dghA2AR-SMALP. After 6 days post-solubilisation, 
around 50% of the Bmax was lost for the dghA2AR-DIBMALPs when compared with the SMALPs 
(figures 41A and 41C). The binding affinity was stable over time after solubilisation, as there was no 
significant difference in pKi between the SMA and DIBMA copolymers (figure 41D). 
4.2.2: Using fluorescence correlation spectroscopy to study A2AR-SMALP pharmacodynamics in 
real-time. 
The FCS project was a part of the Centre of Membrane Proteins and Receptors (COMPARE) scheme. 
The production of the A2AR-A-SMALPs was done by myself. The initial experiments presented in this 
thesis was conducted by myself, alongside Dr. Steve Bridden (University of Nottingham, UK) and Dr. 
Joelle Goulding (University of Nottingham, UK). Further optimisation experiments were conducted by 
Rachael Grime (University of Birmingham, UK), Dr Steve Briddon and Dr Joelle Goulding, using the 
yeast cells prepared by myself. Rachael Grime, Dr Steve Briddon and Dr Joelle Goulding analysed the 
FCS data, using the equations in the recently published paper by Grime et al., (2020). The work was in 
collaboration between Aston University, University of Birmingham and University of Nottingham. My 
contribution to the project is in Grime et al., (2020). 
As FCS has mainly been conducted on live cells, the use of this technique has not been done on SMA 
solubilised GPCRs. Therefore the initial experiments involved the optimisation of FCS in order to detect 
ligand-binding in a SMALP format, using a fluorescent ligand. The experiments presented in figure 42 
and figure 43 were conducted to find a suitable concentration to displace the fluorescent ligand with a 









Figure 42| Fluorescence correlation spectroscopy data showing the displacement of the fluorescent 
ligand, CA200645, by ZM241385. The dghA2AR-SMALP samples were split into two conditions. The 
first condition contained 100 nM CA200645 (total binding) , whilst the second condition contained 100 
nM CA200645 and 1 M ZM241385, in order to displace the fluorescent ligand and measure non-
specific binding of CA200645. Both conditions contained 5 g/ml of dghA2AR-SMALPs. A 633 nm 
photon laser was used to excite and detect the fluorescent CA200645. A) The percentage of the 
fluorescent CA200645-bound SMALPs over time, with or without ZM241386 present. The detection 
volume was gated around the dwell time of the dghA2AR-SMALP:CA200645 complex, which was 
around 625 s. B) The concentration of the unbound, free CA200645 over time, with or without 
ZM241385 pre-incubation. The detection volume was gated around the dwell time of the CA200645, 
which was around 68 s.  
 
The initial FCS experiments were executed to optimise the confocal microscope and the binding 
conditions of CA200645 and its displacement by ZM241385. Figure 42A demonstrated the kinetics of 
total and non-specific binding. The detection volume was filtered to measure the CA200645, bound to 
the dghA2AR-SMALP, which had a dwell time of 625 s. The percentage of CA200645:dghA2AR-
SMALP complexes increased overtime, with a declination after 60 minutes of measurement. Pre-
incubation with ZM241385 revealed non-specific binding, where the percentage of 
CA200645:dghA2AR-SMALP complexes was lower than the total binding condition. Figure 42B 
measured the concentration of free CA200645 overtime, with or without ZM241385 pre-incubation. 
The detection volume was gated around the dwell time of the free fluorescent ligand, which was moving 
at an average of 68 s within the detection volume. For the total binding and non-specific binding 
conditions, the concentration of CA200645 was similar overtime. This differed to the displacement 
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observed between total binding and non-specific binding conditions of the CA200645:dghA2AR-
SMALP, when the microscope was detecting slower moving particles (figure 42A) 
 
Figure 43| Comparing the binding of CA200645 between A2AR-SMALPs and A2AR-A-SMALPs. 5 
g/ml of the A2AR-SMALPs and the A2AR-A-SMALPs were pipetted into a glass chamber. Both 
samples were pre-incubated with 100 nM CA200645. The ZM241385 conditions contained both 100 
nM CA200645 and ZM241385. A 633 nm photon laser was used to excite and detect the fluorescent 
CA200645. The detection volume was filtered to detect fluorescent particles moving at 500 ns A) Table 
showing the diffusion coefficient (D) of CA200645, with (+) and without (-) 100 nM ZM241385 pre-
incubation. B) The concentration of the fluorescent CA200645-bound SMALPs over time, with or 
without ZM241386 incubation. The detection volume was gated around the dwell time of the dghA2AR-
SMALP:CA200645 complex, which was around 625 s. A line of best fit was generated by analysing 
the data using linear regression in Graphpad Prizm 7. 
 
The diffusion coefficient (D) of the CA200645-bound A2AR-SMALP and the A2AR-A-SMALP was 
similar (figure 43A). When ZM241385 was pre-incubated with the SMALPs, D decreased by 5 m2/s 
for the A2AR-A and dghA2AR SMALPs. Figure 43B demonstrated the concentration of 
CA200645:A2AR-A-SMALP complexes formed overtime, after the reaction reached an equilibrium. The 







4.2.3: The use of X-ray radiolytic footprinting to identify water-accessible residues of the SMA 
solubilised A2AR. 
The buffer system during the purification of the A2AR-SMALP was changed into a sodium phosphate 
based system instead of using HEPES and TRIS. This was to prevent the interruption of hydroxyl 
radicals modifying the water-exposed residues. TRIS, HEPES and DMSO can scavenge the hydroxyl 
radicals, reducing the dosage required for residue oxidization, leading to inaccurate modifications and 
skewed data. After the receptor was purified, a soluble protein radioligand binding assay was used to 
determine whether the A2AR-SMALP was pharmacologically stable in a sodium phosphate buffer 
system with a lowered salt concentration. 
The purified A2AR-SMALP, was concentrated to 1 mg/ml. The sample was sent to the ALS Berkeley 
institute (California, USA) for the irradiation of the sample using x-ray light. Dr Sayan Gupta (Lawrence 
Berkeley National Laboratory, California, USA) conducted the synchrotron experiments. After 
fragmentation of the receptor into peptides, Dr Vassiliy Bavro (University of Essex, UK) used mass 







Figure 44| Structure of the A2AR, illustrating the regions of the receptor which were exposed to 
hydroxyl modification by XRF. Structure of the A2AR and surrounding crystallised water molecules 
(blue spheres) (PDB ID: 5OLG) at a 1.86 Å resolution. The water-exposed sequences detected by XRF 
are shown in green. The unmodified sequences are shown in red. A) Side view of the crystal structure. 
B) Molecular analysis of the orange circle (panel A), showing intermolecular hydrogen bonds (blue 
dashed lines) between the hydroxyl-modified, water-exposed amino acid residues of TM6 and TM7 and 
the crystalised water molecules. The residues are shown as grey sticks. C) Intracellular view of the 





The structure in figure 44 was made using the mass spectrometry data, was analysed using Matrix 
Science Mascot. The mass spectrometry data covered 71% of the sequence, with peptide sequence 
modified by oxidisation. The hydroxyl-modified sequences were predominantly found in TMs 2, 3, 4, 
6, 7 and the TM5-ECL2 interface. The intracellular surface of the receptor was also exposed to 
irradiation, as seen with the intracellular loops (ICL) 1 and 2. ICL3 was missing from the structure 
therefore it is unknown whether this region of the sequence was modified. The ECLs were not modified, 
according to the Mascot data and a majority of the ECL2 was not detected by mass spectrometry, which 
could be due to peptide degradation during peptide lysis. Water molecules in the crystal structure are in 
line with the hydroxyl-modified residues within the TM bundle (figure 44A and 44C). A majority of 
the water molecules are present at the extracellular surface and the ligand binding site of the receptor 
(figure 44A). The structure in figure 44B demonstrates potential interactions between the crystallised 
water molecules and the residues of the water-exposed regions of TM6 and TM7.  
4.3: Discussion of chapter 
After the dghA2AR and the A2AR-A-SMALPs were purified, concentrated and dialysed, biophysical 
experiments were performed to confirm the pharmacology of the receptor within the SMALP and to test 
novel properties of the SMA-solubilised receptors. The initial tests were radioligand binding 
experiments, to confirm whether the solubilised and purified A2AR had the same binding affinity for the 
inverse agonist, ZM241385, when compared with the membranes expressing the dghA2AR (figure 39A). 
As there was no significant difference between the binding affinity of membranes and SMALPs, this 
ensured that the solubilisation and purification process did not impact receptor pharmacology (figures 
39A and 39C). The same was done for the modified A2AR-A construct, which also showed no significant 
different in the binding affinities of the purified SMALPs and membranes (figures 39B and 39C). 
Modifying the A2AR-A construct with extra tags did not impede the receptors pharmacology, as shown 
by the pKi being statistically identical to the dghA2AR (figure 39C). The solubilisation and purification 
protocols were similar to the protocols used in Jamshad et al. (2015), where the binding affinity of 
ZM241385 was pKi 7.95 (± 0.45) for the A2AR expressed in Pichia pastoris membranes and 7.79 (± 
0.14) for A2AR-SMALPs (Jamshad et al., 2015). The pKi affinity for ZM241385 for the dghA2AR and 
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the A2AR-A in membranes and SMALPs was slightly higher in figure 39C. The slight difference in 
affinity may be due to alterations in the preparation of the yeast cells and membranes. Comparing the 
data in figure 39 with the data from Jamshad et al., (2015) demonstrated that the solubilisation and 
purification method was reproducible, yielding functional receptors.  
The emerging DIBMA copolymer is of huge interest in SMALP research as it is modified to have less 
impact on the phospholipid core and is tolerable to divalent cations (Oluwole et al., 2017; Danielczak 
et al., 2019). The tolerance to Mg2+ is essential for experiments involving enzymes requiring ATP and 
magnesium, where SMALPs would precipitate to exposure to high concentrations of divalent cations 
(Pollock et al., 2018). The BirA500 enzyme buffers include high concentrations of magnesium as shown 
in chapter 6, where the A2AR-A-SMALP was unsuccessfully biotinylation, unless the magnesium 
concentration was lowered under 4 mM. Replacing SMALPs with DIBMALPs could possibly overcome 
this limitation, however there is limited evidence to support the applicability of DIBMA in the 
solubilisation of conformationally stable receptors (Oluwole et al., 2017; Oluwole et al., 2017; 
Danielczak et al., 2019). To investigate the suitability of DIBMALPs in solubilising pharmacologically 
active receptors, the DIBMA and SMA copolymers were compared to observe the stability of the 
dghA2AR over time (figure 41). The binding affinity of the ligand remained the same between the 
SMALP and DIBMALP conditions (figure 41D), which showed that DIBMA solubilisation does not 
alter the pharmacology of the receptor, with respect to the pKi observed in SMALPs and the yeast 
membranes (figures 39C and figure 41D). The receptor in DIBMALPs is not as stable as SMALPs 
over time, where over 50% of the dghA2AR-DIBMALPs lost their binding capability after 6 days of 
being stored at 4°C (figures 41A-C). The loss of Bmax for the dghA2AR-DIBMALPs could be due to 
the lower effect the DIBMA copolymer has on lipid packing than the SMA copolymer (Gulamhussein 
et al., 2020; Oluwole et al., 2017). This would render the DIBMALP less stable than SMALPs, resulting 
in a reduction in binding over time. This could be problematic for the phage display biopanning rounds, 
which take over a week to develop target-specific phage (Chapter 5), requiring the DIBMALPs to be 
stored in the fridge for over a week. The reduction of folded receptors in DIBMALPs would result in a 
reduction of conformational epitopes for nanobody discovery and can potentially raise nanobodies 
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targeting unfolded receptors. The DIBMA copolymer should therefore be modified to sustain 
conformational stability over time. 
Fluorescence correlation spectroscopy has been implemented to discover the pharmacodynamics of a 
single ligand, binding to a single SMA-solubilised receptor. This technique was successful in analysing 
binding dynamics using a small concentration (5 g/ml) of sample, which was analysed in real-time. 
The total and non-specific binding of the fluorescent ligand, CA200645, was observed for both the 
dghA2AR-SMALP and the A2AR-A-SMALP (figures 42A and 43B), demonstrating that the technique 
can be an alternative to radioligand binding techniques. The diffusion coefficient of the ligand-bound 
dghA2AR-SMALP was slower by approximately 2 m2/s than the A2AR-A-SMALP for the total and non-
specific binding conditions (figure 43A). The diffusion of CA200645 was slightly faster when 
ZM241385 was present. To improve the results, the diffusion coefficient of the free ligand without the 
presense of SMALPs could demonstrate the non-specific interaction between the ligand and the 
SMALP. 
 When observing the concentration of unbound CA200645, the levels of fluorescence were the same for 
the total binding and non-specific binding conditions (figure 42B). The potential reason for this could 
be the lipophilicity of CA200645 and its interaction with the lipid bilayer. The bulk ligand concentration 
a receptor is exposed to can differ from the actual concentration, as ligands can interact non-specifically 
with lipids. With regards to the fluorescent ligand used in the FCS experiments, CA200645 consists of 
the fluorophore, BODIPY, which is lipophilic (Stoddart et al., 2015; Stoddart et al., 2015), explaining 
why the total and non-specific binding conditions showed a similar concentration of CA200645 (figure 
42B). .  
XRF was implemented to study the water networks within an SMA-solubilised GPCR, as water 
molecules are essential for the stability of different conformations of the receptor as well as receptor 
function (Venkatakrishnan et al., 2019). Structures have previously shown the influence of water 
networks on GPCR structures, however as the proteins were processed at cryogenic temperatures, the 
physiological characteristics of the water molecules were not analysed (Venkatakrishnan et al., 2019; 
Rucktooa et al., 2018).  As XRF utilised a short exposure x-ray beam to modify water-exposed regions 
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of the GPCR without any freezing involved, the water-protein interactions were more physiological than 
crystallography-based methods. Solubilising receptors into SMALPs provided a native structure of the 
protein to detect water-interacting residues. The structure in figure 44, illustrates a majority of the TM 
bundle, with exception to TM1, being hydroxyl modified, indicating its exposure to water molecules. 
The positioning of the crystal water molecules iare in close proximity to the water-exposed residues of 
the receptor figure 44 (Rucktooa et al., 2018) and this was further shown by the potential molecular 
contacts being made by the crystal water-molecules and the water-exposed regions of the receptor 
(figure 44B). There was a large cluster of water molecules at the extracellular surface of the A2AR crystal 
structure which were not detected in the dghA2AR-SMALP XRF structure, where the residues were 
either unmodified or undetected by mass spectrometry (figure 44). The ECL2 of the crystal structure 
makes polar contacts with a water network, although this was not detected by XRF (figure 44A) 
(Rucktooa et al., 2018). The similarities between the crystal structure and the XRF-derived structure 
demonstrate that XRF is a useful tool to detect water-exposed residues of membrane receptors 
solubilised in SMALPs. The possible hydrogen bonding in figure 44B demonstrates that the XRF 
technique is useful to study residues of receptors which interact with water under physiological 
conditions 
Literature has mentioned differences in the conserved water-mediated interactions between active and 
inactive conformations of a GPCR (Venkatakrishnan et al., 2019; Sabbadin et al., 2014). The ligand 
binding pocket of the A2AR is within the upper portion of the TM bundle, where water molecules are 
highly mobile, with some stable water-mediated interactions (Venkatakrishnan et al., 2019). Analysis 
of the A2AR-StaR-BRIL-ZM241385 structure (PDB ID: 5OLG) illustrated ZM241385 binding the upper 
portion of the TM bundle and can make electrostatic contacts with the water molecules (figure 45) 
(Rucktooa et al., 2017). Water molecules may play a role in facilitating the binding of the inverse 
agonist, ZM241384, to the receptor (Carpenter and Lebon, 2017; Rucktooa et al., 2017). Water 
molecules for water mediated interactions have been found in the binding site for caffeine and NECA, 
which are similar in structure to ZM241385 (Carpenter and Lebon, 2017). Molecular dynamic 
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simulations have shown a difference in water-mediated interactions in the ligand binding pocket of 









Figure 45| Crystal structure of the A2AR (PDB ID: 5OLG), complexed with ZM241385. The ligand 
binding site of the receptor resides in the upper portion of the TM bundle. The chemical structure of 
ZM241385 is shown as a stick diagram. Electrostatic contacts between the ligand, water molecules and 
the receptor are shown as dashed lines. The receptor is shown in red and the water molecules are blue 
spheres. Structure analysed using BIOVIA Discovery Studio. Diagram taken and modified from 
(Rucktooa et al., 2017). 
 
MD simulations have illustrated that the conserved water-mediated interactions between TM1 and TM2 
are essential for G protein docking (Venkatakrishnan et al., 2018). This was also highlighted in the A2AR 
structure (figure 44), suggesting that the intracellular surface of the receptor may interact with water 
molecules in order for a G protein to bind. Further XRF experiments with the A2AR-SMALP with an 
agonist or an antagonist bound to the receptor would provide novel information on the changes of the 






Chapter 5: Using phage display against A2AR-SMALPs to generate A2AR-specific nanobodies 
5.1: Introduction 
Antibodies have proved to become as essential tool to study GPCR structure and they are useful to 
localise GPCRs. They are also advantageous to study GPCRs as they can have a pharmacological effect 
on the receptors. They can be used to lock a GPCR in one conformational state for structural studies. 
Crystal structures of the beta-2 adrenergic receptor and the A2AR have been made using antibodies to 
stabilise crystal contacts. In 2012, a crystal structure of the A2AR with the monoclonal antibody 
fragment, Fab2838, showed the variable region of the antibody interacting with the intracellular side of 
the receptor (figure 46) (Hino et al. 2012). This antibody locked the receptor in an inactive state by 
forming multiple hydrogen bonds with the receptor, reinforcing the ionic lock. The antagonists’ affinity 
to bind the receptor was not affected by Fab2838, whereas the agonist, adenosine lost binding affinity 
(figure 46) (Hino et al. 2012). The antibody bound allosterically to the receptor, without making contact 
with the orthosteric ligand binding site (Hino et al., 2012). Fab2838 was therefore termed an allosteric 
inverse agonist as it pushed the A2AR into an inactive conformation without binding to the orthosteric 
site (Hino et al. 2012). The study demonstrated the effectiveness of antibodies to generate GPCR 
structures as well as to alter the pharmacological properties of the receptors. Antibodies therefore have 
a therapeutic value in treating receptor-related diseases. The ability of an antibody to alter GPCR 




















Figure 46| A) Crystal structure showing the A2AR (blue TMD) complexed with the Fab portion of an 
intracellular monoclonal antibody (Fab2838). B) Radioligand binding assay demonstrating the ligand-
binding profile of the A2AR antagonist, Theophylline, in wild type A2AR and A2AR-Fab2838. The 
binding profiles for both A2AR and A2AR-Fab2838 were similar. C) Radioligand binding assay 
demonstrating the ligand-binding profile of the A2AR agonist, Adenosine, in wild type A2AR and A2AR-
Fab2838. Fab2838 significantly reduced the affinity of adenosine to bind A2AR due to stabilising the 











Besides the adverse physiological effects associated with small molecule drugs, targeting receptors with 
small molecule drugs is difficult to achieve, as they have limited target specificity and have an increased 
chance of non-specific interactions (Muratspahic et al., 2019). The non-specific interactions could be 
due to the high lipophilicity of a ligand or their small molecular weight (Hutchings et al. 2017). 
Discovering drugs with high specificity to a receptor is important, where nanobodies can create more 
contacts with a receptor than a small molecule ligand. In the case of the CGRPR, the small molecule 
drugs, olcegepant and telcagepant antagonise the CGRPR and the amylin 1 (AMY1) receptor (Walker 
et al., 2018). Phage display can potentially be used to discover nanobodies which specifically interact 
with the CGRPR and not the AMY1 receptor. 
Monoclonal antibody therapeutics have emerged as an alternative to small-molecule drugs as they 
overcome the disadvantages seen with conventional drugs. They can be developed to become highly 
specific to one receptor as they target unique epitopes of a receptor. Monoclonal antibodies are stable in 
serum, therefore they have a long lifespan within the body (Jo and Jung, 2016), which reduces the dosage 
frequency required to treat a patient. Antibodies can prevent a natural GPCR ligand from binding to a 
receptor and can stabilise an active or inactive state of a receptor and act as an allosteric or orthosteric 
modulator, which can affect ligand binding as seen in figure 9 (Hutchings et al. 2017, Hino et al. 2012). 
They can also stabilise a ligand-bound state of a GPCR as well as preventing receptor degradation 
(Hutchings et al. 2017). GPCR oligomerization can potentially be stabilised by monoclonal antibodies 
(Hutchings et al. 2017). The natural ligands for family B GPCRs are peptides, therefore creating small 
molecule drugs against family B GPCRs is less feasible when compared with antibody-based 
therapeutics. Small molecule antagonists have been created against the CGRPR, however they are 
currently not available for clinical use (Tringali and Navarra, 2019). In response, antibody-based 
methods were implemented to create an anti-CGRPR therapeutic antibody (Jain et al., 2018). The 
CGRPR antagonist, Erenumab is the first antibody to be clinically approved to treat migraine (Raidler, 
2019; Jain et al., 2018). Antibodies therefore show great promise to specifically target a GPCR in order 
to tackle diseases (Jo and Jung, 2016). 
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Phage display has been incorporated in the project in an attempt to discovery nanobodies to alter GPCRs. 
Nanobodies are derived from camelid heavy-chain antibodies (HCAb), composed of the antigen-
recognition variable domain (VHH), which are attached to heavy chains (CH) via a hinge region 
(Muyldermans, 2013). There are two types of HCAbs, (IgG2 and IgG3) in the sera of Camelidae, where 
both are similar in composition, with exception to the hinge region being larger in IgG2. The difference 
between HCAbs and conventional IgGs is the lack of the L chain polypeptide and CH1 in the antigen-
recognition region of the HCAbs (Muyldermans, 2013). Instead of having four domains making up one 
section of the Fab region of an IgG, the HCAbs have only one single variable domain, termed VHH 
(figure 47) (Muyldermans, 2013; Resemann et al., 2010). Another difference is the smaller structure of 
the HCAbs when compared with IgG, which may be better adapted to target crevices and hidden targets 
in which conventional IgG may not be able to access (Muyldermands, 2013). The VHH of a HCAbs 
functions similarly o the Fab region of an IgG in antigen-recognition and can be isolated as nanobodies 








Figure 47| Schematic representation comparing the sizes of a conventional IgG antibody, a Camelidae 






A VHH nanobody is composed of a framework of nine strands, configured into a four-stranded -
sheet and a five-stranded -sheet (Muyldermans, 2013). The sheets are joined by loops (H1-H3) and 
two conserved cysteines, which form a disulphide bond (figure 48) (Koch et al., 2017; Muyldermands, 
2013). The variable sequences are compartmentalised into three hypervariable (HV) regions, which 
reside in the loops (H1-H3) that are connected to the strand framework (Muyldermans, 2013). The 
HV region forms a continuous surface at the N-terminal domain of the VHH (Muyldermans, 2013). 
Since the HV is complementary to the target epitopes, the HV loops are termed the complementarity-
determining region (CDR). Loops H1 and H2 are restricted in certain locations of the VHH, where H3 








Figure 48| Crystal structure of the VHH-5 nanobody (PDB ID: 5U64). The strand framework is 
represented by the grey strands. The CDR loops are shown as yellow (H1), green (H2) and red (H3) 










The H locus of the Camelidae genome encodes the genes which make up the antibodies (figure 49) 
(Muhyldermands, 2013). The VHH gene can be digested and cloned into a phagemid vector, with the 
VHH gene being fused to a viral coat protein gene (Wesolowski et al., 2009). The vector is then 
transfected into E.coli, alongside a helper M13 phage to assemble the new phages expressing the VHH 
gene on its surface (Wesolowski et al., 2009). The naïve VHH-conjugated phage is then ready for phage 
panning to select target-specific phage for nanobody generation. 
 
 
Figure 49| Diagram of the H locus and the composition of the VHH gene. Within the H locus of the 
Camelidae genome, there are V genes, D and J gene elements and the constant genes. The ‘n’ represents 
variants of a gene. In B cells, the IGHV3H is reconfigured to one D gene element and one J gene element 
to form the VHH. The grey segments of VHH encode the framework -strands. The blue, green and red 
segments encode the CDR, containing the hypervariable sequences which complement the target 
epitopes. F42, E49, R50, G52 and W118 are hallmark amino acids, encoded by the IGHV and IGHVH 
genes. Diagram taken from (Muhyldermands, 2013). The V genes and D and J elements can be 
rearranged to alter the VHH, through VDJ recombination (Roth, 2014; Achour et al., 2008). 
 
There are many antibody production methods available to create antibodies. Some techniques require a 
lengthy time period to generate target-specific antibodies. The method utilised in this project was phage 
display, where a phagemid vector containing the VHH genes and the helper phage were transfected into 
E.coli to generate phage expressing the VHH (Wesolowski et al., 2009; Yan et al., 2014; Hoogenboom, 
2005). Prior to VHH-phage conjugation, the VHH genes were extracted from non-immunized Llamas, 
where the genes were amplified by PCR to genereate the naïve VHH library (Sabir et al., 2014) The 
filamentous M13 phage used in this project interacts with the F pilus of certain strains of E.coli, via the 
phage coat protein (Ledsgaard et al., 2018). The phage does not cause cell lysis upon infection, instead 
H locus
V genes




generating and releasing new phages (Ledsgaard et al., 2018). The single-stranded DNA of 6407 bp 
makes up the genome of the phage, with nine genes encoding coat proteins, phage assembly proteins 
and replication proteins (Ledsgaard et al., 2018). Once the phage is assembled, the filamentous structure 
of the phage is 900 nm in length and 6.5 nm in width (Ledsgaard et al., 2018). In phage display, 
phagemids are constructed with the VHH genes fused to gene III of the phagemid, which encodes the 
G3P attachment protein, which is associated with phage coat protein generation (Ledsgaard et al., 2018).  
The phagemid is then transfected into bacteria. The phagemid-positive bacteria are infected with helper 
phage, which transcribe and translate the M13 genome as well as VHH-gene III fusion construct of the 
phagemid (Ledsgaard et al., 2018). As the phagemid does not contain the full M13 genome, the helper 
phage are required for virus assembly and replication (Ledsgaard et al., 2018). Once the VHH-
conjugated bacteriophage is extracted from the E.coli, a phage library is formed, with each clone having 
different VHH amino acid combinations. 
The benefits of phage display are: the rapid time to create antibodies, the use of bacterial cells to grow 
and clone the phage and the starting phage library containing ~1012 naı̈ve phages to target different 
epitopes (Hoogenboom, 2005). This makes phage display a versatile and rapid tool for nanobody 
production. The naive phage used in this project express the camelid VHH (V-like domains in camelids) 
fragments, which are significantly smaller than conventional IgG-based therapeutics. This allows the 
llama VHH expressed in phage and later, nanobodies, to bind to crevices in a membrane receptor 
(Holliger and Hudson, 2005). Research has shown improved solubility and enhanced penetration of 
camelid VHH compared to mouse VH domains of antibodies, therefore camelids would be useful to 
target ligands-binding domains and crevices of the extracellular surface of a GPCR (Holliger and 
Hudson, 2005). 
Nanobodies are of current interest to lock GPCRs into particular conformations (Manglik et al., 2017). 
Crystallisation attempts of GPCRs with nanobodies has been successful, as observed with the 2AR and 
the high-affinity, agonistic Nb80 nanobody (Rasmussen et al., 2011). Nanobodies have also been fused 
with GFP to probe the 2AR signalling process (Irannejad et al., 2013). Therapeutic nanobodies have 
also been developed against the CXCR4 GPCR to prevent viral activity (Manglik et al., 2017). 
150 
 
Nanobodies have gained popularity amongst GPCR research due to their compact, spherical and smaller 
shape, allowing them to bind to crevices of a receptor which may be impossible for standard antibodies 
(Manglik et al., 2017). This will be ideal for nanobody generation against family B GPCRs, such as the 
CGRPR, where gepant antagonists bind the extracellular peptide-binding cleft of the receptor and not 
within the chalice (Ter Haar et al., 2010). The high variability and length of the H3 loop, or CDR3, can 
be advantageous for VHH nanobodies to target difficult epitopes (Manglik et al., 2017; Muhyldermands, 
2013). Multiple monomeric nanobodies can be joined to become highly specific to a target or can 
conformationally lock or constrain two proteins, such as CLR and RAMP1 (Muhyldermands, 2013). As 
the SMA copolymer was used to solubilise GPCRs in SMALPs, the native conformation of the receptor 
will enable the discovery of conformation-specific VHH-phage (Manglik et al., 2017).  
 
5.2: Results 
5.2.1: Assessing the A2AR specific binding of phage, conjugated with the positive control Fab2838 








Figure 50| A) An illustration displaying the components which make up an IgG. B) The variable Fab-




Initial tests were conducted to observe whether the M13 bacteriophage, conjugated with either Fab2838 
or ScFv2838, bound specifically to the dghA2AR. Fab2838 is a Fab-fragment from a mouse monoclonal 
antibody, which was specific to the A2AR (Hino et al., 2012). The size of a Fab-fragment is around 55 
kDa (Jara-Acevedo et al., 2016). Fab2838 has previously been used in structural studies to obtain the 
crystal structure of the A2AR with the ICL3 intact (Hino et al., 2012) and also displaying an allosteric 
role in antagonising the GPCR. ScFv2838 is a single-chain fragment variable (ScFv), which is a short 
peptide linker made from fusing the VH and VL antibody genes together (Ahmad et al., 2012). ScFvs are 
half the size of Fab-framents as shown in figure 50. The ScFv2838 was generated by UCB and also 
bound specifically to the dghA2AR. Both the Fab2838 and ScFv2838 fragments were conjugated to M13 
bacteriophage. The phage were used to see if they bound to the dghA2AR-SMALP, which was 







Figure 51| M13 bacteriophage conjugated with either Fab2838 or ScFv2838 bound the SMA 
solubilised A2AR. The A2AR-SMALP, at a concentration of 5 g/ml, was captured onto a NUNC 
maxisorp ELISA plate. 1011 phage/ml of M13 bacteriophage were incubated with the immobilised A2AR-
SMALP. The phage were conjugated with either Fab2838 or ScFv2838, which were the variable 
fragments of an antibody. The helper M13 bacteriophage were used as a negative control. The HRP-
conjugated goat anti-M13 antibody was used to bind to the M13 bacteriophage. A mouse anti-his IgG 
was used to bind the histidine tag of the A2AR. The secondary antibody, HRP-conjugated goat anti-
mouse IgG, bound to the anti-his antibody. OPD was used as the substrate for the HRP-conjugated 
antibodies and the absorbance was detected at a 450 nm wavelength. The graph represents three 
independent experiments. The one way ANOVA test, followed by Dunnett’s multiple comparisons 
(Graphpad Prism 7) was used to compare the means of each bar (*, **, p ≤ 0.05; p ≤ 0.01). The error 
bars represent the standard error of the mean.  
 


























The M13 bacteriophage conjugated with either Fab2838 or ScFv2838 showed a higher signal than the 
negative control helper phage condition, when binding the dghA2AR-SMALP (figure 51). There was no 
significant difference between the absorbance of the M13 bacteriophage conjugated with Fab2838 or 
ScFv2838 (figure 51). The anti-His detection was significantly lower than the M13 phage, conjugated 
with the antibody fragments, and was similar to the helper phage negative control. (figure 51).  
 
5.2.2: Discovering A2AR-specific, VHH-conjugated phage using phage display 
The VHH nanobodies were expressed on the M13 phage. Phage display was used to generate phage-




Figure 52| Illustration of the phage display panning strategy. Initially, the target antigens, which could 
be antibodies, receptors, enzymes and sugars are immobilised onto an ELISA plate. Naïve phage 
libraries are added to the immobilised targets for phage binding. The ELISA plate is washed to remove 
unbound phages. The target-specific phage are eluted and are incorporated into bacteria to expand the 
phage. The target-specific phage are isolated from the bacteria. The panning process is repeated two 






After the three biopanning rounds, the bound phage was eluted from the target SMALPs and expanded 
in bacteria. The phage were tested using phage ELISA to see which VHH-phage bound specifically to 













Figure 53| Phage ELISA plates displaying phage binding to their target protein. Naïve llama VHH 
phage library was incubated with target protein: dghA2AR-SMALP or Fab, which were immobilised 
onto a NUNC maxisorp ELISA plate. Non-binding phage were washed away during biopanning. After 
three biopanning rounds, phage were expanded in TG1 bacteria and single colonies containing 
monoclonal phage were tested in phage ELISA. HRP-linked anti-phage antibody was used to bind the 
phage for ELISA. A) Three conditions were used to identify dghA2AR-specific phage: dghA2AR-
SMALP, DMPC-SMALP and empty wells washed with PBS. The A2AR-SMALP and DMPC-SMALP 
were immobilised onto NUNC maxisorp plates. Monoclonal phage was applied to each well of one 
condition, which was symmetrical for all other conditions. Polyclonal phage was also applied to the 
ELISA plates (red circles). Orange circles represent phage binding to the A2AR in the A2AR-SMALP 
condition and not the other conditions. B) A positive control with Fab protein immobilised onto NUNC 







The dghA2AR-SMALP was immobilised onto NUNC maxisorp plates and served as the target antigen 
for the phage expressing llama VHH (which underwent biopanning rounds to become dghA2AR-
specific). DMPC-SMALPs were also immobilised onto the ELISA plates to act as a negative control to 
detect SMALP/SMA binding phage. The final condition was wells washed with PBS to detect plastic 
binding of the phage and to detect background signal (figure 53A). The monoclonal phages were added 
to every well in each condition. The position of a monoclonal phage in the wells was kept the same 
between all three conditions. Polyclonal phage, derived from a TG1-phage pellet was applied to the first 
wells of each condition (red circle) and phage ELISA confirmed binding of the polyclonal phage in the 
A2AR-SMALP and DMPC-SMALP conditions. Many wells were bound by phage ELISA in both the 
A2AR-SMALP and the DMPC-SMALP conditions and no phage were detected in the PBS washed wells. 
However seven wells, (22.5% of the total monoclonal phage (highlighted in orange)), bound to the target 
but not DMPC-SMALPs and were further investigated (figure 53A). 
For the positive control, Fab fragments were immobilised onto an NUNC maxisorp ELISA plate. 
Monoclonal Fab-specific phage was applied to the immobilised Fab. Monoclonal phage bound to Fab 
in all but one of the 48 wells (figure 53B). 
5.3: Discussion 
Phage display is a technique used particularly by the pharmaceutical industry to rapidly produce 
antibodies or nanobodies for therapeutic use against target antigens. In this case, GPCR-SMALPs were 
the antigens for the naïve phage library. The addition of SMALPs, which provide a native environment 
for the GPCRs, enables nanobody discovery against receptors in their native conformation (Wheatley et 
al., 2016). The experiments within this chapter assessed the suitability of SMALPs for phage binding 
and detection. Figure 51 demonstrated that existing anti-A2AR antibody fragments can be conjugated to 
the M13 phage and bind specifically to the A2AR. It was also essential for the phage to be detected during 
ELISA, where the anti-M13 antibodies conjugated with HRP successfully bound the dghA2AR-specific 
phage. The signal achieved by the dghA2AR-specific phage was greater than the negative control helper 
phage, suggesting that the signal obtained by the Fab2838 and ScFv2838 was greater than background 
levels. The signals of the anti-his antibodies however was similar to the helper phage signal, suggesting 
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that the absorbance achieved by the anti-his antibodies was similar to background binding. Therefore 
the anti-his tag antibody did not bind as efficiently as the Fab2838 and ScFv2838 conjugated 
bacteriophage. According to Dr A. Scott-Tucker, (UCB, Slough, UK), the expected absorbance should 
be around 4.5, whereas the highest signal, achieved by Fab2838 was 0.13, even though the standard 
concentration of protein was used in the assay. The low signal may have been due to the following issues 
of direct capture of SMALPs onto a NUNC maxisorp plate, as shown in figure 54 The SMALPs could 
potentially bind the ELISA wells in an innapropriate orientation, prevent access for the phage to bind 
the receptor. The size of the SMALP could prevent unbound SMALPs from making contact with the 
surface of the ELISA wells. Excess SMA present in the buffer could also pre-coat the wells, limiting 






Figure 54| Potential issues of immobilising SMALPs onto a NUNC maxisorp plate for phage display. 
A) The SMALP could be captured in its wrong orientation, limiting the accessibility of the phage to 
bind the appropriate targets of the receptor. B) Steric hindrance of the immobilised SMALP may prevent 
additional SMALPs from being captured. C) The SMA copolymer within the buffer may pre-coat the 
ELISA wells, interfering with the immobilisation of the SMALPs. As NUNC maxisorp plates have a 
high affinity towards hydrophilic molecules (ThermoFisher Scientific [online] last accessed: 






A B C  
157 
 
Although a low signal was achieved by the positive control assay (figure 51), the dghA2AR-SMALP 
was detectable by the dghA2AR-specific phage. However, the differences between Fab2838 and the 
controls were not significant enough to demonstrate that there was enough dghA2AR-SMALPs captured 
onto the plate for phage display. Also, the anti-his antibody was not able to detect the his-tagged 
dghA2AR-SMALP, which may be due to electrostatic interactions formed by the his-tag and the maleic 
acid of the SMALP. Nevertheless, an attempt was made to discover dghA2AR-specific VHH-conjugated 
phage. From the phage biopanning rounds and the phage ELISA, seven monoclonal VHH expressing 
phage were detected, which bind to the dghA2AR (figure 53A). Two negative controls were used in 
phage ELISA: immobilised DMPC-SMALPs and empty wells washed with PBS. The negative controls 
were used to identify phage binding to the SMA and lipid as well as plastic-binding phage. No 
monoclonal phages bound to the plastic as shown in the PBS negative control (figure 53A), however 
many phages bound to the DMPC-SMALP and so were eliminated from further study. The seven 
monoclonal phages binding to the dghA2AR did not bind to DMPC-SMALPs nor the PBS, hence the 
phages were specific to the dghA2AR only. Phages specific to Fab-fragments were also produced in 
parallel to phages against the dghA2AR (figure 53B). The positive control Fab-fragments were 
immobilised on ELISA plates and were used to test is the phage display was working according to the 
specifications provided by UCB. 96% of the phage were specific to the Fab-fragment, which was greater 
than the amount of phage specific to the dghA2AR, which was 22% of the total naïve phage used. 
According to UCB, a highly successful phage display yields an 80% enrichment of phage specific to the 
target antigen. The lower percentage of dghA2AR-specific phage may have been due to the 
immobilisation issues illustrated in figure 54 as well as the wash cycles in the biopanning rounds, which 
may have removed the SMALPs from the ELISA plate. Avi-tagged GPCR constructs have been 
designed to eliminate the immobilisation issues associated with the SMALPs, which will be described 
in chapter 6. The phage which showed specificity for the dghA2AR was reformatted into a nanobody, 
without the phage intact, within UCB. The nanobodies did bind the A2AR, however they also displayed 
non-specific binding to phospholipids. This could likely be due to the negative control being DMPC-




Chapter 6: The biotinylation and immobilisation of the avi-tagged A2AR-A. 
6.1: Introduction 
Due to the low enrichment of dghA2AR-specific VHH-phage in chapter 6, an avi-tagged A2AR construct 
was designed to enhance the immobilisation of the receptor onto ELISA plates for phage display. Site-
specific protein biotinylation is often preferred for the immobilisation of proteins as fusing biotin to a 
protein is less intrusive to the proteins structure than methods involving antibody or GFP capture 
(Graslund et al., 2017). A recent phage display-focussed study demonstrated the benefits of biotinylating 
a protein-nanodisc via an avi-tag, with a 90% efficiency in streptavidin pull-down for immobilisation 
(Dominik et al., 2016). The avi-tag consists of the amino acid residues: GLNDIFEAQKIEWHE and is 
a highly specific substrate for the enzyme, biotin ligase (BirA). BirA is an enzyme found in Escherichia 
coli, which can modify specific peptides of a protein sequence by adding biotin (Fairhead and Howarth, 
2015). Biotinylation of an avi-tag is irreversible, where proteolytic conditions are the only way to break 
the biotin-avitag complex (Fairhead and Howarth, 2015). The SMA solubilised A2AR-A was 
biotinylated for immobilisation on a streptavidin-coated ELISA plate. Streptavidin is 60 kDa protein, 
originating from Streptomyces avidinii. It is known for its high affinity for binding biotin, with a KD of 
4x10-14 M (Fairhead and Howarth, 2015). This interaction is rapid and specific and the high affinity of 
the biotin-streptavidin interaction makes it ideal for SMALP immobilisation (Fairhead and Howarth, 
2015, Holmberg et al, 2005). 
A flexible 15 amino acid poly-GS linker was incorporated into the C terminus of the A2AR-A, positioned 
before the avi-tag sequence. This was to prevent the steric hindrance between the tag and the A2AR-A-
SMALPs, which could reduce the amount of immobilised SMALPs. Experiments have shown that 
different linker sizes with a biotinylated avi-tag at the end of the C-terminus can affect immobilisation, 
where the longer the linker sequence, the better the immobilisation (Ikonomova et al., 2018). This could 
be due to steric hindrance of the biotin being too close to the protein, preventing the access of biotin to 





6.2.1: Assessing whether the biotinylated A2AR-A-SMALP can interact with streptavidin. 
An indirect ELISA assay was used to test whether the directly immobilised, biotinylated A2AR-A-
SMALP can interact with free streptavidin- alkaline phosphatase (SV-AP). pNPP was used as the 
substrate for the alkaline phosphatase, producing a yellow colour upon catalysis. Avi-tagged myelin 
basic protein (MBP) was bought from Avidity and was used as a positive control (MBP-biotin) and a 
negative control (MBP). The assay investigated whether the biotinylated A2AR-A-SMALP can interact 




Figure 55| The A2AR-A-SMALP was biotinylated through its avi-tag and can interact with 
streptavidin. A) A western blot illustrating the presence of the avi-tag on the A2AR-A. The X33 yeast 
membranes expressing A2AR-A were used for the western blot. The primary antibody was the mouse 
anti-avi-tag IgG. The secondary antibody was the HRP-conjugated goat anti-mouse IgG. EZ-ECL was 
used as the substrate for chemoluminescence. The arrowhead indicates the band representing the A2AR-
A. B) Graph illustrating the amount of SV-AP complexing with the biotin of the A2AR-A-SMALPs. The 
biotinylation reaction was conducted in either the avidity buffer (buffer 1), or the manually constructed 
buffer (buffer 2). The avi-tagged MBP-biotin was used as a positive control. 45 ng of MBP was used as 
the negative control, as it was not biotinylated. pNPP was used as the substrate for SV-AP. After 20 





The avi-tag was confirmed to be present on the A2AR-A, when expressed in Pichia pastoris membranes. 
Multiple bands were detected in the western blot (figure 55A), however the densest band was around 
37 kDa. Another dense band was detected at 55 kDa two faint bands above the 70 kDa marker. There 
were also faint bands below the 37 kDa point, which may be degradative products (figure 55A). After 
solubilisation of the A2AR-A-expressing membrane with SMA2000, nickel resin was used to purify the 
A2AR-A-SMALPs. The Bir500 biotin ligase was used to biotinylated the avi-tag of the A2AR-A. A pNPP 
indirect ELISA assay was used to assess the formation of biotin-streptavidin complexes, where the 
streptavidin was conjugated with alkaline phosphatase (SV-AP) (figure 55B). The absorbance signal 
represented the amount of biotin-SV-AP complexes formed. The MBP-biotin positive control displayed 
a hyperbolic curve, where increasing the amount of MBP-biotin onto the ELISA plate increased the 
amount of biotin-streptavidin complexes being formed (figure 55B). Saturation was reached after 30 ng 
of the positive control was applied to the wells.  
The biotinylated A2AR-A-SMALP in the avidity-supplied buffer (buffer 1) showed a flat signal, below 
the MBP negative control (figure 55B). The increasing trend with MBP-biotin was not observed with 
the biotinylated A2AR-A-SMALP, instead a broadly biphasic trend was observed (figure 55B). The 
highest signal was observed when 10 ng of SMALP was captured onto the NUNC maxisorp plate, where 
the absorbance signal was slightly higher than 10 ng of MBP-biotin (figure 55B). Fluctuations of the 
absorbance were observed between 10 ng and 25 ng of SMALP capture. Further increasing beyond 25 
ng of SMALP capture reduced the amount of biotin-SV-AP complexes formed (figure 55B). The lowest 
signal observed for the A2AR-A-SMALP was when 5 ng and 45 ng was captured onto the ELISA plate, 








6.2.2: The immobilisation of the biotinylated A2AR-A-SMALP 
Once the biotin-streptavidin interaction was confirmed (figure 55B), the A2AR-A-SMALP was 
immobilised onto streptavidin-coated NUNC maxisorp plates. The illustration in figure 56 explains the 










Figure 56| Wells of the NUNC maxisorp ELISA plate were pre-coated with streptavidin (SV). The 
purified, biotinylated A2AR-A-SMALP can be immobilised onto the streptavidin-coated plate, where the 
biotin forms a complex with streptavidin. The biotin was conjugated to the cytoplasmic, C terminal avi-
tag. A flexible GS linker upstream the avi-tag provides flexibility to the SMALP to reduce steric 










Figure 57| Streptavidin-coated ELISA wells enhanced the immobilisation of the A2AR-A-SMALP. 
A) Bar chart illustrating the immobilisation of purified protein-SMALPs onto a NUNC maxisorp ELISA 
plate. The wells were either coated with SV (+) or were covered with PBS (-). The biotinylated A2AR-
A-SMALP and the A2AR-A-SMALP were captured onto the wells. CD81-SMALP was used as a 
negative control due to the non-existence of the avi-tag. 4 g/ml of the SMALPs were pipetted onto the 
wells. The graph represents three independent experiments, with the error bars representing the standard 
error of the mean. The two-way ANOVA statistical test, follow by Sidak’s multiple comparisons test 
(Graphpad Prism 7) was used to compare the mean of each bar (* p ≤ 0.05; ** p ≤ 0.01). B) Graph 
illustrating the displacement of the biotinylated A2AR-A-SMALP when increasing concentrations of free 
biotin was added to the streptavidin-coated ELISA wells. Prior to SMALP immobilisation, free biotin 
at different concentrations was applied to the streptavidin-coated wells and was incubated for 1 hour at 
room temperature. The supernatant was washed from the wells and 2 g/ml of the A2AR-A-SMALP was 
added to each well. For panels A and B, the mouse anti-his IgG was used to bind the histidine tags of 
the proteins and the HRP-conjugated goat anti-mouse antibody targeted the mouse IgG. OPD was used 
as the substrate for the HRP, which was detected at a 450 nm wavelength. Graph is representative of 
one experiment. C) The A2AR-A-SMALP showed high levels of interaction than the CD81-SMALP 
negative control and the MBP-bio positive control. The A2AR-A-SMALP and the CD81-SMALP were 
mixed in a 1 ml cuvette tube containing HABA/avidin. The MBP-biotin was the positive control and 
the MBP was the negative control, also mixed in a cuvette tube containing HABA/avidin. Absorbance 
was read at a 500 nm wavelength. The HABA calculator website from Thermofisher Scientific was used 





The A2AR-A-SMALP, biotinylated and non-biotinylated, showed a significantly higher signal than the 
CD81-SMALP control, when immobilised onto SV-coated wells (figure 57A). The immobilisation of 
the biotinylated A2AR-A-SMALP was more than double the immobilisation of the CD81-SMALP on 
the streptavidin-coated wells (figure 57A). There was however no significant difference between the 
CD81-SMALP negative control and the biotinylated A2AR-A-SMALP, when observing the wells that 
were not coated with streptavidin. Unexpectedly, The A2AR-A-SMALP demonstrated a higher level of 
immobilisation on streptavidin-coated wells than the wells that were left blank (figure 57A). 
Furthermore, a higher signal was observed for the A2AR-A-SMALP than the CD81-SMALP in the 
streptavidin conditions. This indicated that the biotinylation of the A2AR-A-SMALP, using BirA500 
biotin ligase (from Avidity), did not make a significant difference to SMALP immobilisation when 
comparing the absorbance with the non-biotinylated A2AR-A-SMALP. After pre-incubating the 
streptavidin-coated wells with increasing concentrations of free D-biotin, the amount of immobilised 
biotinylated A2AR-A-SMALP declined (figure 57B). Almost half of the total SMALPs were not 
captured by streptavidin when 1 mM of Biotin was pre-incubated in the ELISA plate. However 
increasing the concentration of the biotin to 3 mM did not cause further reduction in SMALP 
immobilisation (figure 57B). Applying 4 mM free biotin to the streptavidin wells further reduced the 
immobilisation of SMALPs (figure 57B). The amount of biotin molecules attached to the A2AR-A was 
analysed using the HABA/avidin assay (figure 57C). The A2AR-A-SMALP displayed a higher level of 
biotinylation than the MBP-Bio positive control. The CD81-SMALP also showed a signal indicating 
biotinylation however the values were lower than the positive control and therefore may be a background 








6.3: Discussion  
Due to the low enrichment of A2AR-specific phage in chapter 6, an attempt to rectify the immobilisation 
issue was conducted by modifying the A2AR construct. A flexible linker sequence and an avi-tag was 
fused to the C terminus of the A2AR construct to enhance immobilisation of the receptor-SMALP, as 
previous research had used nanodiscs with proteins containing a flexible linker and an avi-tag with 
success in immobilisation (Ikonomova et al., 2018). The pPICZ A-A2AR-A construct was successfully 
integrated into the genome of X33 Pichia pastoris, as shown in chapter 3, and the avi-tag was also 
present in the C terminus of the receptor (figure 55A). After solubilisation of the A2AR-A using 
SMA2000 and purification using affinity chromatography, the A2AR-A-SMALP was biotinylated using 
the Bir500 Avidity biotinylation kit. Initially the original buffers, supplied by Avidity, were used to 
biotinylate the A2AR-A-SMALP, however only background signal was observed (figure 55B). The final 
reaction mixture from the buffers provided by Avidity lead to the final concentrations: 10 mM ATP, 10 
mM Mg(OAc)2 and 50 M d-Biotin, using the protocol from Avidity (Avidity [online] last accessed 
9.12.2019). As the final reaction contained 10 mM Mg2+, SMALP precipitation was likely to occur as 
the maximum Mg2+ concentration SMA could tolerate is 4 mM (Oluwole et al., 2017).   The Avidity 
buffers were replaced with ingredients (Chapter 2, table 16) to counteract the negative effects of Mg2+ 
on the SMALPs, where the reaction mixture contained: 2.5 mM MgCl, 10 mM ATP and 0.3 mM D-
Biotin. The reaction condition was optimised based on the procedure used in Li and Sousa, (2012). 
There was some success in the interaction of biotin and streptavidin, when biotin was conjugated to the 
receptor, where the amount of biotin-streptavidin complexes were initially similar to the positive control 
(MBP-biotin) when low amounts of receptor were used to coat the plate (figure 55B). However, adding 
more than 10 ng of biotinylated A2AR-A-SMALP to an ELISA well reduced the amount of biotin-
streptavidin complexes formed, when comparing the signals with the positive control (figure 55B). As 
the SMALPs were directly captured onto the NUNC maxisorp ELISA plate, steric hindrance and the 
washing steps may be responsible for the deficit in biotin-streptavidin complexes being formed, which 
may explain the low enrichment of A2AR-specific phage in chapter 5. 
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Once the biotin-streptavidin complexes have been confirmed, the immobilisation assay was conducted 
to assess whether the biotinylated A2AR-A-SMALP can be captured onto the NUNC maxisorp ELISA 
plate, pre-coated with streptavidin. The data has demonstrated that adding streptavidin to the ELISA 
plate improved the capture of the A2AR-A-SMALP (figure 57A). Interestingly, the biotinylation of the 
avi-tag using Bir500 did not make a significant difference to the immobilisation of the A2AR-A-SMALP 
onto streptavidin wells (figure 57A). However, the incorporation of the avi-tag may have made a 
difference to A2AR-A-SMALP immobilisation, which was significantly higher than the non-avi-tagged 
CD81-SMALPs. This may suggest that a biotin ligase enzyme could possibly be present in the Pichia 
pastoris that may cause in vivo biotinylated of the A2AR-A. Alternatively, the A2AR-A-SMALP may 
form non-specific interactions with the streptavidin-coated wells, as indicated by the high level of 
immobilisation of the non-BirA500 biotinylated A2AR-A-SMALP to the streptavidin wells (figure 57A). 
The HABA/avidin biotin quantitation assay was incorporated into this study to observe the extent of 
biotinylation of the A2AR-A-SMALPs, prior to BirA500 treatment, to determine whether the A2AR-A 
was endogenously biotinylated in Pichia pastoris (figure 57C). The A2AR-A-SMALP showed higher 
levels of biotinylation than the MBP-biotin positive control, which may indicate the GPCR being 
biotinylated when expressed in Pichia pastoris. However as the experiment was conducted once, further 
investigation is required to obtain solid evidence of protein biotinylation in the yeast strain. The biotin 
titration data in figure 57B has demonstrated that the A2AR-A-SMALP was biotinylated by the Bir500, 
since increasing the concentration of free biotin prevented the immobilisation of the biotinylated GPCR-
SMALP. This is due to the free biotin occupying the streptavidin and as this reaction is almost non-
reversible, this will most likely prevent the immobilisation of the biotinylated A2AR-A-SMALP. An 
overall improvement of the immobilisation of the A2AR-SMALP was observed with the avi-tagged 






Chapter 7: The expression of the CGRP receptors in HEK293T mammalian cells 
7.1: Introduction 
The CGRPR-avi-tag (CGRPR-A) was developed to immobilise the receptor using biotin and 
streptavidin, in order to use the receptor for phage display. In this chapter, the CGRPR-A, consisting of 
the CLR-avi-tag (CLR-A) and RAMP1 were expressed in mammalian cells. The receptor was 
solubilised using SMA2000 to form CGRPR-A-SMALPs, with the surrounding mammalian lipid 
bilayer intact, maintaining the receptor in its native conformation. A functional assay and western 
blotting was used to detect the presence of the tags of the receptor and to compare its function to the T8-
HA-CLR, used in previous studies (Barwell et al., 2012; Simms et al., 2018). 
Human embryonic kidney (HEK) cells have proven invaluable in the expression of recombinant 
proteins, as its internal machinery allows the cell to process the post-translational modifications of 
human proteins appropriately (Thomas and Smart, 2004). Compared to alternative mammalian cells, the 
HEK293 cells are often the first choice for protein expression (Thomas and Smart, 2014). The cell line 
can be transiently transfected with a plasmid constructs, which is beneficial for short-scale growth and 
analysis of multiple mutant proteins (Thomas and Smart, 2004). Transient transfection protocols are 
often quick to express the protein of interest within HEK293 cells. The HEK293 cell lines can also be 
stably transfected for large scale growth of cells and high yield production of recombinant proteins (Liu 
et al., 2014). However creating stable cell lines can be time consuming due to the selection of clones 
with the integrated gene of interest (Liu et al., 2014).  
HEK293T cells were used to transiently express CLR or CLR-avi-tag (CLR-A) with RAMP1. The cell 
line was chosen due to previous work with the CGRPR, which was successfully expressed in previous 
literature (Simms et al., 2018; Zhu et al., 2020). There was also no reported endogenous expression of 
the CGRPR within HEK293T cells, which was ideal for expression of recombinant CGRPR (McLatchie 
et al., 1998).  Also established in HEK293T cells was that the CLR cannot be expressed without 
RAMP1, which is advantageous for purifying the CGRPR, knowing that the CLR required RAMP1 for 




7.2.1: Expression and solubilisation of CGRPR-A from HEK293T cell membranes 
HEK293T cells were transiently transfected with pCDNA3.1+- T8-HA-CLR-A and pCDNA3.1+-
FLAG- RAMP1, using Lipofectamine 3000. After two days of growth, the cells were homogenized and 
solubilised using SMA2000. The expression of the CGRPR-A was observed by western blotting 







Figure 58| Expression of the CGRPR-A in transiently transfected HEK293T cell membranes and 
in SMALPs. Panels A and B are western blots representing the expression of A) T8-HA-CLR-A and 
B) FLAG-RAMP1 in HEK293T cell membranes. A) The primary mouse anti-HA antibody was used to 
detect the CLR-A and the HRP-conjugated goat anti-mouse antibody targeted the primary antibody. B) 
The primary rabbit anti-FLAG antibody was used to detect RAMP1 and the HRP-conjugated goat anti-
rabbit antibody targeted the primary antibody. Panels C and D are western blots representing the 
presence of the CLR-A after solubilising the homogenized HEK293T cell membranes using 2.5% (w/v) 
SMA2000. C) The primary mouse anti-HA antibody was used to detect the CLR-A and the HRP-
conjugated goat anti-mouse antibody targeted the primary antibody. 1 represents the CGRPR-A-
SMALP. 2 represents the non-transfected HEK293T membrane-SMALP. PL represents the protein 
ladder. D) The primary mouse anti-avi-tag antibody was used to detect the CLR-A and the HRP-
conjugated goat anti-mouse antibody targeted the primary antibody. 1 represents the CGRPR-A-
SMALP. 2 represents the non-transfected HEK293T membrane-SMALP. PL represents the protein 
ladder.  EZ-ECL was used as the substrate for HRP. The western blots represent three independent 
experiments. For all gels, the black arrowheads indicate the bands which represent the CLR-A and the 






The T8-HA-CLR-A and FLAG-RAMP1 constructs were transiently co-transfected into HEK293T cells 
using lipofectamine 3000. The membrane was extracted from the cells and was resuspended to 80 
mg/ml, using buffer A. The expression of the CGRPR-A was confirmed in figure 58, where a band was 
detected at around 55 kDa (figure 58A), representing the CLR-A. RAMP1 was also expressed alongside 
CLR-A, where a band was detected at around 15 kDa (figure 58B). After confirmation of CGRPR-A 
expression, the membranes were solubilised using SMA2000 to form SMALPs. CLR-A was confirmed 
to be in the SMALPs by western blotting via the HA tag on CLR-A, where a band was detected at 55kDa 
(figure 58C), similarly to figure 58A. The C terminal avi-tag of the CLR-A was also confirmed to be 
intact with the SMA solubilised receptor, where a band was detected at 55 kDa, using an anti-avi-tag 
















7.2.2: cAMP production upon CGRP binding to CGRPR and CGRPR-A 
To test the functionality of the CGRPR-A, the LANCE cAMP accumulation ELISA assay was used to 
detect cAMP release upon ligand incubation. This was to confirm whether the modified CGRPR-A 
construct was functional upon ligand binding. The functionality of CGRPR-A was compared with the 
CGRPR construct, consisting of T8-HA-CLR and FLAG-RAMP1, and non-transfected HEK293T cells 









Figure 59| Dose-response curves of CGRPR and CGRPR-A showed an increased cAMP 
stimulation upon increasing the CGRP concentration. The sigmoidal dose-response curves were 
compared between the CGRPR and the CGRPR-A, which were expressed in HEK293T cells. The non-
transfected HEK293T cells were used as a control. The curves represent cAMP stimulation after 
activation of the receptors using CGRP. Graph is representative of one experiment. 
 
 
The cAMP accumulation ELISA assay was used to detect the functional response of the CGRPR and 
the CGRPR-A (figure 59). The CGRPR and the CGRPR-A showed a high cAMP stimulation after 
receptor activation by the CGRP. At a 10-6 M concentration of the peptide, the Emax of the CGRPR and 
the CGRPR-A were both similar to that of 10 M forskolin. However CGRPR-A displayed an 
approximate 20% decrease in its Emax when compared with the CGRPR. The pEC50 values for the 
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receptors were similar, being: 9.5 for the CGRPR and 9.8 for the CGRPR-A. There was some cAMP 
stimulation detected for the control cells, which increased as the concentration of CGRP increased. 
However the percentage of the maximum forskolin response was 75-95% lower than the CGRPR and 
CGRPR-A. 
7.3: Discussion of chapter 
The CGRPR-A was modified with an avi-tag for downstream applications of the construct, such as 
biotinylation for streptavidin immobilisation and phage display, as shown in chapter 2. Once the 
construct was manufactured by Genscript, the gene was expressed transiently in HEK293T cells. The 
expression of the construct in the cell membrane was confirmed by western blotting (figure 58A and 
58B). As the SDS present in the sampling buffer and the gel break the tertiary structures of proteins, the 
presence of the CLR-A band would be present as a monomer and not as part of the CGRPR-A (Jensen, 
2002). The CLR-A was approximately 60 kDa in size as shown by the band in the blot (figure 58A), 
which is similar to the tagged CLR detected in Buhlmann et al., (2000) and Hilairet et al., (2001). 
Glycosylation events, such as N-linked glycosylation, can occur during the maturation of the CLR 
through the endoplasmic reticulum and the golgi apparatus (Hilairet et al., 2001). The CLR-A in this 
project was likely to be in its glycosylated form, as the Mw of the CLR-A (~60 kDa) (figure 58) was 
close to the 66 kDa myc-tagged, N-linked glycosylated CLR in Hilairet et al., (2001). Deglycosylation 
of the myc-tagged, glycosylated CLR reduced the size of the receptor to 50 kDa (Hilairet et al., 2001). 
Research has shown that there are three putative, extracellular glycosylation sites in the CLR, with 
Asn123 being essential for ligand binding and signalling (Kamitani and Sakata. 2001). RAMP 1 allows 
the transit of the CLR through the Golgi apparatus, allowing the glycosylation of the receptor (Hilairet 
et al., 2001). The RAMP1, which was co-expressed with the CLR-A, was detected at approximately 15-
20 kDa (figure 58B). A band was detected just above the 15 kDa marker, where literature has confirmed 
the size of a monomeric RAMP1 to be around 15 kDa (McLatchie et al., 1998). According to Buhlmann 




After solubilisation of the CGRPR-A from the HEK193T cell membranes using the SMA copolymer, 
western blotting was used to confirm the presence of the CGRPR-A in the SMALP as well as the C 
terminal avi-tag, which was important for downstream experiments. The CLR-A was confirmed to be 
present in the SMALP in figure 58C, where the band around 55 kDa was detected. This was similar to 
the size of CLR in literature (Buhlmann et al., 2000; McLatchie et al., 1998) and the CLR-A expressed 
in the cell membrane (figures 58A and 58C). The anti-avi-tag western blot confirmed the C terminal 
avi-tag to be intact to the CLR, as shown by the band around the 55 kDa in figure 58D. The experiments 
for figure 58 therefore demonstrated the successful expression and solubilisation of the CGRPR-A and 
the presence of the avi-tag allows biotinylation of the receptor for phage display. 
The functionality of the CGRPR and the CGRPR-A was also assessed in HEK293T cells, using a cAMP 
assay to observe cAMP stimulation upon agonist binding (figure 59). The concentration-response 
curves for CGRPR and CGRPR-A were similar, with the pEC50 being close in value for the constructs. 
This showed that the modification of the CLR-A did not impede the receptors ability to bind CGRP 
and its activity. The pEC50 of the CGRPR is often reported to be around 9.5 (Hay et al., 2018; Salvatore 
et al., 2009), which is similar to the pEC50 values obtained for the CGRPR and CGRPR-A used in this 
project (figure 59). Therefore the dose-response curves and the binding affinity of the agonist to the 
CGRPR constructs were concordant with previous literature. The non-transfected controls showed a 
slight increase of cAMP stimulation upon increasing the concentration of the peptide agonist, which 
may indicate endogenous expression of the receptor. This may contradict the literature which state that 
the HEK293T cells do not express CGRP or the calcitonin subfamily of receptors (McLatchie et al., 
1998). As the data was based on one experiment, further repeats are needed to see if the observations 
are consistent. 
As the expression and solubilisation of the CGRPR-A has been confirmed by western blotting, and its 
activity being similar to the CGRPR used in previous studies, the modified receptor construct can be 




Chapter 8: Analysing ligand-receptor binding interactions using photoaffinity cross-linking 
8.1: Introduction 
Photoaffinity cross-linking can be used to identify amino acid residues of a receptor which interact with 
its ligand (Grunbeck and Sakmar, 2013). The technique was implemented in this study to assess the 
binding topology of ECLs 1 and 3 of the CGRPR, when bound to the fluorescent CGRP. The technique 
is also useful to lock the receptor in an active conformation, which could then be SMA solubilised for 
phage display 
 The methodology involves the introduction of a cross-linking unnatural amino acid, such as p-azido-
phenylalanine (AzF), into the protein sequence of the receptor (Wang et al., 2009; Grunbeck and 
Sakmar, 2013; Simms et al., 2018). This is achieved by creating a tRNA and its complementary 
aminoacetyl synthetase to recognise a termination codon and incorporating an unnatural amino acid 
upon translation (figure 60) (Wang et al., 2009; Nodling et al., 2019). The least frequently used 
termination codon in mammalian cells is the amber stop codon, TAG/ UAG, which is frequently used 
in unnatural amino acid incorporation studies (Nodling et al., 2019; Schmied et al., 2014).  
Figure 60| For the translation of an endogenous protein, the tRNA recognises specific codons of the 
mRNA sequence in order to incorporate the correct amino acid into the protein sequence. An 
endogenous aminoacyl synthetase recognises its complementary tRNA in order to charge it with the 
correct amino acid. In an endogenous system, an amber stop codon present in the mRNA sequence will 
terminate translation. For unnatural amino acid incorporation, orthogonal tRNA and synthetases can be 
designed to recognise a stop codon and apply an unnatural amino acid to the translated sequence instead 
of termination. After translation has been completed, the resulting protein sequence will be modified 
with the unnatural amino acid. Diagram taken from (Nodling et al., 2019). 
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AzF can be crosslinked in-vivo and in-vitro (Wang et al., 2009) In cross-linking studies, it is used as a 
nitrene-generating cross-linking amino acid, incorporated into the receptor structure (figure 61) (Shao 
et al., 2015; Seidel and Coin, 2018). The photo-activatable region of AzF in physiological conditions is 
chemically inert, however upon activation by UV exposure, AzF generates the highly reactive nitrene 
(Seidel and Coin, 2018; Shao et al., 2015). The nitrene can form non-specific, covalent interactions with 
surrounding molecules in close proximity (Seidel and Coin, 2018).  In order for covalent bonds to form, 








Figure 61| Chemical structure of p-Azido-L-phenylalanine (AzF). The moiety highlighted in a green 
circle is the photo-activatable nitrene-generating group. Diagram taken and modified from (Seidel and 
Coin, 2018). 
 
In this project, the extracellular loops 1 and 3 of the CLR were modified with the unnatural amino acid 
AzF. The CLR mutants were co-expressed with RAMP1 in HEK293T cells. The fluorescent ligand, 
[Lys(5(6)-carboxyfluorescein)15]-αCGRP (F-CGRP), was incubated with the cells expressing the 
CGRPR mutants. After the ligand binding incubation period, ultraviolet light at 254 nm wavelength was 
used to crosslink the AzF residue of the CGRPR to the bound ligand. Previous research by Simms et al. 
(2018) identified the residues of the ECL2, the ECD and the TMs of the CGRPR which make contact 
with the peptide. The experiments have shown that I284, S286, T288, L290, L291 and Y292 of the 
ECL2 make contact with the peptide, with I284 and L291 forming the most significant contacts (Simms 
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et al., 2018). Tyrosine scanning mutagenesis confirmed that the residues substituted by tyrosine did not 
drastically change the pharmacological properties of the receptor (Simms et al., 2018). As the AzF 
substituted the same sites used in tyrosine scanning, this suggested that the incorporation of AzF would 
not alter the properties of the receptor (Simms et al., 2018). A molecular model was produced, prior to 
the availability of the cryo-EM CGRPR structure by Liang et al., (2018), to visualise the molecular 
contacts made by the cross-linking residues and the CGRP (figure 62) (Simms et al., 2018). As the 
CGRPR:CGRP structure is available in the Protein DataBase, the cross-linked residues in ECL1 and 











Figure 62| Molecular model illustrating the contacts made by residues of the CGRP and the CGRPR. 
Ribbons in orange highlight the CLR and the ribbon in pink illustrates the CGRP. I284 of the CLR ECL2 
is in close proximity to L12 of CGRP. L291 makes contact with T6 of CGRP. Diagram taken from 








8.2.1: Generation of the human CLR mutants with the amber stop codon 
The T8-HA-CLR construct was used as a template to produce the amber stop codon mutants. Primers 
containing the stop codon were designed against the ECL1 and ECL3 of the CLR construct (Appendix). 
Quick-change PCR was used to produce the mutant codons, which were transformed into XL10 Gold 
E.coli, which were subsequently miniprepped. A diagnostic digest was performed to observe whether 
the mutant constructs were incorporated into the plasmid and sequencing was done to identify whether 
the stop codon was present in the mutant DNA sequence. 
 
Figure 63| The pcDNA3.1+ vector successfully incorporated the TAG-mutant hCLR construct. A 
diagnostic digest of hCLR mutants: L195Stop, T196Stop, A197Stop, V198Stop, A199Stop. The 
template was the T8-HA-hCLR construct used to generate the amber stop codon mutants. The restriction 
enzymes: EcoRI and BamHI were used for the restriction digest. 100 ng of digested (+) and non-digested 
(-) DNA were loaded into each well of an agarose gel. Red Safe was used to bind to the DNA for UV 
detection. DL represents the DNA ladder (Gene ruler). The gel represents a snapshot of selected mutants, 
where the same band pattern was observed for the rest of the ECL1 and ECL3 mutants. 
 
The diagnostic digest demonstrated that the mutant DNA were all the same size when non-digested 
(figure 63). The size of the un-cut plasmid construct was positioned at the 7000 base pairs (bp). The 
template DNA however was slightly larger than the mutant DNA, which was positioned at 9000 bp, 
with an additional band on top of the 9000 bp band (figure 63). When the template and mutant plasmid 
constructs were digested using EcoRI and BamHI, the bands were all equal in size. The larger band, 
L195Stop T196Stop A197Stop V198Stop A199Stop Template














representing the plasmid, was around 5000 bp, whilst the smaller band, representing the mutant and 
template hCLR, was around 1500 bp (figure 63). The total bp of the plasmid and the mutant constructs 
was approximately 7000 bp, which was equal to the size of the band for the un-cut mutant DNA (figure 
63). 
8.2.2: Using photoaffinity cross-linking to decipher the ligand binding sites of ECLs 1 and 3 of the 
CGRPR. 
The orthogonal tRNA (code 136) and aminoacyl synthetase (code 192) were kindly provided by Prof. 
Tom Sakmar (The Rockefeller University, NYC). The tRNA was designed to recognise the amber stop 
codon of the mutant hCLR constructs and the aminoacyl synthetase charged the tRNA with AzF. Once 
the mutant constructs were co-expressed with RAMP1 in HEK293T cells, with incubation with AzF, 
photoaffinity cross-linking was performed to observe binding of F-CGRP. The initial experiments were 
conducted to optimise the UV exposure and binding conditions to achieve optimum crosslinking of the 
fluorescent ligand to the receptor. The L291U CGRPR mutant was selected for initial experiments and 
was chosen as a positive control due to giving the highest cross-linking signal out of ECL2 in previous 




















Figure 64| 30 minutes UV exposure achieved the optimum signal and a change in temperature 
affects ligand-receptor interactions over time. A) Increasing the UV exposure time enhances the 
cross-linking reaction between AzF and F-CGRP. hCLR L291U/RAMP1 was expressed in HEK193T. 
F-CGRP bound the mutant CGRPR for 15 minutes at 37°C, 5% CO2. The cells were exposed to UV 
radiation for 5-45 minutes. Samples for the control conditions were covered in foil to prevent their UV 
exposure. B) A 15 minute binding incubation time of F-CGRP to hCLR L291U/RAMP1 at room 
temperature produced the highest cross-linking signal. The hCLR mutant L291U/RAMP1 was 
expressed in HEK193T. F-CGRP bound the mutant CGRPR for 5-60 minutes at either 4°C or 25°C. The 
cells were exposed to UV radiation for 30 minutes. Samples for the control conditions were covered in 
foil to prevent their UV exposure and their values were subtracted from the samples exposed to UV 
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The UV exposure for cross-linking varies amongst different literature, which is probably due to 
differences in the equipment used to emit UV light and the mutant receptor being studied (Simms et al., 
2018; Naganathan et al., 2013). Therefore the initial experiment involved exposing the CGRPR mutant 
to UV light for different time periods (figure 64A). The L291U CGRPR mutant was used for 
optimization due to forming the most cross-linked ligand-receptor complexes out of the ECL2 mutants 
used in Simms et al. (2018). Increasing the UV exposure time from 5 minutes to 30 minutes increased 
the fluorescence absorbance of the samples exposed to UV light (figure 64A). However increasing the 
UV exposure from 30 minutes to 45 minutes did not lead to further increase in fluorescence. The signal 
emitted by the UV-exposed samples at 30 and 45 minute exposure time was approximately double the 
signal achieved by the control conditions which were not exposed to UV light (figure 64A). Once the 
optimum UV exposure time was established, the binding incubation time and temperature were assessed 
(figure 64B). Ligand incubation at room temperature (25°C) achieved the highest fluorescence at 15 
minutes, which was quicker than ligand incubation on ice (4°C).  The ligand incubation condition was 
changed to 15 minutes in a cell incubator set at 37°C, 5% CO2, as the same conditions were used in a 
photoaffinity cross-linking study and for in vivo ligand incubation with CGRP (Woolley et al., 2017; 




















Figure 65| The CGRPR with the ECL1 A199U, N200U and N201U mutations cross-linked with F-
CGRP. The hCGRPR mutants contained the AzF unnatural amino acid and were expressed in 
HEK293T cells. F-CGRP was used to bind the mutant receptors for 15 minutes at 37°C, 5% CO2. The 
cells were exposed to UV radiation for 30 minutes. Cells which were not transfected were used as a 
negative control. Values represent the percentage increase of the control samples not exposed to UV 
light. The graph represents six independent experiments and the error bars represent the standard error 
of the mean. The one-way ANOVA statistical test, followed by Dunnett’s multiple comparisons test 
(Graphpad prism 7) was used to compare the fluorescence of the mutants with the negative control (* p 




























































































































Once the binding and exposure conditions were established with the positive control, L291U CGRPR, 
photoaffinity cross-linking was used on the ECL1 CGRPR mutants, containing the AzF substitution 
(figure 65). The mutants were either exposed to UV light or were covered in aluminium foil during the 
exposure. The percentage increase of the UV exposed samples were calculated using the fluorescence 
absorbance values of the samples covered in foil. The negative control was the non-transfected 
HEK293T cells, which were either exposed to UV radiation or were not exposed. The purpose of the 
negative control was to detect the background signal of the assay in order to compare the value with the 
mutants. Mutants N200U and N201U displayed a significant increase in fluorescence when compared 
with the negative control (figure 65). Mutation A199U also displayed a significant increase in 
fluorescence, with a similar level to the positive control (figure 65). The positive control was also 
significantly higher in fluorescence when compared with the negative control. The rest of the mutants 
displayed a percentage fluorescence that was similar to the background noise, showing no cross-linking 



























Figure 66| No ECL3 CGRPR mutants cross-linked with F-CGRP. The hCGRPR mutants contained 
the AzF unnatural amino acid and were expressed in HEK293T cells. F-CGRP was used to bind the 
mutant receptors for 15 minutes at 37°C, 5% CO2. The cells were exposed to UV radiation for 30 
minutes. Cells which were not transfected were used as a negative control. Values represent the 
percentage increase of the control samples not exposed to UV light. The graph represents three 
independent experiments and the error bars represent the standard error of the mean. The one-way 
ANOVA statistical test, followed by Dunnett’s multiple comparisons test (Graphpad prism 7) was used 
to compare the fluorescence of the mutants with the negative control (**** p ≤ 0.0001). ‘U’ represents 











The ECL3 CGRPR mutants containing the AzF substitutions were also analysed to observe their cross-
linking to the fluorescent CGRP (figure 66). The negative control was used to obtain the background 
signal of the assays and the positive control, L291U CGRPR, was used to compare the levels of cross-
linking between the mutants. All the ECL3 mutants demonstrated a percentage fluorescence that was 
equal to the background noise, as there was no significant change in fluorescence when compared with 
the negative control (figure 66).  
8.3: Discussion of chapter 
Incorporation of an unnatural amino acid into a protein’s primary structure has proven useful for many 
biological applications, such as identifying binding site topology and protein-protein interactions 
(Gagnon et al., 2019; Simms et al., 2018; Naganathan et al., 2013; Wu and Wu., 2015; Wang et al., 
2009). To incorporate a non-canonical amino acid into a protein, a stop codon must replace the codon 
of interest using PCR. As the whole of ECL1 and ECL3 of the hCGRPR was being investigated, 28 
CLR mutations were made to have the amber stop codon to replace the residues of the extracellular 
loops. Once the polymerase chain reaction was complete and the transformation of the E.coli was 
successful, an agarose gel with ethidium bromide was used to confirm the presence of the mutant CLR 
construct in the pcDNA3.1+ plasmid (figure 63). According to Uniprot and sequencing data, the size of 
pcDNA3.1+ is 5248 bp and the size of the T8-HA-CLR construct was 1488 bp, which is concordant 
with the size of the digested bands in figure 63. Integration of the CLR mutant construct into the plasmid 
gives a total size of 6736 bp. Sequencing of the mutant constructs have confirmed the presence of the 







For understanding the topology of the binding sites of receptors, cross-linkable unnatural amino acids 
can be incorporated into a receptor. This has been conducted previously for the CGRPR by Simms et 
al. (2018), where certain residues of the ECD, ECL2 and the TMs have been identified to be in close 
proximity to the residues of CGRP. The ECL2 mutation at residue L291 showed the highest cross-
linking signal with the fluorescent CGRP (Simms et al., 2018). The L291 CLR mutant was used as a 
positive control to assess ECL1 and ECL3 photoaffinity cross-linking. Preliminary experiments were 
conducted to test the pharmacodynamics aspects of the assay, using the positive control (figure 64). 
Increasing binding incubation and UV exposure time lengths were used to identify the optimum 
conditions to achieve the highest signal, where a 15 minute ligand binding incubation at 37°C, 5% CO2 
and UV exposure for 30 minutes was sufficient for subsequent assays (figure 64). One valuable point 
from the binding incubation experiment (figure 64B) was that the ligand-receptor interaction can be 
slowed down at 4°C. This will be useful for assessing the ligand binding dynamics for different residues 
of the receptor binding site. Analysing the residue the ligand makes contact with first can be observed 
using the cross-linking assay, thus mapping the pathway the ligand takes to reach its final binding site 
(Bower et al., 2018). Analysing the binding site topology can also be assessed, where residues 
interacting with CGRP may differ from adrenomedullin and the speed of residue contacts may also 
differ. 
Once the ideal reaction conditions were established, the ECL1 and ECL3 CGRPR mutants were used 
for the cross-linking assay. A clear interaction was observed for three residues of the ECL1, where 
mutants A199U, N200U and N201U demonstrated a cross-linking signal that was similar to the positive 
control (figure 65). The rest of the mutant receptors may not have formed cross-links with the ligand or 
were not well expressed on the cell surface, where western blotting is required to confirm expression of 
all the AzF mutants. The recent cryo-EM structure of the CLR:RAMP1, complexed with CGRP (PDB 
ID: 6E3Y) was used to establish the positioning of the ligand and the ECL1 residues, A199-N201 (figure 
67). The three residues of the ECL1 were in close proximity to the A13, L16 and S17 residues of the 
peptide, which may allow intermolecular contacts to be made between the peptide and the ECL1 
residues, according to the cryo-EM structure (figure 67B). There were no intermolecular hydrogen 
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bonds formed between the residues of the peptide and the ECL1 of the receptor, according to the cryo-
EM structure and the bond-interaction feature of BIOVIA Discovery Studio (figure 67B). Only one 
side-chain interaction was found between residue A13 of the peptide and A199 of ECL1, where an alkyl 
hydrophobic interaction can potentially form between the methyl groups of the two alanine residues 
(figure 67B). The bond length between the two residues is 4.17 Å, which was measured using Discovery 
Studio and Swiss PDB viewer (figure 67B). Residues N200 and N201 do not make any contacts with 
the peptide through their side chains, where the side chain of N201 was facing away from the peptide 
(figure 67A-B). The van der Waals space filling tool from Swiss PDB viewer identified possible 
interactions through van der walls forces between N200 and N201 of the ECL1 and L16 and S17 of the 
peptide, via the backbone of the residues (figure 67C). When observing the side view of the CGRPR 
structure, the C terminus of the CGRP is leaning towards the ECL1 (figure 67A), with the residues, 
A199-N201, being closest to the peptide (figure 67A-B). As the cryo-EM structure is only a snapshot 
of one configuration of the frozen CGRPR, it is probable that the torsion angles of the residues are 
dynamic, where potential contacts may be missing from the structure (Liang et al., 2018). Nevertheless, 
the orientation of the peptide and ECL1 and their potential molecular contacts agree with the cross-
linking data, showing that the three residues make contact with the peptide (figure 65 and figure 67). 
As AzF residues need to be less than 3 Å away from the closest molecule to make contact with the 
peptide, the distance between the A199U, N200U and N201U substitutions are around 3 Å away from 
the peptide. Swiss PDB viewer showed that residues N200 and N201 of the ECL1 are around 4-5 Å 
away from residues L16 and S17 of the peptide. As the residues were mutated to AzF, this may have an 












Figure 67| Ala99, Asn200 and Asn201 of the CLR are in close proximity to Leu16 and Ser17 of 
CGRP. The CLR:RAMP1 cryo-EM structure (PDB ID: 6E3Y by Liang et al., (2018)) was analysed 
using BIOVIA Discovery Studio. Images were taken of the: A) A side-view of the CGRPR structure. 
B) Close-up interactions between residues Ala199, Asn200, Asn201, Ala13, Leu16 and Ser17.The 
orange secondary structure represents the CLR and the red secondary structure represents the RAMP1. 
The structure highlighted in green represents the ECL1 and the purple structure is the CGRP. The grey 
sticks represent carbon chains. The red sticks and spheres mark the OH and CO groups. The blue sticks 
and spheres represent NH groups. The green dashed lines are hydrogen bonds and the purple dashed 
line is a hydrophobic interaction C) Van der Waals contacts between Ala199, Asn200, Asn201 of the 
ECL1 and Ala13, Leu16 and Ser17 of the peptide. The pink ribbon is the CGRP and the orange ribbon 
is the CLR. The red, white and blue spheres mark the van der Waals forces from the residues of interest. 
The van der Waals space filling tool was used to observe the forces and were rendered solid 3D. Image 
created using Swiss PDP viewer. 
 
Evidence from literature has stated that there are limited contacts between ECL1 residues and the peptide 
(Liang et al., 2018) such as the contact between L16 and S17 of the peptide and A199, N200, Q202 and 
V205 of the ECL1 (Liang et al., 2018). As residues A199 and N200 cross-linked with the peptide and 
is concordant with the cryo-EM structure and supporting literature (Liang et al., 2018), the photoaffinity 
cross-linking assay proved to be an accurate and effective technique to identify the ligand binding site 
topology. Q202 was stated to form a weak hydrogen bond with the S17 oxygen backbone, however the 
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interaction between A199 and N200 of the ECL1 and the backbone of L16 and S17 of the peptide was 
not specified (Liang et al., 2018). Therefore it is probable that A199U, N200 and N201 may form non-
covalent interactions with the peptide. Van der Waals forces and a hydrophobic interaction are possible 
interactions that are formed between the ECL1 residues and the peptide, according to the bond-identifier 
tool of Discovery Studio and the van der Waals space filling tool from Swiss PDB viewer (figure 67C).  
The cross-linking data did not show any interaction between residues Q202 and V205 (figure 65) and 
the peptide although Liang et al. (2018) has stated that there was. This absence of cross-linking with the 
Q202U and V205U mutants may be due to the AzF nitrine group not being in close proximity to the 
peptide to form a cross-link, or there may have been an issue with the expression of the two mutants. A 
tyrosine scanning mutagenesis experiment needs to be done, similarly to Simms et al., (2018), to assess 
whether the incorporation of AzF impacts ligand binding. The reason tyrosine can be used for scanning 
mutagenesis is because the orthogonal aminoacyl tRNA synthetise also accepts tyrosine, as well as AzF 
(Simms et al., 2018). As tyrosine shows the highest structural similarity to AzF out of the amino acids, 
the tyrosine-mutated receptors should be able to bind the CGRP (Simms et al., 2018). Alanine scanning 
can also be used to replace the AzF residues with alanine to see if ligand binding is abolished when 
substitutating AzF with alanine. 
From existing literature, alanine mutations of N200 did not affect the potency of CGRP, therefore the 
amino acid side chain has limited importance in the binding of the peptide (Barwell et al., 2011). An 
A199 mutation to leucine however did reduce the potency of CGRP, as indicated by the reduction of 
cAMP (Barwell et al., 2012). There have been speculations where residue A199 can form a hydrophobic 
cluster with residue L195 as both residues have a hydrophobic side chain (Barwell et al., 2012). This 
cluster was suggested to be of importance in CGRP binding. There was uncertainty on whether residues 
L195 and A199 of ECL1 made contact with the peptide, prior to the discovery of the cryo-EM structure 
by Liang et al. (2018). However the photoaffinity cross-linking data demonstrated that only one residue 
of the hydrophobic cluster, A199, interacted with the ligand (figure 65 and 67B). This was also 
supported by Liang et al. (2018), where residue A199, of the hydrophobic cluster, formed an interaction 
with the peptide. Based on mutagenesis studies, residues A203 and A206 of ECL1 were shown to impact 
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CGRP potency (Barwell et al., 2012). It was speculated that A203 and A206 make contact with the 
ligand due to being positioned in the middle of ECL1, however based on the cryo-EM structure (figure 
67), the residues would be positioned further away from the peptide when compared with residues A199-
N201. Liang et al. (2018) however did not specify that residues A203 and A206 make contact with 
CGRP. 
The photoaffinity cross-linking assay did not indicate any cross-linking occurring between the ECL3 
CLR mutants and the fluorescent CGRP (figure 66). This could be due to a lack of expression of the 
mutants on the cell surface, or the ECL3 may not be in close proximaty to the ligand. Western blotting 
is required to confirm the expression of the ECL3 mutant CGRPR. When observing the cryo-EM 
structure of the CGRPR in complex with CGRP, the ECL3 residues seem to be positioned away from 
the peptide ligand (figure 68). Unfortunately, the full ECL3 structure was not resolved in the cryo-EM 
structure (figure 68) (Liang et al., 2018). Therefore there are uncertainties on whether ECL3 can interact 













Figure 68| ECL3 does not form molecular contacts with CGRP. The CLR:RAMP1 cryo-EM 
structure (PDB ID: 6E3Y by Liang et al., (2018)) was analysed using Discovery Studio. A side profile 
image was taken of the receptor. The orange secondary structure represents the CLR and the red 
secondary structure represents the RAMP1. The structure highlighted in green represents the ECL3 and 
the purple structure is the CGRP.  
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Existing literature also showed uncertainty on whether ECL3 of the CLR makes contact with CGRP. 
Mutagenesis experiments involving the ECL3 suggested a few residues having an impact on CGRP 
potency, with I360 being the main residue of ECL3 (Barwell et al., 2012). Experiments involving the 
calcitonin receptor showed that L368, (V364 being the equivalent residue of CLR), was a photoaffinity 
contact for salmon calcitonin (Barwell et al., 2012). It was hypothesized that the top of the ECL3 of the 
CLR could be in close proximity to the CGRP (Barwell et al., 2012). However the contact distance 
between the top of ECL3 and the CGRP may be over 10 Å (Barwell et al., 2012), which may explain 
why no cross-linking was detected between the ECL3 residues of CGRPR and the peptide, since AzF 
must be below 5 Å away (Simms et al., 2018) from a molecule in order to cross-link (figure 67 and 68). 
As no binding interactions were established between ECL3 of CGRPR and the CGRP; it was suggested 
that the ECL3 residues may provide a structural support for the CLR to associate with RAMP1 (Barwell 
et al., 2012). The full structure of ECL3 was not resolved in the cryo-EM structure (PDB ID: 6E3Y) due 
to the high mobility of the loop (figure 68) (Liang et al., 2018). MD simulation programme PLOP50 
was used to generate a full hypothetical ECL3 of the cryo-EM structure, which hypothesised that CGRP 
makes contact with the region of the ECL3 that was missing (figure 68) (Liang et al., 2018). No 
persistent interactions from the simulation were observed as the loop still demonstrated fluidity. As UV 
cross-linking forms strong covalent bonds between the unnatural amino acid, AzF, and the fluorescent 
peptide, a signal would probably be detected if ECL3 did interact with AzF. The high mobility and 
heterogeneity of the ECL3 structure would not have been an issue as the F-CGRP would not dissociate 
from the loop upon cross-linking. As no interaction was observed between the ECL3 mutants and F-







The photoaffinity cross-linking assay has proven useful to decipher the residues of the extracellular 
loops of the CGRPR which make up part of the CGRP binding site. As experiments have shown CGRP 
binding to residues of the ECD, ECL2 and some of the TMs (Simms et al., 2018), the contribution of 
identifying the ECL1 and ECL3 binding site residues will further map the topology of the ligand binding 
site. The assay was also successful in determining the residues which interact with the peptide ligand, 
as comparisons with the recent cryo-EM structure showed high similarity in the residues of the ECL1 
which make up the binding site. Another important feature of photoaffinity cross-linking is that covalent 
bonds can be made between AzF and CGRP, preventing dissociation of the peptide ligand. This will be 
useful in permanently shifting the conformation of the CGRPR to an active state, which will be useful 























Chapter 9: General discussion and future experimental considerations 
Detergents have historically been used to solubilise membrane proteins for structural studies, which 
have provided target sites for drug discovery. Detergents can alter the the native lipid bilayer 
surrounding the protein, which could affect the conformation of the protein or remove the allosteric 
effects of the lipids. In response, SMALPs have been used to retain the native conformation of a 
membrane protein, with the lipid bilayer intact. The A2AR has previously been solubilised into SMALPs 
and showed binding capability after solubilisation and purification (Jamshad et al., 2015). The aim of 
this project was to further characterise the properties of the SMA-solubilised A2AR and the CGRPR 
using various techniques. SMALPs were also tested in the nanobody discovery technique, phage display, 
to assess the suitability of receptor-SMALPs, as a conformational epitope for therapeutic nanobodies. 
The SMA polymer has been used to solubilise the A2AR receptor by Jamshad et al. (2015). The 
deglycosylated human A2AR construct, designed by Fraser et al. (2006), was expressed in yeast and 
mammalian cells to characterise the pharmacology of the receptor when solubilised into SMALPs. The 
A2AR was successfully solubilised in SMALPs and was characterised using different ligands to confirm 
the conformational stability and binding characteristics of the receptor (Jamshad et al., 2015). The A2AR-
SMALP was successfully purified and concentrated into milligram amounts, using the Pichia pastoris 
cell line for high protein expression (Jamshad et al., 2015). Furthermore, the elution of the receptor and 
its purity was characterised using silver staining (Jamshad et al., 2015). The same deglycosylated A2AR 
construct using in Jamshad et al. (2015) and an avi-tag modified A2AR-A construct were were used for 
solubilisation and purification. Chapter 3 has demonstrated that the dghA2AR and the A2AR-A SMALPs 
were successfully purified, showing high purity with a few additional bands which are yet to be 
identified using mass spectrometry. As coomassie staining has been routinely used to assess the purity 
of the receptors, the data cannot be accurately compared to the silver stained gel using in Jamshad et al. 
(2015), which can be implemented in future studies. To remove the remaining contaminating proteins 
from the purified samples, size exclusion chromatography can also be used as an additional purification 
step, eluting the dghA2AR or the A2AR-A SMALPs based on their size.  
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The CGRPR-A receptor was expressed in HEK293T cells in order to SMA solubilise the receptor with 
a mammalian lipid bilayer intact. There is less evidence in the solubilisation of the CLR:RAMP1 in 
literature, however chapter 7 has demonstrated that the receptor was successfully solubilised in 
SMALPs. A cAMP assay was also implemented to compare the pharmacology and functionality of the 
CGRPR-A, comparing the data with an existing CGRPR construct, used previously in Salvatore et al. 
(2010). The CGRPR-A modifications did not affect the pharmacology of the receptor and that the EC50 
was similar to existing research. The next step for the CGRPR-A-SMALP would have been its 
purification using the flag-tag of RAMP1, in order to isolate CLR and RAMP1 as a complex. However 
previous purification attempts did not yield enough protein for downstream experiments, due to the 
construct being transiently transfected into HEK293T cells. The CGRPR-A construct should instead be 
incorporated into a zeocin mammalian plasmid vector, with an inducible gene to create a stable cell line 
that can be grown at a high yield with a high expression of the receptor. A radioligand binding assay 
must also be used to compare the binding capabilities of the receptor in the membrane, after 
solubilisation and purification. This will give a better idea of whether it is properly folded after SMA 
solubilisation. 
Once the dghA2AR and the A2AR-A SMALPs have been purified, a competitive radioligand binding 
assay was used to determine the pharmacology of the receptors. ZM241385 showed a similar affinity 
towards the dghA2AR and the A2AR-A expressed in membranes and after SMA solubilisation. This was 
concordant with the binding data obtained by Jamshad et al. (2015), therefore the methodology of SMA 
solubilisation and purification was reproducible.  
In addition to radioligand binding assay, further techniques have been implemented to study biophysics 
of the SMA-solubilised A2AR. FCS is a recently developed technique to understand the binding kinetics 
of a receptor in real time as well as to identify the non-specificity of ligand binding to a lipid 
environment. FCS has previously been used to study GPCR binding kinetics in living kinetics and has 
more recently been used to study receptors in membrane microdomains (Briddon et al., 2018). In this 
project, the A2AR-SMALP was the first GPCR to be studied under FCS, where a clear displacement of 
the ligand was identified. An important result of FCS was that the fluorescent ligand bound non-
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specifically to the SMALP, which was most likely due to the lipophilic BODIPY that was conjugated 
to the ligand. This finding indicated that in an in vivo environment, the actual concentration of a ligand 
to which a receptor is exposed to may differ from the bulk concentration of ligand administered to a live 
cell sample, as the ligand may non-specifically bind lipids. However this depends on whether lipophilic 
moieties are present on the ligand. Using SMALPs in FCS can be used to screen the lipophilicity of 
different drugs, which is important for drug development. The technique can also be used to conduct 
single molecule studies on the purified A2AR to observe the time length of ligand binding as well as the 
oligomerization capabilities of the receptor. The FCS data in chapter 4 represents the initial studies 
conducted by myself, with assistance from the hosts at University of Nottingham. Further experiments 
have been conducted in collaboration with University of Nottingham and University of Birmingham, 
where a paper has been published (Grime et al., 2020).  
X-ray radiolytic footprinting is becoming a valuable asset in understanding the structural pharmacology 
of receptors. The technique exposes residues of membrane proteins to irradiated water molecules, 
highlighting the regions of the receptor which can interact with water (Gupta et al., 2016). Changes in 
the water networks have been observed when rhodopsin transitions from an inactive to an active state, 
demonstrating the importance of water molecules in receptor conformation (Gupta et al., 2016). Water 
molecules have shown importance in directing the sodium ion to its binding site within the A2AR, where 
the ion acts as a negative allosteric modulator (Carpenter and Lebon, 2017). Although SMALPs have 
been suggested to render a receptor in its native conformation, the effect SMA exerts on the receptor 
and the surrounding lipids is unknown. XRF has been used in this project to assess whether water-
exposed residues are present on the receptor in a SMALP context. The upper portion of the TMs and 
the intracellular surface were identified as interaction sites for water molecules, demonstrating that using 
SMALPs in XRF is possible. Further experiments are required to test whether the water-exposed 
residues change upon agonist and antagonist binding, which can then be compared with the rhodopsin 
data to analyse changes in similar motifs of family A receptors. Using the ligands will also inform which 
conformational state the A2AR is in when SMA solubilised. 
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After the SMA-solubilised dghA2AR demonstrated binding capability with ZM241385, phage display 
was used to generate dghA2AR-specific phage as shown in chapter 5. Although seven dghA2AR-specific 
phages were detected using phage ELISA, the enrichment of specific phage was low when comparing 
the total monoclonal phage bound to the dghA2AR-SMALP and the total monoclonal phage bound to 
the Fab positive control. The most probable issue was that the SMALP was washed away from the 
ELISA plate during the bio-panning wash cycles, therefore an attempt was made to enhance 
immobilisation. In chapter 6, the A2AR-A was biotinylated, in order to immobilise the receptor onto a 
streptavidin-coated ELISA plate. The A2AR-A displayed better immobilisation onto streptavidin-coated 
wells, however the absorbance levels of the ELISA assays are not as high as the required levels by UCB. 
As the biotinylation conditions were sub-optimal, tests need to be conducted with different buffer 
compositions, in particular the ATP, the magnesium and the D-biotin content. A recombinant biotin 
ligase gene should also be expressed in a bacterial vector for an economical supply of the enzyme, 
instead of purchasing a bulk of the enzyme from Avidity. Therefore further optimization experiments 
can be conducted without the worry of limitation of the enzyme. Alternatively, the Pichia pastoris strain 
can be modified to express biotin ligase, prevented the need to use the enzyme after SMA solubilisation. 
Another important consideration is to test different polymers for solubilisation which are not limited by 
their intolerance to divalent cations. Diisobutylene maleic-acid (DIBMA) is one of the latest polymers 
designed after the solubilisation properties of SMA have been discovered. The polymer still renders the 
solubilised protein with a surrounding lipid bilayer intact, however the DIBMA copolymer is less 
disruptive to the lipid acyl-chain order and is less prone to precipitation by divalent cations (Oluwole et 
al., 2017). Therefore the magnesium concentration required for efficient biotin ligase activity will not 
affect the solubility of the copolymer. The experiments conducted in chapter 4 have clearly shown that 
the DIBMA copolymer can solubilise the receptor and retain binding affinity of the ligand, however the 
copolymer was less stable over time when compared with the SMA2000 copolymer. The DIBMA 
copolymer is still in its early stages of discovery and further polymer modifications may be required to 
improve the stability of the DIBMALP. 
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The photoaffinity cross-linking assay was adopted to study the binding site topology of the CGRPR 
extracellular loops. The assay can also be used to covalently bind the CGRP ligand to the receptor, 
stabilising the conformation of the receptor into an active state. A recently published research article 
demonstrated that the CGRP ligand can interact with residues of the ECL2, the TMs and the ECD 
(Simms et al., 2018). Residues I284U and L291U of the ECL2 formed the most prominent contacts with 
the CGRP, which was concordant with the data in the latest cryo-EM structure (Simms et al., 2018; 
Liang et al., 2018). This established the validity of the cross-linking assay to make evident the residues 
of the CGRPR which form the CGRP binding site. The technique was used in chapter 8 to identify the 
residues of ECL1 and ECL3 of the CGRPR. ECL1 formed limited contacts with CGRP, where residues 
A199 and N200 were in close proximity to the peptide, as made evident by the cryo-EM structure (Liang 
et al., 2018) and the data in chapter 8. N201U also cross-linked with CGRP and was in close proximity 
to the peptide according to the cryo-EM structure (Liang et al., 2018). ECL3 has been predicted to not 
form close contacts with the peptide. In this study, no cross-linking was observed between the ECL3 
AzF mutant residues and the fluorescent CGRP, which may be due to an issue with the expression of 
the mutants. Although chapter 8 provided valuable information on the residues of the extracellular loops 
which make contact with the peptide, the recent cryo-EM structure has established some of the residues 
of the CGRPR which form molecular contacts with the ligand (Liang et al., 2018). As the cryo-EM 
structure is based on a frozen sample, the interactions in the structure may not fully reflect the 
interactions which occur within the cell membrane at 37°C, therefore ligand binding experiments are 
essential in identifying interactions which occur in vivo. Further photoaffinity cross-linking experiments 
are required to characterise molecular interactions of the CGRPR. The CGRPR residues which interact 
with the G protein and the RCP are not well established and require further analysis to identify the 
intracellular binding topology. A G protein or the RCP can be fluorescently tagged and intracellular AzF 
mutants of the CGRPR can be made to see if the G protein and the RCP can cross-link with the receptor. 
Since the CGRPR:CGRP interaction has been heavily studied, the CGRPR:adrenomedullin can also be 
observed using photoaffinity cross-linking, as there are limited resources investigating this interaction. 
This is mainly due to adrenomedullin having a lower affinity towards the CLR:RAMP1 complex and 
therefore dissociating faster than the CGRP (Miret et al., 2002). Photoaffinity cross-linking can observe 
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this by covalently binding a fluorescent adrenomedullin to the AzF-CLR:RAMP1 mutants. The data can 
be compared to chapter 8 and Simms et al. (2018). Different RAMPs can also be co-expressed with the 
mutant CLR constructs to observe differences in photo cross-linking with adrenomedullin and CGRP. 
In relation to the project objective, since covalent bonds are formed between the peptide and the receptor 
upon UV exposure, the receptor can be stabilised in different conformations. The conformationally 
stabilised receptor can then be SMA solubilised and phage display can be used to generate nanobodies 
against an inactive and active conformation of the CGRPR, with the native lipid bilayer intact. This will 
generate nanobodies which are biased to certain conformations of the receptor and potentially be biased 
towards a one signalling pathway of the GPCR, whilst inhibiting another pathway. This demonstrates 
the usefulness of combining SMALPs with photoaffinity cross-linking and phage display to generate 
conformation-selective therapeutic nanobodies. 
In conclusion, the use of detergents to solubilise membrane proteins can alter the conformation of the 
protein as the lipid bilayer can be removed (Wheatley et al., 2016). SMA copolymers have been 
designed to overcome the limitations of detergents by solubilising receptors with the lipid bilayer intact. 
SMA has been incorporated in this study to solubilise the GPCRs: A2AR and CGRPR. The properties of 
the A2AR-SMALP was further analysed using techniques such as XRF and FCS. Phage display was also 
incorporated into this project to assess whether the SMALPs were suitable for nanobody generation and 
drug discovery. Currently, there are issues in SMALP immobilisation where an attempt was made to 
use the biotin/streptavidin technique to reduce removal of the SMALPs during phage display panning. 
Generating nanobodies against family B GPCRs would be ideal as to target the v-shaped chalice of the 
receptors, which contains the ligand binding site (Culhane et al., 2015; Karageorgos et al., 2018). 
Production of small molecule drugs to mimic peptide ligands would not be as feasible as generating a 
nanobody which covers all the binding site residues an endogenous ligand would occupy. The 
photoaffinity cross-linking assay demonstrated that the binding topology and the CGRPR can be 
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Sequencing primers for pcDNA3.1- T8-HA-CLR amber stop codon mutants: 
T7 primer 
Forward: 5’ TAATACGACTCACTATAGGGAACCC 3’ 
BGH primer 
Reverse: 5’ TAGAAGGCACAGTCGAGGCTG 3’  
 
Oligonucleotide primers used to generate T8-HA-CLR amber stop codon mutants: 
hCLR cDNA sequence (Residues highlighted in blue were mutated with the ‘tag’ codon): 
atggagaaaaagtgtaccctgtattttctggttctcttgcctttttttatgattcttgtt 
 M  E  K  K  C  T  L  Y  F  L  V  L  L  P  F  F  M  I  L  V  
acagcagaattagaagagagtcctgaggactcaattcagttgggagttactagaaataaa 
 T  A  E  L  E  E  S  P  E  D  S  I  Q  L  G  V  T  R  N  K  
atcatgacagctcaatatgaatgttaccaaaagattatgcaagaccccattcaacaagca 
 I  M  T  A  Q  Y  E  C  Y  Q  K  I  M  Q  D  P  I  Q  Q  A  
gaaggcgtttactgcaacagaacctgggatggatggctctgctggaacgatgttgcagca 
 E  G  V  Y  C  N  R  T  W  D  G  W  L  C  W  N  D  V  A  A  
ggaactgaatcaatgcagctctgccctgattactttcaggactttgatccatcagaaaaa 
 G  T  E  S  M  Q  L  C  P  D  Y  F  Q  D  F  D  P  S  E  K  
gttacaaagatctgtgaccaagatggaaactggtttagacatccagcaagcaacagaaca 
 V  T  K  I  C  D  Q  D  G  N  W  F  R  H  P  A  S  N  R  T  
tggacaaattatacccagtgtaatgttaacacccacgagaaagtgaagactgcactaaat 
 W  T  N  Y  T  Q  C  N  V  N  T  H  E  K  V  K  T  A  L  N  
ttgttttacctgaccataattggacacggattgtctattgcatcactgcttatctcgctt 
 L  F  Y  L  T  I  I  G  H  G  L  S  I  A  S  L  L  I  S  L  
ggcatattcttttatttcaagagcctaagttgccaaaggattaccttacacaaaaatctg 
 G  I  F  F  Y  F  K  S  L  S  C  Q  R  I  T  L  H  K  N  L  
ttcttctcatttgtttgtaactctgttgtaacaatcattcacctcactgcagtggccaac 
 F  F  S  F  V  C  N  S  V  V  T  I  I  H  L  T  A  V  A  N  
aaccaggccttagtagccacaaatcctgttagttgcaaagtgtcccagttcattcatctt 
 N  Q  A  L  V  A  T  N  P  V  S  C  K  V  S  Q  F  I  H  L  
tacctgatgggctgtaattacttttggatgctctgtgaaggcatttacctacacacactc 
 Y  L  M  G  C  N  Y  F  W  M  L  C  E  G  I  Y  L  H  T  L  
attgtggtggccgtgtttgcagagaagcaacatttaatgtggtattattttcttggctgg 
 I  V  V  A  V  F  A  E  K  Q  H  L  M  W  Y  Y  F  L  G  W  
ggatttccactgattcctgcttgtatacatgccattgctagaagcttatattacaatgac 
 G  F  P  L  I  P  A  C  I  H  A  I  A  R  S  L  Y  Y  N  D  
aattgctggatcagttctgatacccatctcctctacattatccatggcccaatttgtgct 
 N  C  W  I  S  S  D  T  H  L  L  Y  I  I  H  G  P  I  C  A  
gctttactggtgaatctttttttcttgttaaatattgtacgcgttctcatcaccaagtta 
 A  L  L  V  N  L  F  F  L  L  N  I  V  R  V  L  I  T  K  L  
aaagttacacaccaagcggaatccaatctgtacatgaaagctgtgagagctactcttatc 
 K  V  T  H  Q  A  E  S  N  L  Y  M  K  A  V  R  A  T  L  I  
ttggtgccattgcttggcattgaatttgtgctgattccatggcgacctgaaggaaagatt 
 L  V  P  L  L  G  I  E  F  V  L  I  P  W  R  P  E  G  K  I  
gcagaggaggtatatgactacatcatgcacatccttatgcacttccagggtcttttggtc 
 A  E  E  V  Y  D  Y  I  M  H  I  L  M  H  F  Q  G  L  L  V  
tctaccattttctgcttctttaatggagaggttcaagcaattctgagaagaaactggaat 
 S  T  I  F  C  F  F  N  G  E  V  Q  A  I  L  R  R  N  W  N  
caatacaaaatccaatttggaaacagcttttccaactcagaagctcttcgtagtgcgtct 
 Q  Y  K  I  Q  F  G  N  S  F  S  N  S  E  A  L  R  S  A  S  
tacacagtgtcaacaatcagtgatggtccaggttatagtcatgactgtcctagtgaacac 




 L  N  G  K  S  I  H  D  I  E  N  V  L  L  K  P  E  N  L  Y  
aattga 






Forward: 5’ GTAACAATCATTCACTAGACTGCAGTGGCCAACAA 3’ 





Forward: 5’ CATTCACCTCTAGGCAGTGGCCAACAACCAGGC 3’ 





Forward: 5’ CATTCACCTCACTTAGGTGGCCAACAACCAGGC 3’ 




Forward: 5’ CATTCACCTCACTGCATAGGCCAACAACCAGGC 3’ 




Forward: 5’ CATTCACCTCACTGCAGTGTAGAACAACCAGGC 3’ 
Reverse:  3’ GCCTGGTTGTTCTACACTGCAGTGAGGTGAATG 5’ 
 
N200stop 
Forward: 5’ CATTCACCTCACTGCAGTGGCCTAGAACCAGGC 3’ 






Forward: 5’ CACTGCAGTGGCCAACTAGCAGGCCTTAGTAGC 3’ 
Reverse:  3’ GCTACTAAGGCCTGCTAGTTGGCCACTGCAGTG 5’ 
  
Q202stop 
Forward: 5’ CACTGCAGTGGCCAACAACTGAGCCTTAGTAGC 3’ 






Forward: 5’ GGCCAACAACCAGTGATTAGTAGCCACAAATCCTG 3’ 




Forward: 5’ GCCAACAACCAGGCCTAGGTAGCCACAAATCCTG 3’ 





Forward: 5’ GGCCAACAACCAGGCCTTAGTATAGACAAATCCTG 3’ 





Forward: 5’ CCAGGCCTTAGTAGCCTAGAATCCTGTTAGTTGCA 3’ 
 




Forward: 5’ CCAGGCCTTAGTAGCCACATAGCCTGTTAGTTGCA 3’ 
 
Reverse:  3’ TGCAACTAACAGGCTATGTGGCTACTAAGGCCTGG 5’ 
 
P209stop 
Forward: 5’ CCAGGCCTTAGTAGCCACAAATTAGGTTAGTTGCA 3’ 
 





Forward: 5’ GTAGCCACAAATCCTTAGAGTTGCAAAGTGTCCCA 3’ 




Forward: 5’ GTAGCCACAAATCCTGTTTAGTGCAAAGTGTCCCA 3’ 






Forward: 5’ CATCTCTAGTACATTATCCATGGCCCAATTTGTGC 3’ 




Forward: 5’ CTTGGCATTGAATTTTAGCTGATTCCATGGCGA 3’ 




Forward: 5’ CTTGGCATTGAATTTGTGTAGATTCCATGGCGA 3’ 






Forward: 5’ CTTGGCATTGAATTTGTGCTGTAGCCATGGCGA 3’ 






Forward: 5’ GAATTTGTGCTGATTTAGTGGCGACCTGAAGGA 3’ 
 







Forward: 5’ GAATTTGTGCTGATTCCATAGCGACCTGAAGGA 3’ 





Forward: 5’ GAATTTGTGCTGATTCCATGGTAGCCTGAAGGA 3’ 




Forward: 5’ GCTGATTCCATGGCGATAGGAAGGAAAGATTGC 3’ 






Forward: 5’ GCTGATTCCATGGCGACCTTAGGGAAAGATTGC 3’ 






Forward: 5’ CCATGGCGACCTGAATAGAAGATTGCAGAGGAG 3’ 
 






Forward: 5’ CCATGGCGACCTGAAGGATAGATTGCAGAGGAG 3’ 
  






Forward: 5’ CCATGGCGACCTGAAGGAAAGTAGGCAGAGGAG 3’ 
 
Reverse:  3’ CTCCTCTGCCTACTTTCCTTCAGGTCGCCATGG 5’ 
 
 
 
 
